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Autologous human saphenous vein (HSV) is commonly used as a conduit for coronary artery 
bypass grafting in patients with ischemic heart disease. However, the primary patency of 
venous grafts is poor, with 30-50% of grafted conduits failing within 10 years post-implantation. 
Early vein graft failure is caused in 10-15% of grafts by thrombosis whilst the remainder fail 
due to late vein graft failure instigated by intimal thickening. The Achilles heel of this surgical 
technique is vascular injury resulting from endothelial cell (EC) damage and inflammation 
which promotes aberrant, uncontrolled migration and proliferation of vascular smooth muscle 
cells (VSMCs) within the intimal layer of the blood vessel wall. Consequent intimal thickening 
triggers the narrowing of the lumen and causes susceptibility of the bypass graft to 
superimposed atherosclerosis and restenosis. Therefore, there is a pressing unmet clinical 
need to identify new approaches that reduce VSMC proliferation and intimal thickening without 
having detrimental effects on endothelial coverage. 
 
Proline Rich Homeodomain (PRH) protein is a transcription factor required for cell growth and 
differentiation. Previous work by our laboratory demonstrated that adenovirus-mediated 
overexpression of S163C:S177C PRH in rat VSMCs and neointimal ex vivo human saphenous 
vein organ cultures effectively prevented intimal thickening of the venous grafts. In this thesis, 
we investigated whether adenovirus-mediated delivery of mutant non-phosphorylated PRH 
protein using Ad: PRH S163C:S177C attenuates VSMC proliferation without detrimental 
effects on the endothelial cells. We observed that overexpression of Ad: PRH S163C:S177C 
in human saphenous vein VSMCs significantly inhibited proliferation, migration and promoted 
the contractile phenotype. Importantly, we also showed that overexpression of Ad: PRH 
S163C:S177C impaired carotid artery ligation induced neointimal proliferation and thickening. 
Importantly, Ad: PRH S163C:S177C did not significantly affect HSV endothelial cell (HSVEC) 
proliferation, migration and apoptosis. However, interestingly, the expression of TNFα-induced 
vascular cell adhesion molecule 1 (VCAM-1) and Intercellular Adhesion Molecule 1 (ICAM-1) 
proteins were significantly reduced in Ad: PRH S163C:S177C treated HSVECs and was 
associated with significantly reduced monocyte adhesion. Other inflammation-related 
molecules such as interleukin-6 (IL-6) and monocyte chemotactic factor-1 (MCP-1) measured 
by ELISA were also significantly attenuated, indicative of suppression of a pro-inflammatory 
response to TNFα. To identify novel PRH S163C:S177C-regulated target genes in HSV 
VSMCs, we have utilised Next Generation Sequencing. Our findings revealed Signal 
 iv 
transducer and activator of transcription 1 (STAT-1) and Histone deacetylase 9 (HDAC-9) as 
novel targets of PRH which were validated by in vitro and in vivo analyses.  
 
Taken together, this study has revealed that overexpression of PRH S163C:S177C attenuated 
VSMC proliferation, migration and apoptosis and induced a contractile VSMC phenotype, 
whilst promoting the endothelial cell repair and anti-inflammatory properties. Importantly, we 
have shown that overexpression of PRH S163C:S177C in vivo attenuated intimal thickening 
without affecting endothelial coverage in a validated mouse carotid artery ligation model. 
Moreover, this study has enabled the identification of novel mechanisms that beneficially 
regulate VSMC behaviour and preserve the endothelial function. These findings have the 
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1.   INTRODUCTION 
1.1   CARDIOVASCULAR DISEASES 
Cardiovascular disease (CVD) is a class of diseases affecting the heart and circulatory system 
(Bhatnagar et al., 2015), and includes stroke and coronary artery disease (CAD). The 
underlying pathology responsible for the majority of CVDs is atherosclerosis. Atherosclerosis 
is characterised by accumulation of lipids, inflammatory cells and a fibrous cap in the 
innermost layer of arteries and results in the formation of an atherosclerotic lesion or plaque 
(see review by Lusis, 2000). The subsequent progression of atherosclerotic disease can result 
in critical narrowing or complete occlusion of arteries. When this occurs in one or more of the 
coronary arteries it can inhibit adequate supply of oxygen-rich blood to the myocardium and 
may lead to the symptoms of angina. Rupture of a coronary artery atherosclerotic plaque and 
ensuing thrombosis which partially or completely occludes the artery can cause catastrophic 
clinical consequences of myocardial infarction (MI), more commonly known as a heart attack, 
or even death (Khan, Farah and Domb, 2012). 
 
According to the World Health Organization (WHO), the most prevalent cause of mortality 
worldwide is CVD, which accounts for 31% of all global deaths (World Heart Day 2017). It is 
estimated as one of the common causes of death in the United Kingdom by claiming 27% of 
deaths (CVD Statistics– BHF UK Factsheet, 2020). The British Heart Foundation (BHF) 
documented that there are currently 7.4 million people living with CVD in the UK (CVD 
Statistics– BHF UK Factsheet, 2020). This equated to an average of 170,000 deaths per 
annum with one death every three minutes. Furthermore, 2.3 million people in the UK suffer 
from CAD, and hospital admissions due to stroke were estimated at around 240,000 cases 
(CVD Statistics– BHF UK Factsheet, 2020).  
 
As one of the leading public health problems in the UK, CVD is a substantial clinical and 
economic burden costing the British economy approximately £19 billion annually (CVD 
Statistics– BHF UK Factsheet, 20120. Despite the significant decline in mortality as a result 
of CVD over the years, it must be emphasised that prescriptions and operations for CVD are 
rising strikingly with time (CVD Statistics– BHF UK Factsheet, 2020). Hence, there has been 







1.1.1          History of Myocardial Revascularization 
Preventative measures and treatments such as lifestyle management, medical therapies and 
myocardial revascularization have yielded clinical benefit for patients with CAD, although, 
these have not eradicated atherosclerosis and the incidence of major adverse cardiovascular 
events. A strong emphasis on mortality caused by CAD have resulted in the development and 
utilisation of cardiac surgical procedures (Bhatnagar et al., 2015). For example, surgical 
interventions to treat coronary artery disease include intracoronary stenting or coronary artery 
bypass graft surgery (CABG) (Schwartz et al., 1995 and Wallitt et al., 2007) to unblock 
coronary stenosis. In percutaneous coronary intervention (PCI), drug-eluting stents (DES) 
demonstrated clear superiority compared to bare metal stents (BMS) because it has better 
survival rates and less adverse event (Khan et al., 2012). Despite success, issues with safety 
and efficacy of DES have been associated with late stent thrombosis and graft occlusion rates 
have not improved over time (Taniwaki et al., 2012; Conte, 2007). Although there has been 
advancement in stenting technology, there remains an unmet challenge faced by the clinicians 
and basic scientists for the development of appropriate materials with preferred specifications. 
For this reason, CABG remains the gold standard therapy for patients with left main disease, 
multivessel coronary artery disease and those with diabetes (Harskamp et al., 2013).  
 
In the late 1930s, cardiac surgery was in its infancy but became more feasible as the first ever 
heart-lung machine was developed by Dr John Gibbon which enabled cardiopulmonary 
bypass (CPB) (Cooper, 2011). Following on from this success, CABG has become one of the 
most important and most utilised surgical revascularizations in the history of medicine. CABG 
involves grafting a section of a blood vessel or vascular conduits from the aorta to the coronary 
artery distal to the stenosed (atherosclerotic) region, to restore blood flow, thereby 
revascularizing the cardiac tissue. Vineberg was the first to pioneer bypass graft surgery in 
1946 by implanting an internal mammary artery (IMA) as the conduit for the treatment of 
cardiac ischemia and angina in dogs (Thomas, 1999). In 1953, Dr Gordon Murray introduced 
experimental arterial-coronary grafting using internal thoracic artery (ITA) in the coronary 
circulation (Murray et al., 1954). The first successful harvest and use of saphenous vein as an 
aorto-coronary conduit was accomplished by Sidney Smith (Smith et al., 1957). The first 
human coronary artery bypass operation was performed in 1961 by Robert Goetz using left 
ITA (Goetz et al., 1961). Major breakthroughs in the field of cardiothoracic surgery persisted 
during the 1960s including the innovative success of left internal mammary artery (LIMA) to 
the left anterior descending (LAD) artery anastomoses in the absence of CPB by Kolesov 
(Konstantinov, 2004). In 1967, René Favaloro led a novel, ground-breaking surgical technique 
to treat coronary stenosis by reconstructing the right coronary artery, and for the first time, 
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using saphenous vein graft interposition (Captur, 2004). During the late 20th century, the 
evolution of surgical procedures and conduits contributed to the increased prevalence of 
CABG and to improve survival of patients by successfully diverting the flow of blood from the 
aorta to the coronary artery, distal to the stenosis caused by an atherosclerotic plaque 
(Gulielmos, 2004; Duhaylongsod, Mayfield and Wolf, 1998). 
 
 1.1.2 Coronary Artery Bypass Graft (CABG) 
The choice of graft conduit is imperative to the success of CABG since the patency of the 
conduit is an important determinant of normal postoperative outcome and patient survival 
(Loop, Lytle and Cosgrove, 1986). 
 
To date, the most commonly used vessel conduit or graft is the autologous saphenous vein, 
in particular, for patients with multi-vessel disease where 75% of grafts utilise saphenous vein 
(Wan et al., 2012). Though patients experience improved survival and symptomatic relief post-
CABG surgery, long-term success is hindered by the high prevalence of vein graft failure 
(VGF). At one year post implantation of saphenous vein grafts the occlusion prevalence is 
10% to 15% (Fitzgibbon et al., 1996). While 5-10 years following CABG, implanted vein graft 
patency is approximately 50-60% (Sabik, 2011). Consequently, there is a high incidence of 
patients undergoing repeat CABG surgery compared to the former surgical procedure (Yap et 
al., 2009). Therefore, CABG cannot be considered a cure but rather a useful palliative 
treatment (Bourassa et al., 1985). Nonetheless, the usage of venous conduits remains a 
fundamental requirement for CABG and are still the most frequently used owing to its length 
and ease of harvesting (Sabik, 2011). 
 
Arterial grafts such as left internal thoracic artery (LITA) exhibit improved long-term patency 
and survival rates compared to venous grafts. Hence, total arterial revascularization has 
gained much prominence for coronary bypass graft surgery (Al-Sabti et al., 2013; Taggart, 
D’Amico and Altman, 2001; Buxton et al., 1998).  Despite the striking resistance to the 
development of intimal thickening and super-imposed atherosclerosis of arterial grafts, use of 
these conduits carries the risk of mediastinitis, a severe complication involving inflammation 
of the tissues in the mid-chest, which inevitably presents a significant drawback. In addition, 
there is a lack of sufficient arterial material to achieve multiple grafts, thus, signifying the need 
to utilise venous grafts (Al-Sabti et al., 2013).  
 
In summary, VGF reduces the long-term success of CABG surgery as it can result in recurrent 
angina and MI which may precipitate the requirement for further treatments including repeat 
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revascularization. This is not only detrimental to CABG patients, but such a clinical burden 
clearly represents a significant strain on the NHS.  
 
1.1.2   Arteries and Veins 
The vascular system is composed of arteries and veins; two separate components which differ 
structurally and functionally (Szasz et al., 2007).  In general arteries transport oxygenated 
blood under a high pressure away from the heart into the systemic circulation. Large arteries 
branch off from the aorta and form smaller divisions known as arterioles. The arterioles 
distribute oxygenated blood to capillary beds, which permit the exchange of oxygen and 
carbon dioxide along with nutrients and metabolic waste products. The capillaries lead back 
to small vessels, termed venules, that flow into the larger veins, which transport blood towards 
the heart from the tissues.  
 
Both arteries (FIGURE 1.1A) and veins (FIGURE 1.1B) consist of a tri-laminar structure: tunica 
externa, tunica media and tunica intima surrounding a central blood-containing space called 
the lumen (Betts et al., 2013). The internal and external elastic membrane separate the three 
tunicae (Kloc and Ghobrial et al., 2014). The tunica externa also known as the adventitia is 
the external substantive layer of a blood vessel, and is comprised of fibroblasts, macrophages, 
nerves and connective tissue, predominantly collagen, which acts as a supportive element by 
anchoring the blood vessel, preventing overexpansion and imparting tensile strength. In veins, 
it is the thickest layer (FIGURE 1.1B). Also characteristic of this tunica is the network of 
nourishing micro-vessels called the vasa vasorum (FIGURE 1.1B), which supplies nutrients 
to the vascular walls of larger arteries and veins (Brown, Williams and George, 2017). The 
tunica media is the middle layer of a blood vessel characterised by the presence of quiescent, 
contractile vascular smooth muscle cells (VSMCs) positioned within a collagen-rich 
extracellular matrix (ECM) and surrounded by the external elastic lamina (EEL). The EEL is 
commonly present in larger arteries but not smaller arteries or veins (FIGURE 1). This 
muscular medial layer is responsible for regulating blood pressure by controlling the arterial 
calibre. The tunica media is generally the thickest layer in arteries, and it is much thicker in 
arteries than veins enabling them to withstand high blood pressure. Moreover, the elastic 
lamina that are present in arteries as continuous layers of elastic but fenestrated in veins 
(Betts et al., 2013) (FIGURE 1A).  The innermost layer of a blood vessel is called the tunica 
intima and is formed of a monolayer of endothelial cells (ECs) also known as the endothelium 
delimited by the internal elastic lamina (IEL), which is not apparent in veins but present in 
arteries. To achieve satisfactory blood circulation under low pressure, many veins possess 
semilunar folds in the tunica intima known as the venous valves which prevent retrograde flow 
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(Betts et al., 2013). In arteries, the tunica intima has an undulating structure due to partial 
constriction exerted by the tunica media, whereas in veins, it characteristically appears smooth 







































FIGURE 1.1: Anatomy of the Blood Vessel Wall  
(A) Arteries and (B) veins contain three structural layers, tunica externa, tunica media and tunica 
intima. The structure and thickness of each layer varies between the vessel types. 
(C) Cross section of a vein and artery. The smooth muscle and connective tissue of the vessels are 







The different properties of arterial and venous grafts used in CABG surgery have inspired 
research to compare these vessel types in an attempt to achieve superior patency rates. The 
higher patency rates of arterial grafts have been considered as a fundamental advantage 
compared with saphenous vein grafts (SVGs).  However, SVGs remains to be the preferred 
conduit of choice due to the need for multiple grafts when there is either insufficient arterial 
material or time to do the more complex arterial surgery. More importantly, in emergency 
situations and for patients at higher operative risk due to the complicated and time-consuming 
nature of arterial grafting (Cuminetti et al., 2017). In addition to structural differences of arteries 
and veins including thickness, presence of elastic membrane and ECM composition, inherent 
differences exist between venous VSMCs and arterial VSMCs. For example, arterial VSMCs 
exhibit a lower growth rate than VSMCs isolated from saphenous veins (Yang et al., 1998) 
which may contribute to the improved patency of arterial grafts.  
 
1.2   PATHOPHYSIOLOGY OF VEIN GRAFT FAILURE (VGF) 
The pathophysiology underlying SVG failure (SVGF) is complex and has not been fully 
defined. Multiple biological processes comprising of acute thrombosis, neointimal hyperplasia 
and atherosclerosis are considered to be the primary contributors to graft failure (FIGURE 1.2) 
(Ward et al., 2017; Shuhaiber et al., 2002). SVGF can be divided into three distinct phases: 
early, intermediate and late graft failure (Motwani and Topo, 1998). 
 
1.2.1  Early Vein Graft Failure 
Early SVGF occurs within one-year post-implantation in 10-15% of venous grafts (Sabik, 
2011). It is considered that the surgical preparation of saphenous vein causes injury to the 
endothelium triggering early occlusion (Shukla and Jeremy, 2012). Within the first month 
following CABG, the risk of thrombosis is elevated by surgical errors associated with 
harvesting, sites of anastomoses or vessels with poor runoff (Conte, 2010) (FIGURE 3). 
During conventional harvesting of SV used as bypass conduits, vascular spasm is triggered 
when the cushion of perivascular fat surrounding the adventitia is stripped off. Consequently, 
uncontrolled hydrostatic distension is required to dilate the vessel leading to extensive 
damage to the endothelium (Hinokiyama et al., 2006). To address this concern, an innovative 
“no-touch” technique (NTT) for vein harvesting was used to ameliorate the physical damage 
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due to dissection, side branch ligation and handling/distension, all of which damage the 
delicate endothelium (Souza, 2002a; Souza 2003).  
Implantation of the SVG into the high-pressure arterial circulation exposes the vein to different 
haemodynamic parameters such as shear “hydrostatic” stress, increased wall tension and 
turbulent flow and results in endothelial injury within the graft (Angelini et al., 1987).  Removal 
of or damage to the endothelium during vein graft preparation as well as after implantation 
exposes the intimal and medial layers of the vessel wall. These adverse conditions permit the 
adherence and activation of blood cells such as platelets, neutrophils and monocytes to the 
vein graft. Further damage the endothelial layer depletes its synthesis and secretion of 
atheroprotective compounds including nitric oxide and prostacyclin, encouraging vasospasm 
and loss of graft patency (Ishiwata et al., 1997). Endothelial injury and dysfunction also 
enhance expression of anti-fibrinolytic proteins including thromboxane A2, fibronectin, 
thrombospondin etc. which promote thrombosis (Wan et al., 2012; Tsui and Dashwood, 2002).  
 
1.2.2   Intermediate to late-stage Vein Graft Failure 
Intermediate (1 month–1-year post-surgery) and late (beyond 1-year post-surgery) graft failure 
occurs in 15–30% of reported cases, respectively (Sabik, 2011). By 10 years post-
implantation, 50-60% of grafts become blocked and a further 30% develop compromised flow 
(Jeremy, Gasdon and Shukla, 2007; Favaloro, 1998; Motwani and Topol, 1988). Intermediate 
to late vein graft failure is commonly attributed to neointimal hyperplasia, particularly at the 
proximal/distal anastomoses, which can lead to late vein graft failure as a result of prolonged 
development of superimposed atherosclerosis (Sabik, 2011). 
The injury to the endothelium not only leads to early thrombosis but precipitates longer term 
effects including inflammation and VSMC activation that contribute to intermediate and late 
vein graft failure. Endothelial damage leads to enhances expression of adhesion molecules 
including vascular cell adhesion molecule 1 (VCAM-1) and intercellular adhesion molecule 1 
(ICAM-1), which facilitate monocyte adhesion and therefore monocyte recruitment and 
inflammation (Wan et al., 2012; Tsui and Dashwood, 2002). Initial vein harvesting from the 
circulation removes the blood supply provided via the vasa vasorum and thereby causes 
susceptibility to hypoxic injury within the first day after surgery which activates VSMCs 
(Vlovader and Edwards, 1971).  
Intact and functional endothelium releases factors that are key inhibitors of VSMC proliferation 
and thereby intimal thickening (Angelini, Soyombo and Newby, 1991). For instance, there is 
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an insufficient endothelial regrowth after denuding injury to the artery which can compromise 
its vascular function and integrity as a result of altered arterial haemodynamic forces. 
Haemodynamic forces are capable of modulating the physiology and disease progression of 
the vascular wall. In addition, activated ECs are a source of VSMC mitogens thereby 
promoting VSMC proliferation (Angelini et al., 1987). Hence, endothelial loss and dysfunction 
is recognised to affect the long-term efficacy of SVG in addition to early vein graft failure. 
The principal cause underlying intermediate to late graft failure is the progressive intimal 
hyperplasia due to VSMC accumulation and ECM deposition, as described in Figure 3 
(Southerland, 2013). Unlike skeletal and cardiac muscle cells, which are terminally 
differentiated, VSMCs have a remarkable characteristic of plasticity that enables them to 
reversibly switch to a less “contractile” phenotype or “synthetic” phenotype (de-differentiation) 
in response to altering environmental cues (Rensen et al., 2007). In the healthy blood vessel, 
‘contractile’ VSMCs exhibit a low rate of proliferation, low synthetic activity and express a 
unique set of contractile proteins, essential for the contraction and relaxation of the vascular 
wall. These proteins either act as structural components of the contractile apparatus or as 
regulators of contraction and include: transgelin (TAGLN), smooth muscle-a-actin (ACTA2), 
calponin (CNN1), smoothelin (SMTN) and smooth muscle myosin heavy chain (MYH11) 
(Rensen et al., 2007).   
Upon injury or insult, the synthetic phenotype is typically characterized by loss of expression 
of contractile proteins and increased expression of synthetic proteins such as osteopontin 
(Alexander and Owens, 2012). Such phenotypic switching is required to maintain vascular 
homeostasis and regulate vascular response to injury and inflammation. "Synthetic" VSMCs 
are characterised and identified by their loss of contractile marker expression and the 
upregulation of selective gene sets, including pro-inflammatory cytokines and matrix 
metalloproteinases (MMPs), leading to increased cell migration, proliferation and secretion of 
pro-inflammatory cytokines (Alexander and Owens, 2012; Clarke et al., 2010; Owens et al., 
2004). Within 24 hours of vein graft insertion, VSMCs exit the quiescent G0 phase and proceed 
into the G1 and G2/S phases of the cell cycle (Bochaton-Piallat et al., 1996). As a response to 
vascular injury, switching of VSMCs from “contractile” or differentiated phenotype to 
“synthetic” or dedifferentiated state is a hallmark in the pathogenesis of VGF. The synthetic, 
migratory and proliferative phenotype enhances the production of inflammatory cytokines and 
growth factors which serve as paracrine factors to stimulate surrounding VSMCs and 
inflammatory cells (Nguyen et al., 2013; Owens et al., 2004). Activated platelets on the 
denuded surface of the vein, and recruitment of macrophages and other inflammatory cells 
into the damaged intimal surface results in the release of mitogens and chemotactic agents 
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which initiate VSMC migration into the intima and further proliferation of VSMCs. In addition, 
the production and activation of matrix-degrading metalloproteinases (MMPs) by VSMCs and 
macrophages enable digestion of ECM and facilitate VSMC migration and proliferation 
(Newby, 2005; George et al., 2000). The VSMC migration and proliferation is observed early 
after implantation and in a rat model migration of VSMCs from the media into the intimal layer 
of the graft was observed on post-operative day 7 (Allaire and Clowes, 1997). Once within the 
intima, VSMCs proliferate and secrete abundant quantities of ECM (collagen and 
proteoglycans, but not elastin) (Mitra, Gangahar and Agrawal, 2006).  
Atherosclerosis leads to the development of an atheromatous plaque within the intima 
composed of a necrotic core encapsulated by a fibrous cap. A crucial initiating stage in 
atherosclerosis is the accumulation of oxidatively modified LDL in the subendothelial matrix 
contributing to the monocyte recruitment and foam-cell formation. The newly deposited matrix 
proteins in the intima are known to enable the trapping of lipid in the intima and act as a soil 
for atherosclerosis. Superimposed atherosclerosis occurs in vein grafts beyond the first year 
after bypass surgery (FIGURE 1.2). The thickened intima resulting from aberrant VSMC and 
ECM accumulation serves as the foundation for the development of superimposed 
atherogenesis (Motwani and Topol, 1998). Compared to native coronary artery atheromas, 
SVG atherosclerosis contains a higher number of foam and inflammatory cells (Southerland 
et al., 2013, Chiu and Chien, 2011). Superimposed and accelerated atherosclerosis is more 
diffuse and concentric yet contains less calcification and lacked fibrous caps than native 
atherosclerotic lesions. Of interest, SVG atherosclerosis is located at either the aorto-ostial or 
the main shaft of the graft. Evaluation of SVG shaft lesions revealed an association with 
increased death rates, MI, enhanced plaque rupture and no-reflow (Hong et al., 2013; Sano 
et al., 2006).
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FIGURE 1.2: Schematic diagram of the events that contribute to Vein Graft Failure 
Early graft failure primarily occurs when the SVG is exposed to altered haemodynamics and surgical trauma which result in endothelial injury. Resultant 
endothelial dysfunction induces leukocyte recruitment and their subsequent release of a plethora of vasoactive mediators, chemotactic agents and growth 
factors initiating VSMC de-differentiation, proliferation, and migration. This leads to progressive intimal thickening. Late vein graft failure is a much slower 
process predominantly due to intimal thickening and superimposed atherosclerosis. EC, endothelial cell; ECM, extracellular matrix; VSMC, vascular smooth 
muscle cell; IEL, internal elastic lamina; EEL, external elastic lamina. Original figure from Ward et al., 2017.
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1.3   CURRENT STRATEGIES TO PREVENT VGF 
Preventive measures and interventional strategies for preservation of vein graft patency is 
essential for long-term surgical success (McKavanaghet al., 2017). This may be accomplished 
through perioperative measures, lifestyle modifications, prescription medication, 
percutaneous coronary intervention (PCI) and repeat CABG surgery. Despite this, such 
interventions have not eliminated the problem of SVGF thereby driving the need to advance 
strategies to improve coronary revascularization (Thomas, Angelini and Zakkar, 2016). 
As mentioned previously, NTT resulted in minimal surgical complications with less endothelial 
damage and less neointimal hyperplasia thereby improving patency in CABG in comparison 
to the conventional harvesting techniques. However, it is postulated that NTT is only effective 
for early, but not late VGF (Souza et al., 2006; Souza et al., 2002b). 
Beyond surgery, optimal secondary prevention involving lifestyle modifications includes 
cessation of smoking, a diet low in saturated fats and carbohydrates and regular exercise 
continues to have an important role in reducing thrombotic risk and management of vein graft 
degeneration (Thomas, Angelini and Zakkar, 2016). In addition, pharmacological intervention 
including aspirin and/or clopidogrel has emerged to prevent SVGF and reduce the need to 
reoperate failed SVGs (McKavanagh et al., 2017; Wijins et al., 2010; Wallentin et al., 2009). 
Aggressive lipid-lowering therapy has been proven to help lower the incidence of early SVGF 
(Kang et al., 2013). The administration of statin therapy following CABG intervention correlates 
to improving the patency of the graft (Kang et al., 2013; Hillis et al., 2012).  
Irrespective of the established pharmacotherapy, intimal thickening persists to be a clinical 
burden (Engelberger et al., 2008). Recognition of the significant unmet clinical need in this 
area presents the potential of gene therapy to improve patency rates of bypass graft by 
inhibiting cellular proliferation that causes intimal hyperplasia (Mann et al., 1999; George et 
al., 2011). Initial optimism to attenuate intimal thickening was observed in the PREVENT II 
study involving 200 patients undergoing CABG surgery in which vein conduits were treated ex 
vivo with edifoligide, an E2F transcription factor decoy that retards VSMC proliferation (Grube 
et al. 2001). However, the success was dampened by a phase 3 randomized, double-blind, 
placebo-controlled trial, PREVENT IV, enrolling 3014 patients.  The researchers found 
edifoligide was no more effective than placebo in preventing clinical consequences of VGF 
(Alexander et al., 2005). In fact, another study from our research group in Bristol illustrated 
that TIMP-3 possess a pro-apoptotic function that retards the development of intimal 
thickening if porcine vein grafts for up to 3 months (George et al., 2011). Of interest, a Medical 
Research Council (MRC)/British Heart Foundation (BHF)-funded clinical trial for TIMP-3 is 
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planned to explore its therapeutic potential in reducing vein graft failure. Other 
pharmacological agents such as nitric oxide-donating aspirin (Wan et al., 2007) and 
endothelin-1 receptor antagonists (Wan et al., 2004) have been tested in pre-clinical studies 
for the treatment of vein graft failure in porcine models. Although, these have not been 
examined in clinical trials. 
Despite the success of identifying a plethora of genes that modulate VSMC proliferation, 
migration and apoptosis, these genes often fail to promote reendothelialization due to lack of 
cell specificity (George et al., 1998; George et al., 2000). As a result, the scope of this strategy 
has potential shortcomings regarding potential translation into a clinical setting (Conte, 2007; 
Harskamp et al., 2013). Preservation of endothelial cell function and structure by inducing 
endothelial cell regrowth on the vein graft is fundamental to sustain the balance between 
inhibition and encouragement of the migration and proliferation of VSMCs in addition to 
platelet aggregation and adhesion (Sena, Pereira and Seiça, 2013). 
In the absence of clinically proven strategies to block VGF, the search for novel therapeutic 
approaches to improve SVG patency and long-term clinical success after CABG are urgently 
needed. Most importantly, anti-proliferative therapies that inhibit VSMC accumulation within 
the inner, intimal layer of the vessel wall whilst preventing damage to the endothelium is an 
attractive strategy to alleviate intimal thickening in the venous bypass graft and enhance 
patency. 
 
1.4   PROLINE RICH HOMEODOMAIN (PRH) 
 
 
1.4.1   Overview of PRH 
The proline rich homeodomain protein (PRH), also known as haematopoietically expressed 
homeobox (HHEX), is a highly conserved transcription factor and belongs to a family of 
proteins that serve key regulatory functions in cellular development and differentiation via both 
transcriptional and post-transcriptional mechanisms. Formerly discovered in screens to 
identify novel homeobox genes in human, mouse and avian hematopoietic cells [Crompton et 
al., 1992; Bedford et al., 1993; Hromas et al., 1993], PRH has since been found to contain 
high sequence similarity between various species including mouse (Hex), xenopus (Xhex), 
zebrafish (hhex) and rat (Ho et al., 1999; Newman, Chia and Krieg., 1997; Tanaka et al., 
1999). Evidence from analysis of mRNA and protein in adulthood indicates that PRH is 
preferentially expressed in pluripotent myelomonocytic cells, erythroid cells and B-cell 
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progenitors although absent in T-cell lineages (Manfioletti et al., 1995; Bedford et al., 1993). 
During embryonic development, PRH is essential for the development of vital organs such as 
the forebrain, heart, liver, thyroid and thymus; it is also required for the formation of the sagittal 
axis at the earlier stages of embryogenesis (Gaston et al., 2016; Keng et al., 2000). In support 
of this notion, in Hhex-null mouse embryos, haematopoiesis, vasculogenesis, forebrain and 
liver generation were impaired, and embryos were unable to survive gestation (Hallaq et al., 
2004). PRH can affect multiple processes since it regulates the expression of a number of 
genes, Table 1 summarizes the list of genes known to be repressed or activated by PRH 

































Table 1: PRH Target Genes 
Gene Regulation Model Method References 
Goosecoid Repressed Xenopus embryos 
ES tissue cultured cells 
Ectopic expression 
Transient transfection 
Brickman et al., 2000 
Chordin Repressed Xenopus embryos Ectopic expression Brickman et al., 2000 
Xtle4, Nodal (Xnr1, Xnr2) Repressed Xenopus embryos 
ES tissue cultured cells 
In situ hybridization 
Ectopic expression 
Conditional expression 
Affymetrix gene chips 
Zamparini et al., 2006 
Tg Repressed FRTL-5 tissue cultured cells Transient transfection Pellizzari et al., 2000 
VEGF, VEGFR-1, VEGFR-2, 
TIE-1, TIE-2, neuropilin-1, integrin 
αV 
 
Repressed HUVEC tissue cultured cells 
 
ES tissue cultured cells 
Adenoviral infection 
 
cDNA microarray analysis, 
quantitative real-time RT-
PCR 
Guo et al., 2003 
Kubo et al., 2005 
Nakagawa et al., 2003 




Quantitative real-time RT 
(reverse transcription)–PCR 
OMM16K Gene chip 
microarray 
Cong et al., 2006 
NTCP Activated PRH knockout in E10.5 embryos Transient transfection Denson et al., 2000 
L-PK Activated Hep G2 tissue cultured cells 
HeLa cells 
Rat cultured hepatocytes 
Transient transfection 
Adenoviral infection 
Tanaka et al., 2005 
NIS  Activated HeLa cultured cells Transient transfection Puppin et al., 2006 
 
Key words: Xtle4; xenopus Tle4, Xnr; xenopus nodal-related genes, Tg; thyroglobulin, VEGFR; vascular endothelial growth factor receptor, TIE; tyrosine kinase with 
immunoglobulin-like and EGF-like domains, ESM-1; endothelial cell specific molecule, NTCP;  sodium-dependent bile acid co-transporter, L-PK;  liver pyruvate kinase, 
NIS;  sodium iodide symporter, ES; embryonic stem, FRTL-5; Fischer rat thyroid cell line-5, EOMA;  murine hemangioendothelioma, HUVEC; human umbilical vein 





1.4.2  PRH Structure 
Human PRH protein encoded by HHEX gene, located on human chromosome 10, is 270 
amino acids in length and is detected as a single band with molecular weight of ∼37 kDa 
(Gaston et al., 2016).  Over recent years, success in biophysical analysis have provided 
structural data on PRH which forms highly stable homo-oligomeric complexes (Soufi and 
Jayaraman, 2008). The PRH protein is highly conserved: a comparison between the human 
and avian PRH homeodomain discovered a 97% homology, whereas the human and murine 
PRH homeodomain differ by only a single amino acid (Crompton et al., 1992). In accordance 
with the general structural modularity found in most transcription factors, the PRH monomer 
consist of three functional domains: N-terminal domain, homeodomain, and C-terminal domain 
(FIGURE 1.3).  
 
 
FIGURE 1.3: The domain organization of PRH 
 PRH protein is approximately 270 amino acids in length and contains three domains: N-terminal 
transcription repression domain (left; NT) required for oligomerisation and serves as an interface for 
protein-protein interactions, homeodomain (middle; HD) that facilitates DNA binding and acidic C-
terminal domain that facilitates transcription activation (right; CT). Numbers indicate position of amino 
acid residues. 
 
1.4.3   N-terminal domain of PRH 
The glycine- (10%), alanine- (15%) and proline-(20%) rich N-terminal domain (amino acids 1–
136) possess dimerization ability as discovered via gel filtration chromatography and analytical 
ultracentrifugation (AUC) studies (Soufi et al., 2006). Amongst its unique properties, the N-
terminal dimer is partially resistant to SDS (sodium dodecyl sulphate) denaturation which 
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results in PRH appearing as a protein band at 37 kDa on a Western blot rather than the 
predicted 30 kDa from its amino acid content.  
To further characterise its functional diversity, deletion studies, mutagenesis and pulldown 
assays have been performed and verified that the dimerised N-terminal domain of PRH can 
repress transcriptional activity once tethered onto a heterologous DNA-binding domain. For 
example, formation of the PRH-GAL4 complex can block transcriptional activity (Soufi et al., 
2009). A strong repression domain has been identified between amino acids 45 and 136 in 
the proline-rich N-terminal domain of rat PRH or the domain that lies downstream of amino 
acid 50 in the N-terminus of avian PRH (Guiral et al., 2001; Tanaka et al., 1999). Furthermore, 
the N-terminal domain operates as an interface to a variety of proteins such as the growth 
control protein promyelocytic leukaemic (PML), protein kinase CK2, eukaryotic initiation factor 
4E (eIF-4E), proteosome subunit C8 and family of the Groucho/TLE (transducin-like enhancer) 
co-repressor proteins (Swingler et al., 2004; Topisirovic et al., 2003; Bess et al., 2003; Topcu 
et al., 1999). In support of this notion, it has been demonstrated that the PML interaction 
domain acts as a co-repressor via functional interaction with other transcription factors such 
as special AT-rich binding protein 1 (SATB1) (Bischof et. al., 2007). In vitro and in vivo, the N-
terminal repression domain of PRH can interact with TLE1 via a short sequence situated within 
the N-terminus (amino acids 32–38) that bares reassembly to an Engrailed homology (Eh-1) 
motif. The interaction between TLE1 and PRH is essential for increased transcriptional 
suppression by PRH. In contrast, the repression ability of PRH declines through a Grg5-
mediated titration of endogenous TLE proteins, presumably because Grg5 retains the ability 
to tetramerize with full-length TLE proteins (Wang et al., 2000). Hence, PRH can co-repress 
transcription with TLE proteins (Swingler et al., 2004).  
 
1.4.4   Homeodomain of PRH 
The homeodomain of PRH, comprised of approximately 60 amino acids, mediates sequence-
specific DNA binding. The homeodomain itself consists of an N-terminal arm and three alpha-
helices forming of a helix-turn-helix motif. Of interest, the two N-terminal α-helices are anti-
parallel and lie approximately perpendicular to the third helix (Crompton et al., 1992). The N-
terminal arm and third alpha helix form specific contacts with the base pairs in the minor and 
major groove of the DNA, respectively. With the application of computational modelling, 
glutamine, and asparagine at residues 50 and 51, respectively, have been implicated to have 
a key role in establishing PRH-DNA interactions (Jalili and Karami, 2012). These interactions 
are distinctively important such that a single mutation of asparagine to alanine at position 187 
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within the PRH homeodomain significantly decreases DNA binding activity, thus, rendering 
PRH defective in repression and activation against its direct target genes. The N187A mutant 
has been characterised to have a trans-dominant negative activity over wild type PRH for 
transcriptional repression by sequestration of TLE proteins into sub-nuclear domains 
(Desjobert et al., 2009; Jankovic et al., 2003).  
In the context of VSMC phenotype modulation it is interesting that the interaction between 
PRH homeodomain with serum-response factor (SRF) induced the expression of α smooth 
muscle actin (αSMA) and smooth muscle protein 22α (SM22α) in embryonic fibroblasts 
(Oyama et al., 2004). Activation of the of smooth muscle myosin heavy chain (SMemb/NMHC-
B) gene in VSMCs has also been shown to be homeodomain-dependent (Sekiguchi et al., 
2001). Moreover, forced expression of CREB (CRE (cAMP-response-element)-binding 
protein) upregulated PRH-induced SMemb promoter activity but it is unclear whether PRH 
binds to the PRH-binding domains or to the CRE element within the SMemb promoter 
(Sekiguchi et al., 2001). Thus, this may explain that PRH may regulate transcription of its 
downstream genes via multiple mechanisms. 
 
1.4.5   C-terminal domain of PRH 
The C-terminal domain of PRH also plays a role in regulation of target genes. PRH can 
activate transcription of some genes via association with other transcription factors to act as 
a transcriptional co-activator, rather than direct binding to promoter domains. For instance, 
stimulation of hepatic nuclear factor 1 alpha (HNF-1α) required interaction with the 
homeodomain and C-terminal domain of PRH at the liver pyruvate kinase gene promoter in 
HeLa cells (Tanaka et al., 2005). Similarly, the C-terminal domain is required for the 
transcriptional activation of the sodium-dependent bile acid co-transporter (NTCP) gene. It 
activates transcription using the homeodomain (amino acids 137–196) and the C-terminal 
domain (amino acids 197–271) and deletion studies have demonstrated a C-terminal domain 
encompassing residue 255–271 is of high importance for activating NTCP promoter 
(Kasamatsu et al., 2004). The mechanism by which PRH affects NTCP activation remains to 
be precisely defined although interaction of the homeodomain and C-terminal domain with 
transcription factor TBP (TATA-box-binding protein) is thought to be involved (Kasamatsu et 




1.4.6   PRH Oligomerisation 
Oligomerisation of PRH in cells is facilitated by the interaction between the N-terminal domain 
and PRH homeodomain.  Recombinant PRH has also been reported to be highly aggregated 
and allows for self-association behaviour when examined under electron microscope. PRH 
self-assembles into larger aggregates due to a dimerization domain that corresponds to N-
terminal 50 amino acids and a homeodomain association domain (50-137 residues) (Soufi et 
al., 2006). In vivo cross-linking data have demonstrated the oligomerisation of PRH, and in 
vitro gel filtration chromatography and analytical ultracentrifugation experiments imply 
formation of discrete disc-shaped octameric complexes and more spherical double octamers 
(hexadecamers) in solution (Soufi et al., 2010). In this respect, a monomeric full-length 
recombinant PRH can access a single DNA binding site, however, binding usually occurs with 
low affinity (Soufi et al., 2006). Conversely, oligomeric forms of PRH allow association to DNA 
fragments with a greater binding affinity; the requirement here for multiple binding sites also 
improves specificity (Williams et al. 2008). Additionally, the promoter regions of several genes 
repressed by PRH, e.g., Goosecoid and endothelial cell specific molecule-1 (ESM-1), include 
tandem arrays of consensus and non-consensus PRH binding sites (Cong et al., 2006; 
Zamparini et al., 2006; Brickman et al., 2000).  This indicates that binding of oligomeric PRH 
is assisted by multiple clustered sites, the nature of which determines the relative importance 
of PRH association and the recruitment other PRH‑interacting proteins and to regulate gene 
expression (Jayaraman et al., 2018). 
 
1.5    THE REGULATION OF PRH 
PRH is regulated by Protein Kinase CK2, also termed “casein kinase-2 or casein kinase II” 
which phosphorylates two serine residues in PRH. CK2 is a constitutively active and 
ubiquitously expressed serine/threonine kinase implicated in the regulation of a wide array of 
physiological and pathological processes in cells including proliferation, migration and 
invasion and stress responses (Ahmed, Gerber and Cochet, 2002). CK2 phosphorylates 
protein substrates with a minimal consensus target sequence of Ser/Thr – X – X – 
Asp/Glu/pSer, where X denotes any non-basic amino acid. It appears as a hetero-tetrameric 
enzyme composed of composed of two catalytic and two regulatory β subunits, or in a 
monomeric form. Human CK2 has two well-characterised isoenzymic forms of the catalytic 
subunit, designated as CK2α and CK2α’, and a third one, i.e., CK2α’’ which is less well-
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understood (Maslyk et al., 2017). The regulatory subunit, CK2β, is responsible for the control 
of substrate specificity (Jayaraman et al., 2018).   
Using yeast two hybrid screening, the N-terminal domain (1-98 residues) of both human and 
avian PRH have been identified to interact with CK2β and is a target for phosphorylation by 
the CK2α. It has been implicated PRH/Hhex as a substrate for protein kinase CK2 (Noy et al., 
2012; Soufi et al., 2009).  Attempts for immunoprecipitation of c-myc tagged-PRH from chronic 
myeloid leukaemia K562 cells, followed by separation of proteins by SDS-PAGE and 
identification by mass spectrophotometry revealed three peptides originating from PRH (Soufi 
et al., 2009). Of interest, the slowest migrating and most prominent PRH band was established 
as phosphorylated by staining with Pro-Q Diamond Phosphoprotein Stain. Therefore, PRH 
can exist as a phosphoprotein in cells (Soufi et al., 2009). 
Substantiating these findings further, incubation with CK2 inhibitors 2-dimethylamino-4,5,6,7-
tetrabromo-1H-benzimidazole (DMAT) or 4,5,6,7-tetrabromo-1H-benzotriazole (TBB) 
significantly decreased the amount of hyper-phosphorylated PRH without influencing hypo-
phosphorylated PRH (Noy et al., 2012). Remarkably, surface enhanced laser 
desorption/ionization-time of flight-mass spectrometry (SELDI-TOF-MS) technology facilitated 
the discovery of CK2 phosphorylation sites within PRH using purified, human PRH protein 
incubated with CK2 and adenosine triphosphate (ATP) (Soufi et al., 2009). These findings 
have shown phosphorylation at two sites residing within the homeodomain: S163 (CK2 
consensus target motif) and S177 (non-consensus site) (FIGURE 1.4). Phosphorylation of 
PRH at said sites has been demonstrated to abrogate DNA-binding affinity, impair repression 
of transcription of multiple PRH target genes as well as affect intracellular protein localisation 
and reduce stability (Noy et al., 2012; Soufi et al., 2009). Diminished DNA binding activity 
mediated by CK2 phosphorylation can be restored with calf intestinal alkaline phosphatase. 
Hence, PRH phosphorylation by CK2 is recognised as a reversible switch for DNA binding 
(Soufi et al., 2009). 
Ectopic overexpression of wild-type PRH in K652 cells repressed the targeted transcription of 
VEGF and VEGF receptor 1 (VEGFR-1) and this effect has been shown to be revoked upon 
co-transduction with CK2α and CK2β transgenes (Noy et al., 2012). A mutant PRH protein, 
PRH S163C:S177C (PRH S163C:S177C), was generated for preventing phosphorylation by 
CK2 at these positions (FIGURE 1.4) (Noy et al., 2012). As expected, co-transfection of PRH 
S163C:S177C with CK2α and CK2β transgenes revealed an increase in the repression activity 
of VEGFR-1 transcription; CK2 overexpression was unable to counteract this repression (Noy 
et al., 2012).  In contrast to wild-type PRH, quantitative chromatin immunoprecipitation (ChIP) 
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analysis was carried out to show that binding of PRH S163C:S177C to VEGFR-1 promoter 
cannot be supressed with CK2 overexpression (Noy et al., 2012). 
Phosphorylation by protein kinase CK2 additionally lowers nuclear retention, stability and 
activity of PRH (Noy et al., 2012). In fact, in situ cell fractionation and biochemical fractionation 
confirmed the influence of phosphorylation in regard to the intracellular localisation of PRH 
protein. Firstly, the wild-type PRH and PRH S163C:S177C are observed tightly bound within 
the nuclear fraction, while the phosphomimetic-CC (PRH EE; replacement of serine residues 
with glutamic acid) is present within cytoplasmic and loosely held nuclear fractions (Noy, et 
al., 2012). In addition, the expression of hypo-phosphorylated PRH was prolonged upon 
incubation with an inhibitor of translation, anisomycin in comparison to hyper-phosphorylated 
PRH (Noy et al., 2012). Hyper-phosphorylated PRH stability was enhanced upon incubation 
with proteasome inhibitors such as MG132 and Lactacystin (Noy et al., 2012). Thus, 
phosphorylation of PRH by CK2 leads to proteasome-mediated proteolysis of PRH.  CK2-
dependent phosphorylation of PRH leads to the formation of a stable, truncated product that 
lacks the C-terminal domain, PRHΔC, due to proteasome-mediated protein cleavage (Noy, et 
al., 2012). Interestingly, forced expression of CK2 increases the production of the PRHΔC 
protein which functions as a trans-dominant negative regulator of PRH by sequestering TLE 
proteins (Noy, et al., 2012).  
To summarise, CK2-dependent phosphorylation of Ser163 and Ser177 within the PRH 
homeodomain significantly damages DNA-binding potential, transcriptional regulation, and 
nuclear localisation (Soufi et al., 2009, Noy et al., 2012). Notably, the mutant PRH 
S163C:S177C maintains putative enhanced stability in the presence of CK2 (Noy et al., 2012), 











FIGURE 1.4: Protein Kinase CK2 phosphorylates two serine residues in PRH (S163 and S177) 
SELDI-TOF-MS analysis and mutation studies revealed two protein kinase CK2 phosphorylation sites located within the PRH homeodomain, Ser163 and 
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1.5.1  PRH in cell proliferation and cell survival 
PRH has been implicated in the control of cell proliferation and cell survival via multiple 
mechanisms in different cell types (Gaston et al., 2016; Soufi and Jayaraman, 2008). For 
example, PRH can repress the transformation and growth-promoting effects of elF4E by 
inhibiting the transport of eIF-4E-dependent cyclin d1 transcripts in U937 leukemic cells 
(Topisirovic et al., 2003). In keeping with an inhibitory role of PRH on proliferation, knockdown 
of PRH in K562 cells upregulates vascular endothelial growth factor (VEGF) autocrine 
signalling leading to increased cell survival (Noy et al., 2010).   Additionally, in this study it was 
demonstrated that cessation of expression of Vegf, Vegfr-1, and Vegfr-2 occurred upon 
overexpression of PRH levels in tumourigenic MCF-7 breast cells (Noy et al., 2010). PRH 
deficiency resulted in attenuated proliferation in T- and B-cell progenitors. Similarly, these 
findings correspond to its role as an oncogene in the T-cell lineage situated downstream of 
LIM domain only 2 (LMO2) (Goodings et al., 2015; McCormack et al., 2010). More recently, 
data suggests an anti-proliferative role for PRH in conditional PRH knockout stem and 
progenitor cell populations under conditions of stress haematopoiesis. (Goodings et al., 2015).   
With regards to hepatocyte proliferation, adenovirus mediated PRH overexpression in liver 
cancer cells attenuated hepatocarcinoma growth in a xenograft mouse model (Su et al., 2012). 
Moreover, direct interaction with c-myc indicates PRH functions as a negative regulator of 
hepatocyte proliferation (Marfil et al., 2015). Moreover, binding of PRH to a transmembrane 
protein known to regulate cellular proliferation and motility, CD81, results in sequestration into 
the hepatocyte cytoplasm at hepatocyte proliferation peak thereby downregulates proliferation 
(Bhave et al., 2013). Clearly, PRH presents divergent actions in the control of proliferation in 
multiple cell types. 
 
1.5.2  PRH in cell migration 
To investigate whether loss of PRH activity alters cell migration, atrioventricular explants 
obtained from a null mutation of PRH in Hhex–/– mice were utilised. They revealed an increase 
in the quantity of collagen-invasive cells in the absence of PRH, suggesting a role in migration 
(Hallaq et al., 2004). It has been demonstrated that PRH induces the movement of breast and 
prostate epithelial cells in part via the direct transcriptional regulation of endoglin, since PRH-
dependent decrease in endoglin expression induces migration and enhanced invasion of 
cancerous cells in Matrigel layer (Kershaw et al., 2013).  In addition, overexpression of CK2 
prevents PRH from inhibiting prostate cancer cell motility. This inhibition occurs through 
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phosphorylation of CK2 phosphorylation sites that lie within the PRH homeodomain and 
thereby the anti-migratory and anti-invasive actions of PRH are lost due to CK2-dependent 
phosphorylation and inactivation of PRH (Siddiqui et al., 2017). 
 
1.5.3  PRH in Vascular Development 
Microarray experiments in PRH deficient embryoid bodies have shown upregulated levels of 
vascular endothelial growth factor (VEGF) mRNA which is essential for vascular development 
(Guo et al, 2003). PRH mRNA and protein levels appears to be downregulated throughout the 
differentiation of most haematopoietic lineages (Soufi et al., 2008). Interestingly in human 
umbilical vein endothelial cells (HUVECs), PRH overexpression results in repression of 
angiogenesis-related genes FLT1 (VegfR1), KDR (VegfR2) and VEGF coreceptor neuropilin-
1 gene (Nakagawa et al., 2003). For Vegfr-2, repression occurs via an interaction with the 
transcription factor GATA-2 in endothelial cells (Minami et al., 2004). Studies in vascular 
endothelial cells have also implicated that xenopus PRH overexpression leads to 
disorganization of the vasculature and increases vascular progenitors suggesting PRH could 
possibly stimulate the proliferation of early endothelial progenitors (Newman, Chia and Krieg, 
1997). 
Collectively, these findings suggest PRH as a negative regulator of vascular and 
hematopoietic cellular growth. Analysis to uncover the features contributing to these 
associations revealed PRH is necessary for controlling cell proliferation and differentiation in 
several tissues. 
 
1.6     OVEREXPRESSION OF PRH RETARDS VSMC    
............PROLIFERATION 
In a previous study by Sekiguchi and co-workers, the expression of PRH protein during 
neointimal hyperplasia has been assessed in balloon-injured rat aorta model. It was observed 
that PRH was significantly induced in neointimal VSMCs; although expression was absent in 
normal, healthy aortas. This study also demonstrated that PRH transactivated SMemb/NMHC-
B, known to be a marker of dedifferentiated VSMC synthetic phenotype, thereby facilitating 
neointima formation (Sekiguchi et al., 2001).  
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However, these findings and conclusions are contradicted by a subsequent study in which it 
was demonstrated that PRH is anti-proliferative in VSMCs as observed in other cell types as 
outlined above. Firstly wild-type PRH overexpression in primary cultures of rat aortic VSMCs 
blocked cell cycle progression (Wadey et al., 2017). Secondly, siRNA-induced knockdown of 
PRH stimulated VSMCs proliferation (Wadey et al., 2017). Most remarkably, overexpression 
of PRH S163C:S177C allowed for a prolonged cell cycle arrest for up to 96 h post-
nucleofection compared to wild-type PRH which is stable for up to 24 h post-nucleofection 
(Wadey et al., 2017). 
It was previously stated that CK2-dependent phosphorylation of PRH lowers DNA-binding 
potential, transcriptional regulation, and nuclear localisation of PRH (Noy et al., 2012). 
Knockdown of CK2α and α’ catalytic subunits retarded VSMC proliferation (Wadey et al., 
2017). Correspondingly, pharmacological inhibition of CK2 using the synthetic inhibitor K66 
(1-carboxymethyl-2-dimethylamino-4,5,6,7-tetrabromo-benzimidazole), significantly hindered 
VSMC proliferation in vitro.  To ascertain that the effects of CK2 were mediated at least in part 
by PRH, CK2 was inhibited in either control VSMC or VSMC with depleted PRH. Results 
demonstrated that inhibition of CK2 showed an anti-proliferative action only in cells expressing 
PRH (Wadey et al., 2017). 
 
1.7     OVEREXPRESSION OF PRH RETARDS NEOINTIMA     
.............FORMATION EX VIVO  
Since PRH retarded VSMC proliferation it was assessed whether PRH had the capacity to 
attenuate neointima formation. Adenovirus-mediated gene delivery of PRH S163C:S177C 
impaired intimal thickening and VSMC proliferation in segments of human saphenous vein 
(Wadey et al., 2017). Quantification of bromodeoxyuridine (BrdU) incorporation exhibited clear 
depletion in neointimal and medial proliferation compared to the controls. Moreover, scratch 
wound assays and cleaved caspase-3 immunocytochemistry revealed that PRH 
S163C:S177C intervention did not influence migratory and apoptotic state respectively in 
primary cultures of rat aortic VSMCs (Wadey et al., 2017). These findings suggested that 
overexpression of PRH S163C:S177C may be beneficial for reducing intimal thickening and 
incidences of SVGF via inhibition of VSMC proliferation. 
However, it is important that strategies to reduce VSMC proliferation do not have a detrimental 
effect on endothelial coverage of the saphenous vein graft. Endeavours to preserve 
endothelial cell integrity and function must be considered when identifying new targets for 
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therapeutic intervention. In cultured endothelial cells, human umbilical vein endothelial cells 
(HUVECs) and human saphenous vein endothelial cells (HSVECs), inhibition of CK2 activity 
using K66 antagonised cell cycle progression by only ~25% but did not influence cell migration 
and apoptotic rate (Wadey et al., 2017). With regards to PRH overexpression, via jet-PEI-
HUVEC-mediated transfection or adenovirus-mediated delivery, no significant effect on either 
the proliferative, apoptotic and migratory rate of cultured endothelial cells was observed 
(Wadey et al., 2017). 
In summary, these data indicate CK2-dependent phosphorylation as a potent mediator of PRH 
inactivation and a potential mechanism for the regulation of cell proliferation. Recent work is 
consistent with this hypothesis and highlights the anti-proliferative properties of non-
phosphorylatable PRH S163C:S177C mutant in VSMCs and could thereby abrogate 


















1.8    JUSTIFICATION OF RESEARCH 
Bypass surgery is extremely beneficial in the short-term, however long-term success is 
reduced by vein graft failure. In particular, intimal thickening and resultant superimposed 
atherosclerosis remains a clinical concern. Considering the considerable burden of 
cardiovascular diseases and wide use of SVG, there is a pressing unmet need to discover 
therapeutic whether over-expression PRH S163C:S177C can effectively retard smooth 
muscle proliferation and migration and intimal thickening without damaging endothelial 
function has been investigated.  
 
1.9    HYPOTHESIS 
It is hypothesised that local overexpression of PRH protein with enhanced stability could be 
advantageous to prevent the development of intimal thickening without impairing endothelial 
function. Furthermore, it is hypothesised that the identification of PRH target genes in VSMCs 














1.10   EXPERIMENTAL AIMS 
 
1. To determine the effect of overexpression of non-phosphorylatable PRH S163C:S177C 
on human SV (HSV) EC and VSMC proliferation, migration and apoptosis in vitro. 
2. To determine the effect of overexpression of non-phosphorylatable PRH S163C:S177C 
on phenotypic switching in HSV VSMCs in vitro. 
3. To determine the effect of overexpression of non-phosphorylatable PRH S163C:S177C 
on vascular inflammation in HSV ECs in vitro. 
4. To compare PRH target genes in HSV VSMCs and ECs and thereby identify genes that 
specifically repress VSMC proliferation. 
5. To validate PRH target genes repress HSV VSMC proliferation in vitro. 
6. To determine the effect of overexpression of non-phosphorylatable PRH S163C:S177C 













2.   MATERIALS AND METHODS 
2.1   MATERIALS 
Laboratory reagents were purchased from Sigma Aldrich unless specified otherwise in the 
text. All reagents purchased were of the highest possible quality and purity. 
 
2.1.1  Tissue Culture Media 
Table 2.1 The composition of media for culture of human saphenous vein VSMCs 
 
Table 2.2 The composition of media for culture of human saphenous vein ECs 
 
2% (v/v) Foetal Bovine 
Serum (FBS)/Serum-
Free Endothelial Cell 
Growth Medium 
 
Endothelial Cell Basal Medium (catalogue number: C-22210) 
were purchased from Promocell. Penicillin and streptomycin 
(PAA Laboratories; catalogue number: P11-010) and Foetal 




Endothelial Cell Growth 
Medium 
Endothelial Cell Growth Medium Kit (catalogue number: C-
22010), Endothelial Cell Growth Supplement (ECGS: catalogue 
number: C-22010, includes bovine hypothalamic extract, but 
contains basic Fibroblast Growth Factor, Insulin-like Growth 
Factor (Long R3 IGF-1), and Vascular Endothelial Growth 
Factor. Endothelial Cell Basal Medium (catalogue number: C-
22210) were purchased from Promocell. Penicillin and 






10% (v/v) Foetal Bovine 
Serum (FBS)/DMEM 
 
Dulbecco's Modified Eagle's Medium (DMEM: 1.0g/L glucose, 
without L-glutamine; catalogue number: E15-005) and DPBS 
(Ca2+ and Mg2+ free; catalogue number: D8537) were 
purchased from GE Healthcare and Sigma, respectively. Foetal 
bovine serum (FBS) gold (catalogue number: A15-151), L-
glutamine (catalogue number: M11-004), penicillin and 
streptomycin (catalogue number: P11-010), and gentamicin 
(catalogue number: P11-004) were acquired from PAA 
Laboratories.   
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Table 2.3 The composition of media for culture of human saphenous vein VSMCs 
 
 
2.1.2  Immunochemical Reagents 
The immunochemical reagents utilised in the experiments outlined in this thesis are listed in 





Roswell Park Memorial Institue-1640 medium (RPMI-1640 
buffered with 25mM HEPES; catalogue number: 42401018) 
was used purchased from Gibco. Other tissue culture reagents 
included:  10% (v/v) heat-inactivated FBS (Gibco; catalogue 
number: 10082147), 2mM L-glutamine (PAA Laboratories; 
catalogue number: M11-004), and 100μg/mL penicillin and 




Table 2.4: Primary Antibodies used for Western Blotting 
Antibodies were diluted in 1% (w/v) bovine serum albumin (BSA) / phosphate buffered saline (PBS), 5% (w/v) 
BSA/PBS, 5% (w/v) BSA/ tris-buffered saline (TBS), 5% (w/v) BSA/ tris-buffered saline-tween (TBS-T) or 5% (w/v) 
skimmed milk powder in TBS-T (5% milk/TBS-T) depending on manufacturer’s instructions or in-house 
optimisation. 



















Anti-HDAC-9 Rabbit 1:500 5% (w/v) 
BSA/TBS-T 
0.5μg/mL Abcam Ab239979 
Anti-ICAM-1 Rabbit 1:2000 5% (w/v) 
BSA/TBS 
0.3μg/mL Abcam Ab53013 















Anti-VCAM-1 Rabbit 1:1000 5% (w/v) 
BSA/TBS-T 
0.44μg/mL Abcam Ab134047 
Abbreviations. HRP: Horseradish Peroxidase; ICAM-1: Intercellular Adhesion Molecule 1; HDAC-9: Histone 
Deacetylase 9; STAT-1: Signal Transducer And Activator Of Transcription 1; VCAM-1: Vascular cell adhesion 
protein  
 
Table 2.5: Secondary Antibodies used for Western Blotting 
Antibodies were diluted in PBS, 5% (w/v) BSA/TBS-T or 5% milk/TBS-T depending on manufacturer’s instructions 
or in-house optimisation. 
Antibody Host 
Species 







WB: 1:2000  










WB: 1:2000  









WB: 1:5000  









WB: 1:2000  









Table 2.6: Primary Antibodies used for Immunocytochemistry, Immunohistochemistry and 
Immunofluorescence 
Abbreviations. HRP: Horseradish Peroxidase; ICC: Immunocytochemistry; IF: Immunofluorescence; IHC: 
Immunohistochemistry; BrdU: 5-bromo-2'-deoxyuridine; CD31: Cluster of Differentiation 31; HDAC-9: Histone 
Deacetylase 9; STAT-1: Signal Transducer And Activator Of Transcription 1. 
 
Table 2.7: Secondary and Tertiary Antibodies used for Immunocytochemistry, Immunohistochemistry and 
Immunofluorescence 
Abbreviations. HRP:  Horseradish Peroxidase; IgG: Immunoglobulin-G. 











R & D systems 
 
AF835 
Anti-Myc Tag Mouse ICC: 4μg/mL Millipore 16244 
Anti-α Smooth 








































































Antibody Company Catalogue Number 
AlexaFluor-488 goat anti-rabbit IgG Invitrogen A11008 
DyLight-488 goat anti-rabbit IgG Vector D1-1488 
Biotinylated goat anti-mouse IgG Vector BA-9200 
Biotinylated goat anti-rabbit IgG Sigma Aldrich B7389 
Dylight-488 Streptavidin Vector SA-5488 
ExtrAvidin-peroxidase Sigma Aldrich E2886 
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2.1.3  Details of Suppliers 
The location and website details of suppliers of laboratory reagents and equipment are 
summarised in Table 2.8. 
Table 2.8: Contact details of suppliers from which Immunochemical Reagents were acquired 
Company Location Website 
2B Scientific Upper Heyford, UK 2bscientific.com 
Abcam Cambridge, UK www.abcam.com 
Addgene Middlesex, UK www.addgene.org 
Bio-Rad Hertfordshire, UK www.bio-rad.com 
Cell Signalling Technologies Hertfordshire, UK www.cellsignal.com 
Dako Cambridgeshire, UK www.dako.com 
Enzo Life Sciences Exeter, UK www.enzolifesciences.com 
GE Healthcare 
(including PAA) 
Buckinghamshire, UK www.gehealthcare.com 
Geneflow Staffordshire, UK www.geneflow.co.uk 
Generon Slough, UK www.generon.co.uk 
Life Technologies 
(including Ambion, Applied Biosystems, 
Gibco, Invitrogen, Molecular Probes) 
Paisley, UK www.lifetechnologies.com 
Merck Millipore 
(including Calbiochem) 
Hertfordshire, UK www.merckmillipore.com 
Qiagen Manchester, UK www.qiagen.com 
R&D Systems Oxfordshire, UK www.rndsystems.com 
Sigma Aldrich Dorset, UK www.sigmaaldrich.com 
Roche West Sussex, UK www.roche.com 
Stratech Cambridge, UK https://stratech.co.uk/ 
Thermo Fisher Scientific Massachusetts, USA www.thermoscientific.com 
Vector Laboratories Peterborough, UK www.vectorlabs.com 





2.1.4  Adenoviruses 
In this study, replication-defective adenovirus (Ad) based on the adenovirus type-5 vector were 
used. The recombinant adenoviral constructs were depleted of ΔE1E3 by site-specific FLP-
mediated recombination and create replication incompetence. The empty adenoviral vector 
lacking a transgene (Ad: Control) and c-myc-tagged S163C:S177C mutant PRH (Ad: PRH 
S163C:S177C) were prepared using the shuttle vector pDC 515 (Microbix Biosystems; 
catalogue number) by Dr. Graciela Sala-Newby and Tom Hathaway (University of Bristol). 
Plaque-pure viruses were propagated on HEK293 cells, purified by caesium chloride density 
gradient centrifugation and the number of plaques forming units (pfu) per ml was titred using 
the end-point dilution assay (Anderson et al., 2000). All Ad: PRH S163C:S177C preparations 
were tested for transgene production using Western blotting, lack of toxicity and ability to 
inhibit VSMC proliferation as previously reported (Wadey et al., 2017) in isolated VSMCs in 
vitro. Adenoviral stocks were stored at -70°C in aliquots and thawed immediately before use. 
 
2.1.5  Infection of cultured cells with adenoviruses 
Cells were infected with Ad: PRH S163C:S177C diluted in the cell type specific culture medium 
to a final concentration of at 5 x 108 pfu/ml in VSMCs, and a combined dose of 4 x 108 pfu/ml 
Ad: Control and 1 x 108 pfu/ml in HSVECs. The controls for both cell types were cells infected 
with 5 x 108 pfu/ml of Ad: Control or uninfected cells (media alone). Cell culture medium was 
refreshed 18 h after infection. 
 
2.2   METHODS: CULTURE OF HSV VSMCs 
2.2.1  Isolation and primary culture of HSV VSMCs 
With Research Ethical Committee approval (number 04/Q2007/6), human saphenous vein 
(HSV) VSMCs were isolated using a medial explant method. Briefly, segments of human 
saphenous veins, obtained from patients undergoing coronary artery bypass surgery, were 
collected in 10% (v/v) FBS/DMEM. Prior to dissection of veins immersed in 10% (v/v) 
FBS/DMEM in a glass petri dish with set Sylgard resin, the cannulae were removed by cutting 
the vein segment at the end of the cannula with micro-scissors. Veins were cut longitudinally 
and pinned using 23-gauge syringe needles to the resin endothelium uppermost. Removal of 
the endothelial layer was performed by rubbing the endothelial surface with firm pressure 
using the insert of a 1ml syringe. The medial layer was isolated from the adventitia using a 
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scalpel and forceps, then cut into approximately 2mm x 2mm explants. The explants were 
transferred into T25 tissue culture flasks and allowed to adhere onto the growth surface of the 
flasks for 30 minutes. Then, explants were covered with 10% (v/v) FBS/DMEM and incubated 
at 37°C and 5% CO2. Fresh VSMC culture media was provided on a weekly basis until the 
VSMCs reached confluency.  
 
2.2.2  Cell Passage of VSMCs 
Cell passage by trypsin digestion was performed on fully confluent cell culture flasks for further 
propagation of primary VSMCs. VSMCs were briefly washed with Dulbecco’s phosphate-
buffered saline (DPBS: Ca2+ and Mg2+ free; company; catalogue number: D8537) before 
incubation with 0.05% (w/v) trypsin-ethylene diamine tetraacetic acid (EDTA: PAA 
Laboratories; catalogue number: L11-003) at 37°C for 4 minutes. After incubation, VSMCs 
were checked under a microscope to ensure the detachment of adherent cells from the culture 
flask. Subsequently, trypsin was quenched with an equal volume of 10% (v/v) FBS/DMEM to 
neutralise trypsin activity. For gentle mechanical removal, adherent VSMCs were scraped 
from the flask using a cell scraper. VSMCs were then centrifuged at 433g for 5 minutes. The 
supernatant was removed, and the cell pellet re-suspended in 1ml 10% (v/v) FBS/DMEM. 
Cells were then re-cultured in a larger flask or split into two flasks containing VSMC culture 
medium and incubated at 37°C and 5% CO2. VSMC culture medium was routinely changed 
once a week to optimize growth. All experiments were performed with VSMCs between 
passages 2 and 8. 
 
2.2.3  Cell Freezing 
Confluent VSMCs were detached from cell culture flasks with 0.05% (w/v) Trypsin-EDTA as 
described above and centrifuged at 433g for 5 minutes. Supernatant was discarded and the 
cell pellet re-suspended in fresh VSMC culture medium supplemented with 10% (v/v) dimethyl 
sulfoxide (DMSO). The cell suspension was quickly transferred to a sterile cryovial and frozen 
to -80°C in a freezing chamber overnight to enable 1°C decrease per minute, then moved to 






2.2.4  Cell Counting  
Cells in suspension were counted using a cover-slipped Neubauer haemocytometer. The 
following formula was employed to calculate cell density: 
Average cell count per 1mm2 = Number of cells per mL x 104 
 
2.2.5  Revival of frozen HSV VSMCs  
HSV VSMCs were thawed rapidly by holding a vial of cells under running hot water. The vial 
contents were transferred to a centrifuge tube containing 9 mL of pre-warmed VSMC culture 
medium and centrifuged at 433g for 5 minutes. The cell pellet was resuspended in 1 mL of 
pre-warmed VSMC culture medium and added to an appropriate culture flask already 
containing 10-12 mL pre-warmed VSMC culture growth medium and incubated at 37°C and 
5% CO2. 
 
2.3   METHODS: CULTURE OF HSVECs 
2.3.1  Culture of HSVECs 
Primary human saphenous vein endothelial cells (HSVECs, Promocell; catalogue number: C-
12231 and Stratech; catalogue number: HEC18) were obtained from single donors. HSVECs 
were cultured in endothelial cell growth medium and incubated at 37°C and 5% CO2. The 
experiments were performed with cells at passage 3-6.  
 
2.3.2  Cell Passage 
Cell passage by trypsin digestion was performed on fully confluent cell culture flasks for further 
propagation of primary HSVECs. HSVECs were briefly washed with DPBS before incubation 
with 0.05% (w/v) Trypsin-EDTA at 37°C for 1-2 minutes. After incubation, HSVECs were 
checked under a microscope to ensure detachment of adherent cells from the culture flask. 
Subsequently, trypsin was quenched with an equal volume of endothelial cell growth medium 
to neutralise trypsin activity. For gentle mechanical removal, adherent cells were scraped from 
the flask using a cell scraper. HSVECs were then centrifuged at 330 g for 4 minutes as 
recommended by the manufacturer’s instructions. The supernatant was removed, and the cell 
pellet re-suspended in 1ml endothelial cell growth medium. HSVECs were then re-cultured in 
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a larger flask or split into two flasks containing endothelial cell culture media and incubated at 
37°C and 5% CO2. Endothelial cell culture media was routinely changed once every 2-3 days 
to optimize growth. All experiments were performed with ECs between passage 3 and 6. 
 
2.3.3  Cell Freezing 
Confluent cells were detached from cell culture flasks with 0.05% (w/v) Trypsin-EDTA as 
described above and centrifuged at 330 g for 4 minutes. Supernatant was discarded and the 
cell pellet re-suspended in fresh endothelial cell culture media supplemented with 10% (v/v) 
DMSO. The cell suspension was quickly transferred to a sterile cryovial, frozen to -80°C in a 
freezing chamber overnight, then moved to liquid nitrogen for long-term storage. 
 
2.3.4  Cell Counting  
HSVECs in suspension were counted using a cover-slipped Neubauer haemocytometer. The 
following formula was employed to calculate cell density: 
Average cell count per 1mm2 = Number of cells per mL x 104 
 
2.3.5  Revival of frozen HSVECs 
HSVECs were thawed rapidly by holding a vial of cells under running hot water. The vial 
contents were transferred to a centrifuge tube containing 9 mL of pre-warmed endothelial cell 
growth medium and centrifuged at 330 g for 4 minutes. The cell pellet was resuspended in 1 
mL of pre-warmed endothelial cell growth medium and added to an appropriate culture flask 
already containing 10-12 mL pre-warmed endothelial cell growth medium and incubated at 
37°C and 5% CO2. 
 
2.4   METHODS: CULTURE OF THP-1 CELLS 
2.4.1  Culture of THP-1 cells 
THP-1 human monocytic-like cells obtained from THP-1 ATCC® TIB-202™ (lgcstandards-
atcc.org) were cultured in suspension in RPMI medium. THP-1 cells were incubated at 37°C 
and 5% CO2.  
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2.4.2  Cell Passage 
For sub-culturing, every 3 to 4 days, cell density was assessed by cell counting and a density 
above 1 × 106 cells/mL was prevented. Briefly, any loosely adhered cells were dislodged using 
a cell scraper and the cell suspension was centrifuged at 300 g for 5 minutes, the supernatant 
was discarded, and cell-pellet re-suspended in 1 mL pre-warmed RPMI medium, a further 14 
mL was added to the cell suspension, prior to cell counting as described in 2.2.4 and 2.3.4. 
Cells were then seeded into flasks containing 20 mL of pre-warmed RPMI at a density of 1 × 
105 cells/mL. 
 
2.4.3  Cell Freezing  
For cryopreservation, cells were sub-cultured as described in 2.4.2 and resuspended at a 
density of 1 × 105 cells/mL in 1 mL 10% (v/v) DMSO in RPMI medium. The cell suspension 
was quickly transferred to a sterile cryovial, frozen to -80°C in a freezing chamber overnight, 
then moved to liquid nitrogen for long-term storage. 
 
2.4.4  Cell Counting  
Cells in suspension were counted using a cover-slipped Neubauer haemocytometer. The 
following formula was employed to calculate cell density: 
Average cell count per 1mm2 = Number of cells per mL x 104 
 
2.4.5  Revival of frozen THP-1 CELLS  
For resuscitation, THP-1 cells were thawed rapidly by holding a vial of cells under running hot 
water. The vial contents were transferred into 20-25 mL pre-warmed RPMI medium in a T175 
flasks and incubated at 37°C and 5% CO2. RPMI medium was replaced on a weekly basis. 
 
2.5   METHODS: WESTERN BLOTTING 
2.5.1.  Protein Extraction 
Cells were washed twice with DPBS and then sodium dodecyl sulphate (SDS) lysis buffer (50 
mM Tris-HCl (pH 8), 10% (v/v) glycerol, 5% (w/v) SDS) added. Wells were scraped with the 
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insert of a 1 mL syringe and lysates transferred to eppendorf tubes. Samples were kept on ice 
until protein quantification or stored at -80°C. 
 
2.5.2  Protein Quantification 
The protein concentrations of cell lysates were determined using the Micro Bicinchoninic Acid 
(BCA) Assay Kit (Thermo Scientific; catalogue number: 23235). In a 96-well plate, 1 μL of cell 
lysate was diluted in 140 μL of HPLC water. The protein concentration of cell lysates was 
determined in duplicate wells by reference to a standard curve consisting of known 
concentrations of BSA: 0, 0.1, 0.25, 0.5, 1.0, 2.5, 5.0 and 10 μg/mL. Prior to incubation at 37°C 
for 30-60 minutes, 150μl of Micro BCA reagent (reagents A: B: C in a ratio of 25:24:1) was 
added to each well. Absorbance of each well was read at 560 nm wavelength using the 
GloMax® Explorer Multimode Microplate Reader (Promega; catalogue number: GM3500). 
 
2.5.3  Gel Electrophoresis 
To immunologically detect specific proteins, cell lysates were first separated by size using 
SDS–polyacrylamide gel electrophoresis (PAGE). Cell lysates were prepared by adding HPLC 
water to ensure equal protein concentration and volume. One volume Laemmli Sample Buffer 
(Bio-Rad; catalogue number: 161-0737) with 5% (v/v) β-mercaptoethanol was added to each 
of the samples, followed by heating to 95°C for 5 minutes. 5 μL of BLUeye Prestained Protein 
Ladder (Geneflow; catalogue number: S6-0024) with 5% (v/v) β-mercaptoethanol was also 
heated to 95°C for 5 minutes and served as a molecular weight marker. Samples and marker 
were electrophoresed on a 4-12% Mini-PROTEAN TGX Gels (Bio-Rad; catalogue number: 
456-1084) using 1X Tris/Glycine/SDS (TGS) running buffer (Bio-Rad; catalogue number: 161-
0772) and 300 V for 15-20 minutes. 
 
2.5.4  Stain-free Gel 
Stain-free technology allows for immediate visualisation of proteins following electrophoresis 
and normalisation of bands to total protein (refer to http://www.bio-rad.com/en-
uk/product/mini-protean-precast-gels/mini-protean-tgx-stain-free-precast-gels for more 
details). Immediately after electrophoresis, the gel was removed from the cassette and placed 
directly into the ChemiDoc MP System (Bio-Rad; catalogue number: 170-8280).  To acquire 
a stain-free gel image, 1 minute UV activation provided adequate signal intensity. 
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2.5.5  Protein Transfer 
Following protein separation by SDS-PAGE and stain-free imaging, gels were transferred to 
Trans-Blot Mini Nitrocellulose Membranes (Bio-Rad; catalogue numbers: 170-4158 and 170-
4159, respectively) using the Trans-Blot Turbo Transfer Starter System (Bio-Rad; catalogue 
number: 170-4155) for fast and efficient electrophoretic protein transfer, following the 
manufacturer’s instructions. 
 
2.5.6  Antibody Labelling 
To reduce non-specific binding, nitrocellulose membranes were placed in blocking solution 
consisting of 5% (w/v) fat-free milk powder diluted in TBS-T (20mM Tris, 137mM NaCl, 0.1% 
(v/v) Tween 20; pH 7.6) for 30 minutes at room temperature (RT). The membranes were 
incubated with diluted primary antibodies detailed in Table 2.1, overnight at 4°C. Following 
incubation, the nitrocellulose membranes were washed with TBS-T for 5, 10 and 20 minutes 
prior to incubation in diluted horseradish peroxidase (HRP)-labelled secondary antibodies 
detailed in Table 2.2 for 1 hour at RT.  Following three more washes with TBS-T for 5, 10 and 
20 minutes, membranes were incubated with Luminata Forte Western HRP substrate (Merck 
Millipore; catalogue number: WBLUF0100) for 1 minute to detect bound antibodies. Finally, 
the luminescence was detected using the ChemiDoc MP System (Bio-Rad, 170-8280) with 1 
minute length of exposure to avoid saturation of bands.   
 
2.5.7  Densitometry 
Quantification of the density of the detected protein band was performed using Image Lab 
Software (Bio-Rad, 170-8280). Optical density was expressed in units of mm2 (OD x mm2) and 
normalised to the most prominent stain-free band in the same MW range for the sample. 
 
2.6   METHODS: IMMUNOASSAYS 
For ELISA assays, primary HSVECs conditioned media was collected and was either stored 
at -80oC or analysed immediately. Quantikine ELISA (enzyme-linked immunosorbent assay) 
kits were used to detect the following pro-inflammatory mediators: human IL-6 Quantikine 
ELISA Kit (R&D Systems; catalogue number: D6050), human IL-8 Quantikine ELISA Kit (R&D 
Systems; catalogue number: D8000C) and human CCL2/MCP-1 Quantikine ELISA Kit (R&D 
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Systems; catalogue number: DCP00). Conditioned media was diluted with Calibrator Diluent 
RD6Q to ensure detection within the linear range of the standard curve. 50 μL of Assay Diluent 
RD1-83 was added to each well. Then, 200μl of standard, sample or control was added per 
well followed by sealing the plate with the adhesive strip and incubation for 2 hours at RT.  
Each well was aspirated and washed using 400 μL Wash Buffer repeating the process twice 
for a total of three washes. To ensure complete removal of liquids, the ELISA plate was 
inverted and blotted against clean paper towel. Subsequently, 200 μL of human IL-6, IL-8 or 
MCP-1 Conjugate was added to each well. The plate was covered by an adhesive strip 
followed by incubated for 1 hour at RT. Wells were aspirated and washed with 400 μL Wash 
buffer three times. Subsequently, 200 μL of Substrate Solution was added to each well 
followed by a 30-minute incubation at RT protected from the light. This was followed by the 
addition of 50 μL of Stop Solution to each well to encourage a colour change from blue to 
yellow. To ensure thorough mixing the plate was tapped. The absorbance of each well was 
determined at 450 nm wavelength using a GloMax® Explorer Multimode Microplate Reader 
within 30 minutes. The concentration of the detected protein was calculated by the average of 
duplicate readings for each standard, control, and sample and subtract the average zero 
standard absorbance. 
 
2.7   METHODS: IMMUNOCYTOCHEMISTRY 
2.7.1  Immunocytochemistry for c-myc tagged PRH 
Primary HSVECs or HSV VSMCs (2 x 104 cells) were seeded on glass coverslips in a 24-well 
plate. Cells were washed twice in PBS prior to fixation in 250 μL of 3% (w/v) 
paraformaldehyde/PBS (PFA/PBS) for 10 minutes. Cells were rinsed once with PBS and 
permeabilised with three 5-minute washes in 500 μL of 0.2% (v/v) Triton X-100/PBS, then 
rinsed twice with PBS and blocked in 250 μL of 20% (v/v) goat serum/PBS for 30 minutes at 
RT. Cells were washed again with PBS followed by incubation with 4 mg/mL of anti-c-myc-tag 
antibody, clone 4A6, Alexa Fluor 488 Conjugate (Millipore; catalogue number: 16-244) diluted 
in 5% (w/v) BSA/PBS, overnight at 4°C. 4 μg/mL of non-immune mouse IgG diluted in 5% 
(w/v) BSA/PBS was used as a negative control. Following three PBS washes, cells were 
mounted with Prolong Gold Antifade Reagent with 4’,6-diamidino-2-phenylindole (DAPI) 
(Molecular Probes; catalogue number: P36931), then stored at 4°C in the dark until 
visualisation using fluorescence microscopy. 
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The cells were imaged using an Olympus BX41 microscope and Q-capture pro 6.0 software. 
Cells with nuclear and cytoplasmic c-myc-tagged staining (green) were identified as positive. 
Cells without distinct green staining were denoted as negative. Overall, 20 images were taken 
in 20x magnification to represent approximately 200-400 cells per condition. The number of c-
myc-tag-positive cells was expressed as a percentage of the total number of cells counted.  
 
2.7.2  Immunocytochemistry for EdU - Proliferation Assay 
Proliferative cells were identified using the Click-iT 5-ethynyl-2'-deoxyuridine (EdU) Alexa 
Fluor 488 Imaging Kit (Invitrogen; catalogue number: C10337). Unlike traditional cell 
proliferation assays, the Click‑iT® Plus EdU proliferation assay does not rely on radioactivity 
or antibodies for detection of the newly incorporated deoxyribonucleoside. Primary HSVECs 
or HSV VSMCs were seeded at 2 x 104 in 24-well plates with an appropriate cell growth 
medium supplemented with 10 μM EdU. Cells were washed twice in PBS and then fixed with 
250 μL of 3% (w/v) PFA/PBS for 15 minutes. Following a single wash in PBS, cells were 
incubated in 500 μL of 0.5% (v/v) Triton X-100/PBS to permeabilise the cells for 20 minutes 
prior to rinsing twice in 3% (w/v) BSA/PBS. The Click-iT reaction cocktail was prepared as 
stated in the Click-iT handbook such that the final Click-iT reaction cocktail contained 758 μL 
deionised water, 100 μL reaction buffer, 40 μL catalyst solution, 2 μL Alexa Fluor azide and 
100 μL buffer additive, all prepared in the said order for optimal performance. 250 μL of Click-
iT reaction cocktail was added to cells within 15 minutes of preparation and incubated for 30 
minutes at RT, protected from day light. Cells were washed thrice in PBS. To stain nuclei, cells 
were mounted with Prolong Gold Antifade Reagent with DAPI (Molecular Probes; catalogue 
number: P36931), then stored at 4°C in the dark until visualisation using a fluorescent 
microscope. 
The cells were imaged using an Olympus BX41 microscope and Q-capture pro 6.0 software. 
EdU-positive cells were identified as those with green-coloured nuclei whereas negative cells 
were those with only blue-coloured (DAPI) nuclei. To determine the proliferative rate per 
condition, the percentage of EdU-positive cells was calculated.  Overall, 20 images were taken 
in 20x magnification to represent approximately 200-400 cells per condition. The number of 





2.7.3 Immunocytochemistry for Cleaved Caspase-3 -   
Apoptosis Assay  
Primary HSVECs or HSV VSMCs at a cell seeding density of 2 x 104 were seeded in 24-well 
plates. As a positive control, cells were incubated with 200 ng/mL human recombinant Fas-
ligand (Enzo Life Sciences; catalogue number: ALX-522-020-C005) to induce apoptosis. Cells 
were washed twice in PBS and then fixed in 250 μL of 3% (w/v) PFA/PBS for 15 minutes. 
Following a single wash in PBS, cells were permeabilised with three 5-minute washes in 500 
μL of 0.2% (v/v) Triton X-100/PBS then rinsed twice with PBS and blocked in 250 μL of 20% 
(v/v) goat serum/PBS for 30 minutes at RT. Cells were washed once with PBS and incubated 
with 250 μL of 1 mg/mL rabbit anti-cleaved caspase-3 antibody (R & D systems; Catalogue 
number: MAB835) diluted in 1% (w/v) BSA/PBS, overnight at 4°C. Following three PBS 
washes, cells were incubated with 250 μL of biotinylated goat-anti-rabbit (Sigma; Catalogue 
number: B7389) diluted 1:200 in PBS for 1 hour at RT. Following another two PBS washes, 
cells were incubated with 250 μL of Streptavidin-488 antibody (Vector Laboratories; catalogue 
numbers: SA-5488-1) diluted 1:200 in PBS for 1 hour at RT, protected from day light. Following 
two washes with PBS, cells were mounted with Prolong Gold Antifade Reagent with DAPI 
(Molecular Probes; catalogue number: P36931), then stored at 4°C in the dark until 
visualisation using fluorescence microscopy. 
The cells were imaged using an Olympus BX41 microscope and Q-capture pro 6.0 software. 
Cells with nuclear cleaved caspase-3 (green) were identified as apoptotic. All nuclei were 
stained blue with DAPI. To determine the apoptotic rate per condition, the percentage of 
cleaved caspase-3 positive cells was calculated. Overall, 20 images were taken in 20x 
magnification to represent approximately 200-400 cells per condition. The number of cleaved 
caspase-3 positive cells was expressed as a percentage of the total number of cells counted. 
 
2.8   METHODS: MIGRATION ASSAY 
Cell migration was analysed by measuring the decrease in wound size 24 hours after 
scratching a wound on the monolayer of cells. Firstly, primary HSVECs (4x104 cells) or HSV 
VSMCs (4x104 cells) were seeded on fibronectin-coated glass coverslips in a 24-well plate 
and cultured in the appropriate cell growth medium. Following infection with the adenovirus 
for 18 hours, wells were washed twice in PBS and then the confluent cells were scratched 
using a 1 mL pipette tip to create two parallel straight lines, simulating a wound. Cells were 
washed once with PBS to remove debris, then treated with 2 mM hydroxyurea to prevent cell 
proliferation. Using the EVOS FL Color Imaging System (Thermo Fisher Scientific; Catalogue 
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number: AMEFC4300) with a 10x objective lens, images of the wound edges were taken 
immediately after wounding and 24 hours post incubation at 37°C in 5% CO2. 
Four fields were photographed per condition and five measurements taken per field at each 
time point. Migration was quantified and expressed as the distance migrated in pixels between 
0 and 24 hours. 
 
2.9   METHODS: MONOCYTE ADHESION ASSAY 
2.9.1  Monocyte Adhesion Assay: Static Condition 
Monocyte adherence to an endothelial monolayer was assessed using THP-1 monocytes 
under static conditions. HSVECs (2 x 104 cells) were seeded in wells of 24-well plates and 
grown to confluency. Following infection with the adenovirus for 18 hours, wells were washed 
twice in PBS. Then, cells were incubated with 10ng/ml recombinant human Tumor Necrosis 
Factor α (TNFα) (PromoKine; Catalogue number: C-63721) in 2% (v/v) FBS endothelium cell 
medium for 24 hours. After 24 hours, THP-1 cells were fluorescence-labelled with 100 μM 
calcein-AM by incubation for 30 minutes at 37°C amd 5% CO2.  Then, 2 x 104 calcein-labelled 
THP-1 monocytes were added to each well of confluent HSVECs and then co-incubated for 1 
hr at 37°C adn 5% CO2 in 2% (v/v) FBS endothelium cell medium. Non-adherent cells were 
then removed by washing wells twice with PBS. Ten fields were photographed per condition. 
Adhered THP-1 cells (green) were visualised and counted using the EVOS FL Colour Imaging 
System (Thermo Fisher Scientific; Catalogue number: AMEFC4300) and divided by the total 
number of HSVECs in the viewing channels. 
 
2.9.2  Monocyte Adhesion Assay: Low Shear Stress Model 
Monocyte adherence to an endothelial monolayer was assessed using THP-1 monocytes 
under ‘low shear stress’ conditions. HSVECs (2 x 104 cells) were seeded in wells of 24-well 
plates and grown to confluency. Following infection with the adenovirus for 18 hours, wells 
were washed twice in PBS and endothelial cell growth medium was replenished. Then, cells 
were subjected to ‘low shear stress’ for 24 hours at 37°C and 5% CO2 using fixed-angle 
platform rocker (Grant Instruments, Fisher Scientific, UK) with a maximum tilt angle of 7° at 
10 oscillations per minute. ‘Static’ control group were kept in the same incubator but were not 
subjected to ‘low shear stress’. After 24 hours, THP-1 cells were fluorescence-labelled with 
100 μM calcein-AM by incubation for 30 minutes at 37°C and 5% CO2.  Then, 2 x 104 calcein-
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labelled THP-1 monocytes were added to each well of confluent HSVECs and then co-
incubated for 1 hr at 37°C and 5% CO2 in 2% (v/v) FBS endothelium cell medium. Non-
adherent cells were then removed by washing wells twice with PBS. Ten fields were 
photographed per condition. Adhered THP-1 cells (green) were visualised and counted using 
the EVOS FL Colour Imaging System (Thermo Fisher Scientific; Catalogue number: 
AMEFC4300) and divided by the total number of HSVECs in the viewing channels. 
 
2.10  METHODS: TRANSWELL PERMEABILITY ASSAY 
To measure endothelial permeability, HSVECs (4 x 104 cells) were seeded on in Transwell 
inserts (Corning, catalogue number: 3413) suspended within a 24-well plate and cultured in 
endothelial cell growth medium. To ensure the maximal growth of the HSVEC monolayer, cell 
growth medium was replenished every two days. Endothelial cell growth medium was replaced 
with 2% (v/v) FBS endothelial basal media containing streptavidin-HRP (R&D Systems, 
catalogue number: DY998) followed by a 5-minute incubation at 37°C and 5% CO2. Then, 20 
µL of media from the lower chamber was collected and added to a 96 well plate in triplicate. 
50 µL of 3,3’,5,5’-tetramethylbenzidine (TMB) substrate (Sigma-Aldrich, catalogue number: 
T0440) was added into each well of the 96 well plate followed by incubation at RT for 5 
minutes.  25 µL of stop solution (2N H2SO4 water solution) (Sigma-Aldrich, catalogue number: 
30743) was added to each well and absorption was determined at 450 nm wavelength using 
a GloMax® Explorer Multimode Microplate Reader. The absorption readings were normalised 
to control. 
 
2.11 METHODS: COLLAGEN GEL CONTRACTION 
ASSAY 
VSMC contractile capability was assessed using Cell Biolabs’ Collagen-based Contraction 
Assay Kit (Cell Biolabs; Catalogue Number: CBA-201) following the manufacturer’s 
instructions. Primary HSV VSMCs at a cell seeding density of 1 x 105 were seeded in wells of 
a 24-well plate. Post adenoviral infection as described in 2.1.7, VSMCs were detached using 
0.05% (w/v) Trypsin-EDTA at 37°C for 5 minutes and resuspended in desired 10% (v/v) 
FBS/DMEM at 0.5 x 105 cells/mL. Cold collagen gel working solution was prepared by mixing 
the following components in this order collagen solution, 5 x PBS and neutralizing solution. 
The collagen gel working solution and VSMCs at 0.5 x 105 cells/mL were mixed on ice at a 
ratio of 1:4. Following this, 500 μL of the final mixture was cast into each well of a 24-well 
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culture plate. The solution was then allowed to polymerize at RT, which generally completed 
in 30 minutes, then 1.0 mL of culture medium was added atop each collagen gel lattice. After 
polymerization for 48 hours, using a sterile needle, the gels were gently released from the 
plates in which they were cast to allow contraction. The gels were photographed at different 
time-points after collagen release and the diameter of each gel was measured using Image J. 
Data were expressed as the distance of contraction (arbitrary units). 
 
2.12  METHODS: IN VIVO EXPERIMENTS 
2.12.1  Intimal thickening in C57BL/6 mice 
To address whether PRH S163C:S177C expression affected intimal thickening, VSMC 
proliferation, migration and VSMC differentiation in vivo, mouse carotid artery ligation was 
performed. Intimal lesions are predominantly formed of VSMCs in this well-established model 
(Johnson et al, 2005; Tsaousi et al, 2011; Williams et al, 2016). Male and female, 8-week-old 
C57BL/6 mice were purchased from Charles River and housed in the University of Bristol 
animal unit. Mice were anaesthetized by inhalation of isofluorane in 100% oxygen for 30 
minutes after intraperitoneal administration of 1.5 μg buprenorphine hydrochloride for 
analgesia (Vetergesic). The left common carotid artery was isolated and the first 5-0 silk suture 
was placed at the bifurcation of the common carotid artery (Singh et al, 2001). Right carotid 
arteries acted as unligated controls. The exposed left carotid arteries were coated with 100 μl 
of 30% (w/v) pluronic gel containing 1.33 x 108 pfu of the Ad: PRH S163C:S177C (with c-myc-
tag) or Ad: Control. Mini osmotic pumps (model 2004 Alzet) were primed with BrdU and 
inserted into the mice to quantify proliferation. After suturing the wound, animals were left for 
28 days. At 7 days, very little intimal formation is detectable however medial VSMC migration 
and proliferation is activated, while at 28 days a substantial intima is formed (reference).  After 
allowing 28 days for intimal thickening to occur, mice were culled using 20 mg pentobarbital 
sodium (Euthatal). The left and right carotid arteries were fixed in 10% (v/v) formalin/PBS for 
24 hours, then transferred into PBS and stored at 4°C until processing. The carotid arteries 
were paraffin wax-embedded longitudinally and then subjected to histological staining to 
enable accurate analysis of the lesion size as described below. All in vivo work was performed 






2.12.2  Histological Analysis 
The arteries were gently held upright (7-day study) and horizontal (28-day study) in heated 
molten agar using forceps until the agar solidified. The agar plugs containing the arteries were 
then processed using the Shandon Excelsior Tissue Processor (Thermo Electron 
Corporation). Arteries were then embedded in paraffin wax using the Shandon Histocentre 3 
(Thermo Electron Corporation). Blocks were cooled to -20°C using a block cooler (Elstat 
Electronics Limited) for at least 30 minutes and then 3-4 μm transverse sections (7-day study) 
and longitudinal sections (28 days study) were cut using a Reichert-Jung 2030 Biocut 
microtome or Bright M3500 microtome and dried onto Superfrost Plus slides (Thermo Fischer 
Scientific, catalogue number: 10149870). 
 
2.12.2.1 Elastic Van Gieson Staining 
Elastic van Gieson (EVG) staining was performed to stain elastin and collagen to enable 
measurement of the intimal area and the cross-sectional area of the left carotid arteries. EVG 
staining was performed in a Shandon Varistain 24-4 Automatic Slide Stainer (Thermo 
Scientific), in accordance with the protocol outlined in Table 2.9. Slides were mounted in DPX 
mounting medium (Thermo Fisher Scientific, catalogue number: 10050080), cured overnight 
and imaged using an Olympus BX40 microscope at x40 magnification using Q-capture pro 6.0 
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2.12.2.2  Image Analysis  
The borders of the lumen and internal elastic lamina (IEL) were traced on a digitizing board 
and analysed using the Image J software. The intimal area was calculated by subtracting the 
luminal area from the IEL area (Figure 2.1). The ratio of intimal/medial area (I/M ratio) was 
calculated by dividing the intimal area by medial area. Percentage occlusion was calculated 

























FIGURE 2.1: Visual representation of the parameters used to calculate neointimal area in EVG 
stained ligated carotid artery 
Representative images of left carotid arteries of C57B/L6 mice 28 days after ligation stained with 
EVG. Green dashed lines indicates the luminal area boundary; Yellow dashed lines indicate IEL 










2.12.3  Immunostaining of tissue sections 
2.12.3.1  Immunofluorescence for c-myc tagged PRH 
Paraffin-wax sections (3-4μm) were de-waxed by three 5-minute incubations in 100% (v/v) 
clearene and rehydrated by two consecutive 5-minute washes in 100% (v/v) alcohol, a single 
5-minute wash in 70% (v/v) alcohol and then distilled water. Slides were then briefly washed 
in distilled water then antigen retrieval was achieved by submerging the slides submerged in 
10mM citrate buffer (pH 6.0) and microwaving at 800 W for 5 minutes. Distilled water was then 
added if necessary, to re-submerge slides, and slides were microwaved for a further 5 minutes 
at 800 W and then allowed to cool for 30 minutes at RT. Afterwards, the slides were transferred 
to cold running tap water for 5 minutes, then washed three times with PBS and sections were 
delineated using a hydrophobic pen. Following three washes of PBS, sections were incubated 
with approximately 50 μL/section of Image-iT FX Signal Enhancer (Molecular Probes; 
catalogue number: I-36933) for 30 minutes at RT.  Sections were incubated overnight at 4°C 
with 50 μL/section of 1 μg/mL anti-c-myc-tag antibody (Cell Signalling; catalogue number: 
2276) or non-immune rabbit IgG diluted in PBS. Slides were then washed three times in PBS. 
Sections were incubated with 50 μL/section of biotinylated goat anti-rabbit IgG diluted 1:200 
in 1% (w/v) BSA/PBS and incubated for 45 minutes at RT. Slides were again washed three 
times in PBS followed by incubation with 50 μL of Dylight 488 Streptavidin (Vector 
Laboratories; catalogue number: SA-5488-1) diluted 1:200 in PBS for 45 minutes at RT, 
protected from day light. Slides were then washed four times with PBS and then mounted with 
Prolong Gold Antifade Reagent with DAPI (Molecular Probes; catalogue number: P-36931) 
overnight at 4°C in the dark until analysis. 
The following day the sections were imaged using an Olympus BX41 microscope and four 
images of the vessel wall were taken at x60 magnification using Q-capture pro 6.0 software. 
C-myc-tag positive nuclei appeared green whilst all nuclei were stained blue with DAPI. The 
number of c-myc-tag positive nuclei were counted and expressed as a percentage of the total 
number of medial cells in the four images and the average calculated per artery.  
 
2.12.3.2  Immunofluorescence for α smooth muscle cell actin  
Paraffin-wax sections (3-4μm) were de-waxed by three 5-minute washes in 100% (v/v) 
clearene and rehydrated by two consecutive 5-minute washes in 100% (v/v) alcohol, a single 
5-minute wash in 70% (v/v) alcohol and then distilled water. Slides were then briefly washed 
in distilled water then antigen retrieval was achieved by submerging the slides submerged in 
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10mM citrate buffer (pH 6.0) and microwaving at 800 W for 5 minutes. Distilled water was then 
added if necessary, to re-submerge slides, and slides were microwaved for a further 5 minutes 
at 800 W and then allowed to cool for 30 minutes at RT. Afterwards, the slides were transferred 
to cold running tap water for 5 minutes, then washed three times with PBS and sections were 
delineated using a hydrophobic pen. The Fluorescein Vector mouse-on-mouse (M.O.M) 
Immunodetection Kit (Vector Laboratories; catalogue number: FMK-2201) was utilised since 
the anti-αSMA antibody (Sigma Aldrich, catalogue number: A2547) was raised in mouse, 
following the manufacturer’s instruction to inhibit non-specific binding of the antibody to mouse 
tissue. Slides were incubated with M.O.M mouse IgG blocking reagent for 1 hour at RT. Then 
slides were washed three times in PBS then incubated in M.O.M diluent for 5 minutes at room 
temperature. The diluent was then gently removed with tissue paper and 50 μL/section 3.1 
μg/mL of anti-αSMA antibody (Sigma Aldrich, catalogue number: A2547) diluted in M.O.M 
diluent was added for 30 minutes at room temperature. As a negative control, the primary 
antibody was not added. Slides were washed three times in PBS and then incubated in 50 
μL/section of M.O.M biotinylated anti-mouse IgG reagent for 10 minutes at room temperature. 
Following two washes in PBS, 50 μL/section of Fluorescein Avidin DCS was added for 5 
minutes at room temperature. Finally, the slides were then washed twice in PBS and mounted 
in Prolong Gold with DAPI (Invitrogen, catalogue number: P36931).  
The following day the sections were imaged using an Olympus BX41 microscope and Q-
capture pro 6.0 software. Four images at x60 magnification were taken of each vessel. α-
SMA-positive cells were identified as those with green-coloured whereas negative cells were 
those with only blue-coloured (DAPI). The number of nuclei associated with a green cytoplasm 
was counted in each x60 image and expressed as a percentage of the total nuclei present. To 
calculate the mean percentage of α-SMA positive cells per vessel, the percentage from all 4 
images was averaged. In addition, one image at x20 magnification was taken of blue DAPI 
staining to permit quantification of total cell number and cell density.  
 
2.12.3.3  Immunohistochemistry for BrdU 
Paraffin-wax sections (3-4μm) were de-waxed by three 5-minute washes in 100% (v/v) 
clearene and rehydrated by two consecutive 5-minute washes in 100% (v/v) alcohol, a single 
5-minute wash in 70% (v/v) alcohol and then distilled water. Slides were then briefly washed 
in distilled water then antigen retrieval was achieved by submerging the slides submerged in 
10mM citrate buffer (pH 6.0) and microwaving at 800 W for 5 minutes. Distilled water was then 
added if necessary, to re-submerge slides, and slides were microwaved for a further 5 minutes 
at 800 W and then allowed to cool for 30 minutes at RT. Afterwards, the slides were transferred 
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to cold running tap water for 5 minutes, then washed three times with PBS and sections were 
delineated using a hydrophobic pen. Next, the slides were incubated in 2N HCL at 37oC for 
30 minutes, then washed three times with PBS. To inhibit endogenous peroxidase activity, 
slides were incubated with 0.3% (v/v) H2O2 for 7 minutes at RT. Following three washes of 
PBS, sections were incubated with approximately 50 μL/section of 20% (v/v) goat serum/PBS 
for 30 minutes at RT.  The goat serum was then removed and 50 μL/section of 1 μg/mL anti- 
Bromodeoxyuridine (BrdU) antibody (Sigma; catalogue number: B2531) or non-immune rabbit 
IgG diluted in 1% (w/v) BSA/PBS was added and incubated overnight at 4°C. Slides were then 
washed three times in PBS. Sections were incubated with 50 μL/section of biotinylated goat 
anti-rabbit IgG (Sigma Aldrich, catalogue number: B7389) diluted 1:200 in 1% (w/v) BSA/PBS 
and incubated for 30 minutes at RT. Following three washes of PBS, the slides were incubated 
with ExtrAvidin-peroxidase (Sigma Aldrich, catalogue number: E2886) diluted 1:200 in 1% 
(w/v) BSA/PBS and incubated for 30 minutes at RT. Slides were again washed three times in 
PBS followed by incubation with the HRP substrate, SigmaFast 3,3’-diaminobenzidine (DAB: 
Sigma Aldrich, catalogue number: D4293) for 2 minutes at RT. The ExtrAvidin-peroxidase-
DAB reaction produces a brown precipitate. Slides were washed twice distilled water, and then 
stained with Mayer’s haematoxylin for 2-5 minutes. Haematoxylin was washed off with tap 
water until the water appeared clear and blue colour is produced in nuclei. Slides were then 
dehydrated by one 5-minute incubation in 70% (v/v) alcohol, two 5-minute incubation in 100% 
(v/v) alcohol and then three 5-minute incubations in 100% (v/v) clearene. Slides were then 
mounted in DPX mounting medium (Thermo Fisher Scientific, catalogue number: 10050080) 
overnight at RT. 
 
2.12.3.4 Immunohistochemistry for Smoothelin and Calponin 
Paraffin-wax sections (3-4μm) were de-waxed by three 5-minute washes in 100% (v/v) 
clearene and rehydrated by two consecutive 5-minute washes in 100% (v/v) alcohol, a single 
5-minute wash in 70% (v/v) alcohol and then distilled water. Slides were then briefly washed 
in distilled water then antigen retrieval was achieved by submerging the slides submerged in 
10mM citrate buffer (pH 6.0) and microwaving at 800 W for 5 minutes. Distilled water was then 
added if necessary, to re-submerge slides, and slides were microwaved for a further 5 minutes 
at 800W and then allowed to cool for 30 minutes at RT. Afterwards, the slides were transferred 
to cold running tap water for 5 minutes, then washed three times with PBS and sections were 
delineated using a hydrophobic pen. To inhibit endogenous peroxidase activity, slides were 
incubated with 0.3% (v/v) H2O2 for 7 minutes at RT. Following three washes of PBS, sections 
were incubated with approximately 50 μL/section of 20% (v/v) goat serum/PBS for 30 minutes 
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at RT. The goat serum was then removed and 50 μL/section of 0.2 μg/mL anti-calponin (Novus 
Biologicals; catalogue number: NBP1-87029) or non-immune rabbit IgG diluted in 1% (w/v) 
BSA/PBS was added and incubated overnight at 4°C. To stain for smoothelin protein, 1μg/mL 
anti-smoothelin (Novus Biologicals; catalogue number: NBP2-3797) or non-immune rabbit IgG 
diluted in 1% (w/v) BSA/PBS was added and incubated overnight at 4°C.  Slides were then 
washed three times in PBS. Sections were incubated with 50 μL/section of biotinylated goat 
anti-rabbit IgG (Sigma Aldrich, catalogue number: B7389) diluted 1:200 in 1% (w/v) BSA/PBS 
and incubated for 30 minutes at RT. Following three washes of PBS, the slides were incubated 
with ExtrAvidin-peroxidase (Sigma Aldrich, catalogue number: E2886) diluted 1:200 in 1% 
(w/v) BSA/PBS and incubated for 30 minutes at RT. Slides were again washed three times in 
PBS followed by incubation with the HRP substrate, SigmaFast 3,3’-diaminobenzidine (DAB: 
Sigma Aldrich, catalogue number: D4293) for 2 minutes at RT. The ExtrAvidin-peroxidase-
DAB reaction produces a brown precipitate. Slides were washed twice distilled water, and then 
stained with Mayer’s haematoxylin for 30 seconds – 2 minutes. Haematoxylin was washed off 
with tap water until the water appeared clear and blue colour is produced in nuclei. Slides were 
then dehydrated by one 5-minute wash in 70% (v/v) alcohol, two 5-minute washes in 100% 
(v/v) alcohol and then three 5-minute washes in 100% (v/v) clearene. Slides were then 
mounted in DPX mounting medium (Thermo Fisher Scientific, catalogue number: 10050080) 
overnight at RT. 
 
2.12.3.5 Immunohistochemistry for STAT-1 
Paraffin-wax sections (3-4μm) were de-waxed by three 5-minute washes in 100% (v/v) 
clearene and rehydrated by two consecutive 5-minute washes in 100% (v/v) alcohol, a single 
5-minute wash in 70% (v/v) alcohol and then distilled water. Slides were then briefly washed 
in distilled water then antigen retrieval was achieved by submerging the slides submerged in 
10mM citrate buffer (pH 6.0) and microwaving at 800 W for 5 minutes. Distilled water was then 
added if necessary, to re-submerge slides, and slides were microwaved for a further 5 minutes 
at 800 W and then allowed to cool for 30 minutes at RT. Afterwards, the slides were transferred 
to cold running tap water for 5 minutes, then washed three times with PBS and sections were 
delineated using a hydrophobic pen. To inhibit endogenous peroxidase activity, slides were 
incubated with 0.3% (v/v) H2O2 for 7 minutes at RT. Following three washes of PBS, sections 
were incubated with approximately 50 μL/section of 20% (v/v) goat serum/PBS for 30 minutes 
at RT.  The goat serum was then removed and 50 μL/section of 1 μg/mL anti-Stat-1 (Cell 
Signalling; catalogue number: 14994S) or non-immune rabbit IgG diluted in SignalStain® 
Antibody Diluent (Cell Signalling; catalogue number: 8112) was added and incubated 
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overnight at 4°C. Slides were then washed three times in PBS. Sections were incubated with 
50 μL/section of SignalStain® Boost IHC Detection Reagent for rabbit (Cell Signalling; 
catalogue number: 8114P) diluted 1:200 in 1% (w/v) BSA/PBS and incubated for 45 minutes 
at RT. Slides were again washed three times in PBS followed by incubation with the HRP 
substrate, SigmaFast 3,3’-diaminobenzidine (DAB: Sigma Aldrich, D4293) for 2 minutes at 
RT. Slides were washed twice distilled water, and then stained with Mayer’s haematoxylin for 
30 seconds–2 minutes. Haematoxylin was washed off with tap water until the water appeared 
clear and nuclei appeared blue. Slides were then dehydrated by one 5-minute wash in 70% 
(v/v) alcohol, two 5-minute washes in 100% (v/v) alcohol and then three 5-minute washes in 
100% (v/v) clearene. Slides were then mounted in DPX mounting medium (Thermo Fisher 
Scientific, catalogue number: 10050080) overnight at RT.  
 
2.12.3.6 Immunohistochemistry for HDAC-9 and CD31 
Paraffin-wax sections (3-4μm) were de-waxed by three 5-minute washes in 100% (v/v) 
clearene and rehydrated by two consecutive 5-minute washes in 100% (v/v) alcohol, a single 
5-minute wash in 70% (v/v) alcohol and then distilled water. Slides were then briefly washed 
in distilled water then antigen retrieval was achieved by submerging the slides submerged in 
10mM citrate buffer (pH 6.0) and microwaving at 800 W for 5 minutes. Distilled water was then 
added if necessary, to re-submerge slides, and slides were microwaved for a further 5 minutes 
at 800W and then allowed to cool for 30 minutes at RT. Afterwards, the slides were transferred 
to cold running tap water for 5 minutes, then washed three times with PBS and sections were 
delineated using a hydrophobic pen. To inhibit endogenous peroxidase activity, slides were 
incubated with 0.3% (v/v) H2O2 for 7 minutes at RT. Following three washes of PBS, sections 
were incubated with approximately 50 μL/section of 20% (v/v) goat serum/PBS for 30 minutes 
at RT.  The goat serum was then removed and 50 μL/section of 1 μg/mL anti-HDAC-9 antibody 
(Abcam; catalogue number: ab239979) or non-immune rabbit IgG diluted in 1% (w/v) 
BSA/PBS was added and incubated overnight at 4°C.  To stain for CD31 protein, 0.4μg/mL 
anti-smoothelin (Abcam; catalogue number: ab28364) or non-immune rabbit IgG diluted in 1% 
(w/v) BSA/PBS was added and incubated overnight at 4°C. Slides were then washed three 
times in PBS. Sections were incubated with 50 μL/section of biotinylated goat anti-rabbit IgG 
(Sigma Aldrich, catalogue number: B7389) diluted 1:200 in 1% (w/v) BSA/PBS and incubated 
for 30 minutes at RT. Following three washes of PBS, the slides were incubated with 
ExtrAvidin-peroxidase (Sigma Aldrich, catalogue number: E2886) diluted 1:200 in 1% (w/v) 
BSA/PBS and incubated for 30 minutes at RT. Slides were again washed three times in PBS 
followed by incubation with the HRP substrate, SigmaFast 3,3’-diaminobenzidine (DAB: 
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Sigma Aldrich, catalogue number: D4293) for 2 minutes at RT. The ExtrAvidin-peroxidase-
DAB reaction produces a brown precipitate. Slides were washed twice distilled water, and then 
stained with Mayer’s haematoxylin for 30 seconds–2 minutes. Haematoxylin was washed off 
with tap water until the water appeared clear and nuclei stain blue. Slides were then 
dehydrated by one 5-minute wash in 70% (v/v) alcohol, two 5-minute washes in 100% (v/v) 
alcohol and then three 5-minute washes in 100% (v/v) clearene. Slides were then mounted in 
DPX mounting medium (Thermo Fisher Scientific, catalogue number: 10050080) overnight at 
RT. 
 
2.13   METHODS: QUANTITATIVE RT-PCR (RT-qPCR) 
2.13.1  RNA Extraction 
Total RNA extraction and purification was performed using the miRNeasy Mini kit (Qiagen; 
catalogue number: 217004). Cells were washed briefly in DPBS and lysed in 350 or 700 μL 
Qiazol lysis reagent (Qiagen; catalogue number: 79306) for approximately 30 seconds. The 
wells were scraped with the plunger of a 1mL syringe and lysates were transferred into 
RNAse-free eppendorfs then kept on ice or stored at -80°C until RNA purification was 
performed.  
 
2.13.2  RNA Purification 
According to QIAGEN’s instructions, RNA was purified from cell lysates to remove DNA from 
total nucleic acid samples. 140 μL of chloroform was added to each sample and vortexed to 
disperse any visible precipitate. Then, samples were left to incubate at room temperature for 
2-3 minutes then micro-centrifuged at 4°C for 15 minutes at 12,000 g. Then, the colourless 
upper layer from each sample was carefully removed and transferred into a new eppendorf 
and mixed with 1.5 volumes of 100% RNA-grade ethanol. Samples were then transferred to 
purification columns and micro-centrifuged at 12,000g for 15 seconds at RT. The resultant 
flow-through was discarded and columns were washed once with 700 μL of buffer RWT, and 
twice with 500 μL of buffer RPE at 12,000 g for 15 seconds each. Flow-through was discarded 
and spin cartridges were reinserted into new collection tubes. Samples were eluted in 30μl 
RNAse free water by micro-centrifuging at 12,000 g for 1-2 minutes. Then, samples were 




2.13.3  RNA Quantification 
The quality and quantity of RNA was assessed using a QIAxpert Nanodrop spectrophotometer 
(QIAGEN, 9023460). 2 μL of each RNA sample was added into the cassettes to the Nanodrop 
spectrophotometer and the absorbance at 230 nm, 260 nm and 280 nm was recorded. The 
RNA concentration (ng/mL) was determined by measuring the absorption at 260 nm. The 
260/230 nm ratio corresponded to ethanol contamination, with a 260/230nm ratio of ≥1.8 
indicative of minimal ethanol content. Meanwhile, the 260/280nm absorbance ratio describes 
RNA purity in which a ratio of <2.0 suggests nucleic acid contamination. If contamination was 
detected, samples were discarded. 
 
2.13.4  Reverse Transcription (RT) 
cDNA was synthesized from 100-500 ng/mL purified RNA using the High-Capacity RNA-to-
cDNA Kit (Applied Biosystems; catalogue number: 4387406). RNA samples were made up to 
a total volume of 9 μL with RNAse-free water to equalise RNA concentration.  In accordance 
with the manufacturer’s instructions, 10 μL of 2 X RT Buffer Mix and 1 μL of 20 X RT Enzyme 
Mix was added to each RT reaction to give a final volume of 20 μL. Reactions were then 
incubated for 1 hour at 37°C, 5 minutes at 95°C and held at 4°C. cDNA samples were stored 
at -20°C until analysis.  
 
2.13.5  Quantitative PCR 
Quantitative PCR analysis was performed using the LightCycler 480 real-time PCR System 
(Roche) and LightCycler 480 SYBR Green I Master (Roche; catalogue number: 04707516001) 
in combination with primers described in Table 2.4. Each 10 μL reaction consisted of: 1μL of 
cDNA, 5μL 2 x SYBR green, 3μL PCR-grade water and 1 μL primer sets (0.5 μL of both 
forward and reverse primers). Each cDNA sample was analysed in triplicate to account for 
technical variation. As an internal control, the cDNA was substituted with 1 μL of PCR-grade 
water or 1 μL of blank RT negative control. Plates were sealed (Greiner Bio-one; catalogue 
number: 676040) and centrifuged for 30 seconds at 250 g (Labnet; Mini PCR plate spinner; 




 Table 2.10: RT-qPCR program conditions 
 
A mean cycle threshold (CT) value was generated from cDNA samples analysed in triplicate 
by averaging the closest two CT values, and then values were normalised with 36B4 RNA 
levels. The samples with two CT values less than 0.5 cycle apart were included in analysis 
which was used to calculate fold changes in expression. The following equation was used to 
determine fold change: 
 
Fold change = 2-∆CT 
∆CT = CT (Target RNA) – CT (Reference RNA) 
 
The specificity of the real-time PCR assay can be confirmed by analysing the melting curves. 
All primers used throughout the study gave a single peak on the melting curves indicating that 





















Denaturing 95 10 sec 
Annealing 60 10 sec 





95 5 sec 












2.13.6  Primer Design 
Pre-designed primers for qPCR analysis were purchased from Qiagen or designed using 
Primer-BLAST software and ordered from Sigma (Table 2.11). Filters for design included: 
• specificity for the target gene  
• a product size of between 100 and 250 base pairs 
• an optimal melting temperature (Tm) of 65°C 
• an optimal primer size of between 22 and 26 base pairs 
• a primer GC content of 40-65% 
• a requisite for spanning exon-exon junctions 
• lack of secondary structures 

















































































































2.14  METHODS: TRANSCRIPTOMIC PROFILING 
2.14.1 Next Generation Sequencing 
In this study, we have utilized high-throughput RNA sequencing to perform genome wide 
analysis of transcriptional diversity and regulation using the TruSeq stranded mRNA kit 
(QIAGEN). Total RNA extraction, purification and quantification were performed, as described 
in sections 12.13.1, 12.13.2 and 12.13.3, respectively. All analysis was performed using CLC 
Genomics Workbench (version 12.0.2) and CLC Genomics Server (version 11.0.2). In 
addition, the human genome version used is hg38 with an annotation of ENSEMBL 
Homo_sapiens.GRCh38.97.  
RNA-seq libraries were successfully prepared, quantified and sequenced for all of the 
samples. The collected reads were subjected to quality control, alignment and downstream 
analysis. The principal structure of the results data is summarized in FIGURE 2.3, which 
outlines the workflow of an RNA NGS service project with QIAGEN Genomic Services. The 
samples have been run on an Illumina NextSeq 550 and the aim was to acquire an average 
of 30 million reads per sample. The parameters were: 100 ng input RNA, 15 cycles of PCR in 
the fragment enrichment step and the loading molarity used was 1.5 pM. The sequencing was 
performed in accordance with the manufacturer’s instructions and an overview of the protocol 
is briefly described in FIGURE 2.2. The sequencing company supplies an Expression Browser 
List of genes annotated with: Gene Name, Gene Identifier, Max Group Means, Fold Change, 




















FIGURE 2.2: Schematic representation of steps taken during RNA Sequencing using Illumina 
NextSeq 550 
The protocol for the NGS procedure: the mRNA in a total RNA sample is used to generate a library of 
template molecules of known strand origin using the reagents provided in an Illumina® TruSeq® 
Stranded mRNA library prep kit. 
 
Purify and Fragment mRNA Synthesize First Strand cDNA
Synthesize Second Strand cDNA A-Addition












FIGURE 2.3: NGS Workflow 
Simple outline of the RNA NGS service project with QIAGEN Genomic Services Information adapted 




Consultation and Experimental Design
Initial Consultation with Genomic Services scientists 
tailoring the experimental design to suit your research 
needs and budget
Sample Submission and preparation
Purified RNA Samples are sent to QIAGEN (Germany)
Sample Quality Control (QC) - STOP/GO point
Mandatory quality control of samples to ensure highest 
possible quality and identify potential bias before 
proceeding to RNA Sequencing. STOP/GO point where it is 
possible to omit samples, replace samples before 
proceeding or terminating project. 
Library Preparation
Library generation including rRNA depletion or mRNA 
enrichment and poly-A tailing, depending on RNA NGS 
project type, fragmentation and adaptor ligation
Library Q - STOP/GO point
Quality control of sequencing libraries to ensure they have 
the correct inserts that are correct in size. STOP/GO point 
where it is possible to terminate or adjust project before 
proceeding to data analysis. 
RNA Sequencing 
mRNA and whole transcriptome sequencing performed 
using Illumina NextSeq 550 sequencing technology (Fig. 6).
Data analysis, QC and interpretation
Complete data analysis, quality control and biological 
interpretation including mapping, transcript assembly, gene 
and transcript quantification, normalization, differential 
expression analysis, PCA and Volcano plots, heat maps and 
GO enrichment analysis.
Data analysis report and delivery
Easy data delivery and storage via XploreRNA cloud. 
Download data anytime, anywhere and use the Gene 
Sorting Wizard to filter data for better detection of 
candidate genes for downstream validation. You receive a 
comprehensive Data Analysis Report with publication-ready 
results.




2.14.2 Ingenuity Pathway Analysis (IPA) 
Bioinformatic analysis was used to prioritise the differentially regulated genes (DEGs) 
identified by NGS to determine those most likely associated to VSMC proliferation and 
migration. Analysing unprecedented DEGs identified through NGS is a significant challenge. 
The Ingenuity Pathway Analysis program (IPA version 8.0, Ingenuity Systems Inc, California, 
USA. www.ingenuity.com) functions to analyse, interrogate and interpret data derived from 
‘omics experiments such as RNA-seq. IPA was utilised to obtain a deeper understanding of 
the significantly altered canonical pathways and biological functions associated with the DEGs 
regulated by PRH S163C:S177C. IPA also creates networks where the uploaded DEGs can 
be connected by either direct or indirect interactions, based on published interactions. It is a 
powerful tool that is based on Ingenuity knowledge which is linked to published literature and 
QIAGEN Knowledge Base. This approach offers the advantage of identifying canonical and 
metabolic signalling pathways that are enriched in the data. To prioritise potential DEGs, a 
series of filtering strategies were implemented, outlined in the following sections and FIGURE 
2.3. 
 
2.14.2.1  Data Upload and Data Annotation 
The raw RNAseq dataset files generated from NGS by QIAGEN were imported to IPA. In this 
study, the RNAseq dataset files were expressed in two separate datasets: Dataset A denotes 
DEGs obtained from HSV VSMCs infected with Ad: Control or Ad: PRH S163C:S177C 
whereas Dataset B denotes DEGs obtained from HSVECs infected with Ad: Control or Ad: 
PRH S163C:S177C. The imported ‘omics data is annotated by mapping the molecules to the 
corresponding gene ID that exists in the IPA’s Knowledge database. A dataset file may contain 
more than one identifier source in different columns. Multiple identifier columns, such as 
GenBank, Gene Symbol-Human (HUGO) and Ensembl, can be assigned to increase the 
chance that a row will be mapped in IPA. The raw data was then allocated to ‘Observation 1’ 
describing a single observation dataset which contains only one experimental comparison 
(e.g., experimental vs. control). Subsequently, the corresponding measurement values can be 
assigned to the correct columns. For example, the next column was mapped to reads per 
kilobase million (RPKM). RPKM is a normalised unit of transcription. It corrects differences in 
both sample sequencing depth and gene length. The ‘Expression Fold Change’ determines 
the magnitude of change between two measurements. The ‘Expression Log Ratio’ is the 
logarithm base 2 of fold change and ‘Expression p-value’ represents the significance of the 
variation in gene expression changes. Lastly, the ‘Expression False Rate Discovery (FDR)’ is 
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a p-value adjusted for multiple sets using the Benjamin-Hochberg procedure. It is a method 
used to conceptualise the expected proportion of false positives per transcript. Once data 
annotation has been completed, the dataset can be processed for the next stage of data 





















Log Ratio RPKM 
FIGURE 2.4: Data Formatting and Upload using an unfiltered Dataset A 
 During Data Upload, each column has been annotated with appropriate headers including Gene 
Identifier. The remaining columns within a dataset can be annotated manually to indicate the 
type of measurement value including reads per kilobase million (RPKM), false discovery rate 
(FDR), fold change, p-value, log ratio to help IPA assign the correct data type. 
Dataset A 
FDR 






The differential expression (DE) calculation can be calculated using the following: 
 
Recommended Log2(ratio):       Log2 =   (                                                      ) 
Ratio DE:                               (                                                      ) 
Fold Change:            Increased             (                                                      ) 
     Decreased                (                                                      ) 
RPKM of a gene:                                               (                                                                                                   ) 
 
 
2.14.2.2 Data Filtering 
The first criterion to prioritise the DEGs was data filtering. ‘Ideal’ set size for IPA core analysis 
from gene expression data is typically <3000 molecules. In the Set Cutoffs section, reasonable 
cut-off values can be specified to reduce the number of DEGs from >26,000 genes in each 
RNAseq datasets for statistical analysis. Only features that pass the cut-offs that have been 
specified at this step will be used for further IPA analysis. For example, set analysis 
parameters for each of the dataset include: + 1.5 for Expr Fold Change (Up-regulated/Down-
regulated) and 0.05/0.01 for Expr p-value, to produce statistically significant DEGs in the 
transcriptomic experiment.  
 
Experimental Condition 
exp.  Control Condition 
exp.     
Experimental Condition 
exp. Control Condition 
exp. 
Experimental Condition 
exp. Control Condition 
exp. DE 
Experimental Condition 
exp. Control Condition 
exp. 
-1 
No. of reads mapped to a gene x 103 x 
106 Total no. of mapped reads from a given 






2.14.2.3 Compare Data  
Using the ‘Compare Data’, filtered datasets are compared to run set operations like Union 
(Sum), Common (Intersection) and Unique DEGs between the different datasets being 
compared (FIGURE 2.5). This will produce an interactive Venn diagram to display the DEGs 
that are VSMC-specific and EC-specific and then a ‘final’ dataset was created from there to 














2.14.2.4 Core Analysis 
Core Analysis was performed on the final dataset using ‘Expression Analysis’. This identifies 
the canonical pathways, upstream regulators, regulator effects (molecular networks), and 
disease and biological functions based on the changes of expression of genes or proteins 





FIGURE 2.5: Interactive Venn diagram for the ‘Compare Data’ tool 
Two entities which were the previously filtered datasets were uploaded into the ‘Compare Data tool’ 
for further filtering of DEGs which are VSMC-specific and PRH S163C:S177C-specific. A new 




value was calculated using a Right-Tailed Fisher’s Exact Test which determines the probability 
that the association or overlap between a set of significant molecules from the data and a 
given biological function is due to random chance. The Z-score takes into account the 
directional effect of one molecule on another molecule or on a process, and the direction of 
change of molecules in the dataset. 
 
2.14.2.5 Canonical Pathways 
The first criterion used to prioritise the DEGs was Canonical Pathways. Canonical Pathways 
provide information about what is known from literature to occur on the cellular level in 
signalling and metabolic cascades. In this study, the 15 most significant IPA Canonical 
Pathways have been selected determine which signalling pathways were regulated by 
overexpression of PRH S163C:S177C. The significance of the association between the PRH 
S163C:S177C DEGs and canonical pathways was assessed based on the following 
measures: 1) the number of occurrences of DEGs in a given canonical pathway; 2) the p-
value; 3) the degree of fold change and 4) an extensive review of each DEG (Section 2.14.2.6).  
 
2.14.2.6 Biological analysis of PRH S163C:S177C-regulated gene 
targets 
For an in-depth literature retrieval, ‘vascular smooth muscle cell’, ‘cell proliferation’, ‘cell 
contractility’, ‘phenotypic switching’, ‘cell migration’, ‘endothelial cell’, and ‘inflammation’ was 
used as the keywords to search for the association of DEGs with a cellular function. The DEGs 
obtained from the top enriched Canonical Pathways were subjected to biological annotation 
to determine those most likely associated with VGF. Due to the expanse of biological 
information, there are a number of databases that integrate the functional interpretation of 
NGS molecules for target prioritisation. The following public databases were utilised to 
conduct searches and find relevant information from the literature. PubMed 
(https://pubmed.ncbi.nlm.nih.gov) utilise search interfaces to allow for interrogation of the 
literature. In addition, UniProtKB (https://www.uniprot.org) and The Human Protein Atlas 
(https://www.proteinatlas.org) are comprehensive databases that provides concise evidence 
about molecular function, tissue expression, protein interactions, biological process and 
involvement in disease. The IPA Gene View (ttps://reports.ingenuity.com/) generated by IPA 
also retrieves a wealth of experimental evidence for the DEGs obtained from QIAGEN 
Knowledge Base. IPA’s Map Overlay Tool also quantitatively integrates direct and indirect 
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protein interactions derived from four sources: genomic context, high-throughput experiments, 
co-expression data and previous knowledge. Each DEG was annotated by gene name, p-
value score and fold change, protein name, gene function, cellular location and association to 
the VSMC proliferation and migration. 
 
2.14.2.7 Downstream Effects Analysis: Disease and Function 
To identify key biological processes influenced by the DEGs within the dataset, IPA allows for 
a novel approach to visualize and predict biological impact of the observed gene expression 
changes. Using the ‘Disease and Function’ tab, IPA identifies a small subset of genes that 
were predicted to be involved in several biological processes which can be utilised to validate 








FIGURE 2.6: Schematic representation of downstream effect analysis 
Prioritised DEGs from the top enriched canonical pathways were described in ‘grey’. ‘Inhibited’ and 
‘Activated’ DEGs identified in IPA’s downstream effect analysis were described in ‘red’ or ‘green’ 
respectively. 
 
2.14.2.8 Upstream Regulator and Functional Network Analysis 
IPA’s upstream regulator analysis function was used to identify potential transcriptional 
regulators that could explain the observed changes in gene expression between Ad: Control 
and Ad: PRH S163C:S177C (FIGURE 2.7). The extent of relevant biological functions of the 
prioritised DEGs was further validated using functional analysis of a network generating 
biological functions associated with a given network, pathway, or neighbourhood (FIGURE 
Disease or Function Disease or Function 
Downstream Effects Analysis 
Canonical Pathway 




2.8). This combination of filtering strategies to evaluate and validate prioritised DEGs within 
our dataset is powerful in leading the identification of relevant PRH S163C:S177C-regulated 
gene targets.  
 
2.15  METHODS: STATISTICAL ANALYSIS 
Statistical analysis was performed using Graphpad Instat statistical software. For experiments 
comparing the two groups, a Student’s t-test was used for normally distributed data and a t-
test with Welch Correction was employed for non-normally distributed data with N less than 6 
or a Mann Whitney test was employed for non-normally distributed data with an N greater than 
6. For experimental data comparing three or more groups, an Analysis of Variance (ANOVA) 
with the Student-Newman-Keuls Multiple Comparisons Test was utilised. p<0.05 was 
acknowledged as significantly different in all statistical tests. All graphical data was displayed 





































Disease or Function 
FIGURE 2.7: IPA Mechanistic Networks 
The IPA Upstream Regulator computationally seeks pairs of regulators based on causal 
relationships predicted to affect expression of similar set of DEGs within the dataset. It also 
indicates the molecules predicted to be in the signalling cascade on a hypothesis basis. DEGs 
denotes ‘Differentially Expressed Genes’. 
FIGURE 2.8: IPA Functional Network Analysis 
Combinatorial strategy to strengthen the justification of the selected prioritised DEGs. Prioritised 
DEGs that have been identified in the downstream effect analysis and as an upstream regulator can 
be further analysed in functional network analysis. 
A B C D 
Upstream Regulator 
Transcription Factors (DEGs) 
Other DEGs 
A B 
Upstream Regulator Analysis 
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DEGs within the dataset 
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THE EFFECT OF PRH S163C:S177C ON  







3.1  INTRODUCTION 
The PRH/HHex transcription factor is an oligomeric protein that is required for multiple 
processes during early development including axis formation, haematopoiesis and 
development of the vasculature (Kershaw et al., 2017). Intima thickening is caused by VSMC 
migration and replication and subsequent build-up VSMCs and ECM within the intima that 
thickens the intima and reduces the lumen area (Harskamp et al., 2013). A previous study 
identified PRH to be up-regulated within intima thickenings of balloon-injured rat aortae 
(Sekiguchi et al., 2001). In apparent contradiction with these findings, knockdown and 
overexpression studies revealed that PRH exerted an anti-proliferative action in primary 
cultures of rat aortic VSMCs (Wadey et al., 2017). Moreover, adenoviral-mediated expression 
of a mutated form of PRH S163C:S177C with enhanced stability abrogated intima thickening 
in human saphenous vein organ cultures (Wadey et al., 2017). This suggest that 
overexpression of S163C:S177C PRH may present a novel therapeutic approach for reducing 
intima thickening in VGF. 
 
Aberrant VSMC behaviour is a key component of multiple vascular pathologies including post-
angioplasty restenosis, atherosclerosis, and aneurysms (Pahk et al., 2017). In the healthy 
vasculature, VSMCs are typically ‘contractile’ and quiescent exhibiting very low proliferative 
and migratory rates. The ‘contractile’ phenotype has increased expression of contractile 
markers calponin, smoothelin, smooth muscle myosin heavy chain and alpha smooth muscle 
actin (αSMA). Vascular injury initiates phenotypic switching from the ‘contractile’ phenotype to 
the ‘synthetic’ phenotype and induces migration to the intima and proliferation of VSMCs. 
Synthetic VSMCs lose the expression of said contractile markers. Hence, de-differentiation of 
VSMCs results in impaired contractility and facilitates intima thickening (Petsophonsakul et 
al., 2019). The contractile and synthetic phenotypes are characterized and distinguished by 
notable differences in marker expression, morphology, and activity (Petsophonsakul et al., 
2019; Biswas et al., 2014). Unravelling ways to maintain or restore the ‘contractile’ phenotype 
is an attractive strategy for efficiently preventing vascular remodelling disorders.  
 
In this chapter, I evaluated whether overexpressing the mutated form of PRH (PRH 
S163C:S177C) retards proliferation, apoptosis, and migration of human saphenous vein 
VSMCs. Additionally, VSMC de-differentiation was evaluated by quantifying the protein levels 





3.2  HYPOTHESES 
The hypotheses for this chapter were: 
▪ PRH S163C:S177C overexpression reduces HSV VSMC proliferation, and migration. 
▪ PRH S163C:S177C overexpression promotes the contractile phenotype in HSV 
VSMCs. 
 
These hypotheses were tested by: 
▪ Adenoviral-mediated overexpression of PRH S163C:S177C and quantification of 
VSMC proliferation, apoptosis and migration using appropriate assays (EdU; Cleaved-
Caspase-3 and Scratch Wound Assays). 
▪ Adenoviral-mediated overexpression of PRH S163C:S177C and evaluation of 
expression levels of contractile SMC-specific marker proteins by Western blotting. 
▪ Adenoviral-mediated overexpression of PRH S163C:S177C and measurement of 
VSMC contractility using collagen contraction assay.  
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3.3  RESULTS 
3.3.1 Adenovirus-mediated overexpression of PRH 
S163C:S177C in HSV VSMCs 
To determine the optimal concentration of adenoviral particles for high infection efficiency and 
achieve maximal overexpression of PRH S163C:S177C in HSV VSMCs, a dose response 
was performed utilising three different adenoviral concentrations. Infection of HSV VSMCs 
with an adenovirus without a transgene (Ad: Control) or c-myc-tagged PRH S163C:S177C 
encoding recombinant adenoviruses was performed at three different viral concentrations: 1 
x 108 pfu/mL, 2.5 x 108 pfu/mL and 5 x 108 pfu/mL. Uninfected cells served as an additional 
negative control. Following an 18-hour incubation to allow for viral infection of HSV VSMCs, 
the culture media containing the virus was removed and cells were incubated for a further 24 
hours in 10% (v/v) FBS/DMEM. Subsequently, overexpression of c-myc-tagged PRH 
S163C:S177C was assessed using Western blotting (FIGURE 3.1) and immunofluorescence 
(FIGURE 3.2) for the c-myc-tagged transgene. Western blotting and immunocytochemistry 
showed all doses are significantly different from uninfected and Ad: Control. A significant 
elevation in c-myc-tagged protein expression of approximately 90% was observed in cells 
infected with 5 x 108 pfu/mL of adenoviral vector with respect to lower doses, and thus this 
dose was selected as the optimal viral concentration. As expected, c-myc-tagged PRH 


















FIGURE 3.1 - Detection of c-myc-tagged PRH S163C:S177C in HSV VSMCs using Western Blotting 
HSV VSMCs were either infected with 1 x 108 pfu/mL, 2.5 x 108 pfu/mL or 5 x 108 pfu/mL Ad: Control  
or Ad: PRH S163C:S177C or were left uninfected. 
A – Densitometric analysis of c-myc-tagged PRH S163C:S177C protein. * indicates p<0.05 vs. uninfected, $ 
indicates p<0.05 vs. all Ad: Control, # indicates p>0.05 vs 1 x 108 pfu/mL and 2.5 x 108 pfu/mL Ad: PRH 
S163C:S177C, ANOVA, Student-Newman-Keuls Multiple Comparisons Test, n=4. Error bars represent 
standard error of mean (SEM). 
B - Representative Western blot of c-myc-tagged PRH S163C:S177C protein. Stain-free bands served as a 
loading control. Approximate molecular weight of detected band indicated in kDa. 
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FIGURE 3.2 - Detection of c-myc-tagged PRH S163C:S177C in HSV VSMCs using 
Immunocytochemistry 
HSV VSMCs were either infected with 1 x 108 pfu/mL, 2.5 x 108 pfu/mL or 5 x 108 pfu/mL Ad: Control 
or Ad: PRH S163C:S177C or were left uninfected. 
A – Quantification of percentage of cells expressing c-myc-tagged PRH S163C:S177C protein. * 
indicates p<0.05 vs. uninfected, $ indicates p<0.05 vs. all Ad: Control, ANOVA, Student-Newman-
Keuls Multiple Comparisons Test, n=4. Error bars represent SEM. 
B – Representative images of immunocytochemistry for c-myc-tagged protein. Positive cells have 
green nuclei and examples are indicated with red arrows; all nuclei are stained blue with DAPI. Scale 



































































1 x 108   pfu/mL 
S163C:S177C 
1 x 108   pfu/mL 
S163C:S177C 
1 x 108   pfu/mL 
S163C:S177C 
2.5 x 108   
pfu/mL 
S163C:S177C 
2.5 x 108   
pfu/mL 
S163C:S177C 
2.5 x 108   
pfu/mL 
S163C:S177C 
5 x 108   pfu/mL 
S163C:S177C 
5 x 108   pfu/mL 
S163C:S177C 




3.3.2  PRH S163C:S177C attenuated HSV VSMCs proliferation 
To investigate whether increasing PRH S163C:S177C levels affected proliferation of human 
saphenous vein VSMCs, cells were infected with either 5 x 108 pfu/mL adenovirus encoding 
c-myc-tagged PRH S163C:S177C and compared to VSMCs infected with Ad: Control or 
uninfected VSMCs. After 18 hours the culture medium was replaced with 10% (v/v) 
FBS/DMEM supplemented with 10 μM EdU and cells incubated for a further 8 hours for Click-
iT EdU incorporation analysis, or a further 24 hours for Western blot analysis of cell cycle 
regulators p21 and cyclin D1. The rate of proliferation detected by EdU was similar in VSMCs 
infected with Ad: Control as that seen in uninfected VSMCs. Quantification of EdU 
incorporation showed that overexpression of PRH S163C:S177C significantly retarded the 
rate of proliferation in HSV VSMCs compared to cells infected with Ad: Control and uninfected 
cells (FIGURE 3.3).  There was also no significant difference in the amount of p21 and cyclin 
D1 detected in the VSMCs infected with Ad: Control and uninfected VSMCs. Although, cells 
infected with PRH S163C:S177C showed dramatically elevated p21 protein levels (FIGURE 
3.3 A&C) and suppressed cyclin D1 protein levels (FIGURE 3.2.2 B&D) with respect to 
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FIGURE 3.3 - Overexpression of c-myc-tagged PRH S163C:S177C in H V VSMCs retarded 
proliferation 
HSV VSMCs were infected with 5 x 108 pfu/mL Ad: Control or Ad: PRH S163C:S177C or were left 
uninfected.  
A – EdU incorporation was quantified and expressed as the percentage of EdU-positive cells. ** 
indicates p<0.01, ANOVA, Student-Newman-Keuls Multiple Comparisons Test, n=4. Error bars 
represent SEM. 
B – Representative images of Click-iT EdU imaging assay. Positive cells are green, and examples 
are indicated with red arrows; all nuclei are stained blue with DAPI. Scale bar indicates 50μm and 
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FIGURE 3.4 - Overexpression of c-myc-tagged PRH S163C:S177C in HSV VSMCs retarded 
proliferation 
HSV VSMCs were infected with Ad: Control or Ad: PRH S163C:S177C or were left uninfected.  
Densitometric quantification of p21 protein (A) and cyclin D1 (B) expression by Western blotting; data 
was normalised by stain-free bands and expressed as a fold change from uninfected control.  
* indicates p<0.05, ANOVA, Student-Newman-Keuls Multiple Comparisons Test, n=4 (A) and n=3 (B). 
Error bars represent SEM. 
Representative Western blot for p21 (C) and cyclin D1 (D). Stain-free bands served as a loading 























































3.3.3  PRH S163C:S177C did not affect HSV VSMCs apoptosis  
To investigate the effect of PRH S163C:S177C overexpression on VSMC apoptosis, HSV 
VSMCs were infected with 5 x 108 pfu/mL of adenovirus encoding either empty vector or c-
myc-tagged PRH S163C:S177C, or were left uninfected, for 18 hours. Subsequently, cells 
were incubated for a further 24 hours after replenishing the 10% (v/v) FBS/DMEM. Apoptosis 
was then quantified via immunofluorescence for cleaved caspase-3. As a positive control, cells 
were incubated with 200 ng/mL human recombinant Fas-ligand in 2% (v/v) FBS/DMEM. The 
rate of apoptosis was similar in uninfected cells as those infected with Ad: Control with rates 
between 5 and 9%. Quantification of the percentage of cleaved caspase-3 (CC-3) positive 
cells showed that rate of apoptosis in VSMCs overexpressing PRH S163C:S177C was not 
significantly different from that detected in HSV VSMCs infected with Ad: Control or uninfected 
cells (FIGURE 3.5. Fas ligand-induced VSMCs apoptotic cell death as expected and acted as 












FIGURE 3.4 - Overexpression of c-myc-tagged PRH S163C:S177C did not affect HSV VSMCs 
apoptosis 
HSV VSMCs were infected with Ad: Control or Ad: PRH S163C:S177C or were left uninfected. Fas 
ligand was used as a positive control. 
A – The rate of apoptosis was quantified and expressed as the percentage of cleaved caspase-3-
positive cells. NS denotes not significant. ANOVA, Student-Newman-Keuls Multiple Comparisons 
Test, n=4. Error bars represent SEM. 
 B – Representative images of immunocytochemistry for cleaved caspase-3 (CC-3). Positive cells 
(white arrow) are green, and all nuclei are stained blue with DAPI. Scale bar measures 25 μm and 
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3.3.4  PRH S163C:S177C reduced HSV VSMCs migration 
The scratch wound assay was utilised to investigate the effect of PRH S163C:S177C 
overexpression on VSMC migration. Confluent HSV VSMCs were wounded then incubated 
with 5 x 108 pfu/mL of adenovirus encoding either empty vector or c-myc-tagged PRH 
S163C:S177C, or were left uninfected, for 24 hours. Concurrent treatment with 2 mM 
hydroxyurea inhibited cell proliferation enabling migration to be accurately quantified. The 
migrated distance was quantified by measuring the wound width at 0- and 24-hours post-
wounding. VSMCs migrated approximately 400 mm in uninfected cells (FIGURE 3.6). Infection 
with Ad: Control did not significantly affect the distance migrated (FIGURE 3.6).  The distance 
migrated by HSV VSMCs infected with Ad: PRH S163C:S177C was significantly less than that 
























FIGURE 3.6 – Overexpression of PRH S163C:S177C reduced migration of HSV VSMCs 
The scratch wound assay was used to assess migration of HSV VSMCs infected with Ad: Control or 
Ad: PRH S163C:S177C or were left uninfected. 
A – Migration was quantified in μm; * indicates p<0.05. ANOVA, Student-Newman-Keuls Multiple 
Comparisons Test, n=4. 
B – Representative images of scratch wound assay. Dashed line indicates wound edge. T0 indicates 
Time = 0 hr; T24 indicates Time = 24 hr. Scale bar represents 1 mm and applies to all panels.  
AD: PRH S163C:S177C AD: CONTROL UNINFECTED 
T0 
A   
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3.3.5 PRH S163C:S177C induced protein expression of 
contractile markers 
The contractile markers smoothelin and calponin were quantified using Western blotting. HSV 
VSMCs were infected with 5 x 108 pfu/mL of adenovirus encoding either empty vector or c-
myc-tagged PRH S163C:S177C, or were left uninfected, for 18 hours. Subsequently, cells 
were incubated for a further 24 hours after replenishing the culture medium. Smoothelin and 
calponin proteins were detected at a similar level in both uninfected VSMCs and VSMCs 
infected with Ad:  Control (FIGURE 3.7). Both smoothelin and calponin proteins were 
significantly upregulated in the PRH S163C:S177C-infected VSMCs compared to uninfected 
VSMCs and VSMCs infected with the Ad: Control (FIGURE 3.7). This finding indicates that 
ectopic overexpression of PRH S163C:S177C in VSMCs promotes the contractile and 
























FIGURE 3.7 – The effect of PRH S163C:S177C on contractile protein markers in HSV VSMCs 
HSV VSMCs were infected with Ad: Control or Ad: PRH S163C:S177C or were left uninfected. 
Quantification of smoothelin (A) and calponin (B) protein expression by Western blotting. Data was 
normalised by stain-free bands and expressed as a fold change from uninfected control. * indicates 
p<0.05 vs. uninfected, ** indicates p<0.01. ANOVA, Student-Newman-Keuls Multiple Comparisons 
Test, n=4. Error bars represent SEM. Representative Western blots for smoothelin (C) and calponin 
(D) proteins. Stain-free bands served as a loading control. Approximate molecular weights are 
indicated on the right in kDa. 
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3.3.6  PRH S163C:S177C facilitated HSV VSMCs contraction 
The observation of increased amounts of contractile proteins as a result of PRH S163C:S177C 
overexpression is suggestive of increased contractile potential, and therefore contraction was 
quantified using a collagen contraction assay. HSV VSMCs were infected with 5 x 108 pfu/mL 
of Ad: Control or Ad: PRH S163C:S177C, or were left uninfected, for 18 hours.  Post-infection, 
cells were detached by 0.05% (w/v) Trypsin-EDTA. The collagen gel working solution and 
VSMCs at 0.5 x 105 cells/mL were mixed on ice at a ratio of 1:4. After polymerization for 48 
hours, gels were gently released to allow contraction and then photographed to quantify time-
specific gel contraction. As expected, collagen gel diameter at time 0 was similar in all 
treatment groups and contraction was evident at each time point from 24, 48 and 72 hours in 
all treatment groups (FIGURE 3.8). However, contraction was significantly greater in VSMCS 
infected with Ad: PRH S163C:S177C compared to the uninfected and adenovirus controls at 



























































FIGURE 3.8 – Adenovirus-mediated delivery of Ad: PRH S163C:S177C enhanced contraction of 
VSMCs 
A - Contraction was measured by the relative changes in collagen gel diameter. Serial changes in gel 
area at time 0hr (B), 24hr (C), 48hr (D)  and 72hr (E) with an uninfected control, Ad: Control and 
Ad:PRH S163C:S177C. White lines indicate the size of gel diameter for quantification. Error bars 
indicate SEM.  * indicates p<0.01 vs. uninfected, $ indicates p<0.01 vs. Ad: Control. ANOVA, Student-
Newman-Keuls Multiple Comparisons Test, n=4. 
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3.4  DISCUSSION 
The first objective was to determine the optimal adenoviral concentration for high transfection 
efficiency of adenovirus to achieve high levels of overexpression of S163C:S177C mutant 
PRH (PRH S163C:S177C) in vitro using HSV VSMCs. The second aim was to ascertain 
whether overexpressing PRH S163C:S177C affected the following cell behaviour indices: 
proliferation, apoptosis and migration. The final aim was to discover the effects of PRH 
S163C:S177C on VSMC phenotype.  The ability of PRH S163C:S177C to significantly reduce 
VSMC proliferation and migration without affecting cell death would be attractive properties 
for reducing intima thickening and thereby treating late vein graft failure. A previous study from 
our group found that PRH S163C:S177C can reduce VSMC proliferation and migration without 
affecting cell death in rat cultured VSMCs. For this to be translatable in human grafts, it is 
important to validate these findings in human cells. Hence, the current study utilises human 




3.4.1  PRH S163C:S177C was overexpressed in HSV VSMCs 
It is important to reiterate the advantage of the constitutively active, non-phosphorylatable 
PRH S163C:S177C mutant form over the wild-type PRH counterpart. Wadey and colleagues 
previously demonstrated PRH S163C:S177C PRH was resistant to CK2 phosphorylation and 
therefore exhibited an extended half-life and effectively suppressed rat aortic VSMC 
proliferation and intima thickening in HSV organ cultures (Wadey et al., 2017). For these 
reasons, PRH S163C:S177C was selected for this study.  
 
The current project assesses the efficiency of PRH S163C:S177C overexpression using 
adenoviral-mediated delivery in vitro. The feasibility of vascular gene transfer was first 
established by Nabel et al., in 1989 by seeding retrovirally transduced endothelial cells in 
porcine arteries to study atherosclerosis. Since then, the potential of gene therapy has been 
proclaimed (Williams and Kingston, 2011). Several pre-clinical VGF gene therapy trials for 
potential molecular targets including tissue inhibitor of MMPs (TIMPs), MCP-1 and eNOS 
(George et al.,   1998; George et al.,   2000; West et al.,   2001; Turner et al.,   2005; Akowuah 
et al.,   2005; Schepers et al.,   2006; George et al.,   2011) have shown promising results. 
Nonetheless, up to the present time, the PREVENT-IV study (Lopes et al., 2005) remains as 
the sole randomised clinical trial for VGF which utilises gene expression modification. The 
PREVENT-IV study utilised edifoligide, an E2F transcription decoy, acknowledged to inhibit 
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neointimal lesion formation (Lopes et al., 2005). Despite the promising initial results, the trial 
failed at stage IV as edifoligide did not prevent VGF or adverse events (Lopes et al.,   2005). 
 
Viral vectors are typically used to deliver genetic information to cells (Southerland et al., 2013). 
The viral vector system must perform genetic transfer efficiently and safely.  Adenovirus-based 
gene therapy emerges to be a valuable strategy into ameliorating vein graft disease due to its 
features that permit efficient infection of cells. Adenoviruses can be used to effectively deliver 
transgenes into both dividing and quiescent cells (Lee et al., 2017). This feature is 
advantageous for vein graft gene therapy since many cells within the saphenous vein are 
quiescent, and also following transplantation, a population of VSMCs adopt a proliferative 
phenotype (Mali, 2013). These advantages make adenoviral vectors a good candidate for 
gene therapy for saphenous vein graft failure (Mali, 2013). 
 
Dose-response experiments were performed in this study to achieve a high infection efficiency 
and assess the functional effects of PRH S163C:S177C without the virus causing cell toxicity.  
To directly ascertain that the effect was specifically due to PRH S163C:S177C, a recombinant 
adenovirus expressing an empty vector (Ad: Control) was utilised as well as an uninfected 
control cell. The ΔE1E3 empty construct within Ad: Control is the identical vector to Ad: PRH 
S163C:S177C and as it is an empty vector it does not express a transgene.  Previous findings 
in primary rat aortic VSMCs revealed overexpression of wild-type PRH and PRH 
S163C:S177C via AMAXA plasmid transfection reduced VSMC proliferation (Wadey et al., 
2017). In this current study 5 x 108 pfu/mL was selected as the optimal concentration for high 
transfection efficiency of HSV VSMCs to achieve overexpression of PRH S163C:S177C. 
Western blotting showed that the level of c-myc-tagged PRH S163C:S177C protein was 
significantly elevated in lysates obtained from HSV VSMCs infected with an Ad: PRH 
S163C:S177C compared with those from uninfected VSMCs or VSMCs infected with Ad: 
Control. In addition, immunocytochemistry showed >80% of cells were positive for c-myc-
tagged PRH S163C:S177C protein. Staining was restricted to the nuclear compartment 
suggesting that PRH S163C:S177C is of the hypo-phosphorylated, active state and more 
stable compared to its wild-type protein counterpart. 
 
 
3.4.2 PRH S163C:S177C retarded VSMC proliferation and 
migration 
A previous report demonstrated that in adult male Wistar rats, PRH protein expression was 
undetectable in healthy aorta though abundant levels were observed in neointimal VSMCs of 
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aortas injured with a balloon embolectomy catheter. Reportedly, expression of PRH reached 
its peak 2 weeks following injury then declined thereafter (Sekiguchi et al., 2001). In addition, 
PRH induced expression of a dedifferentiated VSMCs marker, SMemb/NMHC-B (Sekiguchi 
et al., 2001).  As a result, it was proposed that PRH mediates intima thickening in-part via 
promotion of VSMC dedifferentiation (Sekiguchi et al., 2001), although this was not directly 
verified. By way of contradiction, the works of Wadey et al., directly showed that rather than 
inducing intima thickening, ectopic overexpression of PRH S163C:S177C reduced VSMC 
proliferation in cultured rat aortic VSMCs and retarded intima thickening in human saphenous 
vein organ cultures measured by BrdU Assay (Wadey et al., 2017). These data support an 
anti-proliferative role for PRH, contradicting what was previously postulated by Sekiguchi and 
colleagues. It was therefore proposed by Wadey et al. that the PRH protein accumulates in 
proliferating VSMCs of the neointima of injured vessels in order to prevent uncontrolled cell 
proliferation. The results of this current study from EdU incorporation and markers of cell cycle 
progression corroborate the observations of Wadey et al clearly illustrating the anti-
proliferative effects of PRH. 
 
It has been shown that PRH S163C:S177C exerted a prolonged anti-proliferative action with 
respect to wild-type PRH when transiently transfected into primary rat aortic VSMCs (Wadey 
et al., 2017). As mentioned previously, mutation of Ser163 and Ser177 within the PRH 
homeodomain to cysteine residues is preventative of CK2 proliferation therefore increasing 
protein stability, DNA binding potential and transcriptional activity (Noy et al., 2012; Soufi et 
al., 2009).  
 
In support of the anti-proliferative effect of PRH S163C:S177C on EdU incorporation cell cycle 
progression proteins were quantified by Western blotting. Cell cycle progression is a tightly 
controlled event regulated positively by cyclin-dependent kinases and their cyclin- regulatory 
subunits, and negatively by cyclin-dependent kinase inhibitor (CKI) (Andres, 2004). p21 is a 
potent cyclin-dependent kinase inhibitor (CKI) that promotes G1 or G2/M cell cycle arrest in 
response to a variety of stimuli (Andres, 2004). On the other hand, cyclin D1 is another 
important regulator of cell cycle progression that inhibits cell cycle arrest at the G1 phase 
(Topisirovic et al., 2003). A number of reports have demonstrated that p21 inhibits VSMC 
proliferation and injury-induced intima thickening (Bond et al., 2006; Han et al., 2015; Xie et 
al., 2017). Interestingly, it has been previously reported that PRH can repress cyclin D1 protein 
production implicating PRH to arrest cells during the cell cycle phase by decreasing the 
transport of cyclin D1 mRNA via elF4e and PML nuclear bodies (Topisirovic et al., 2003; 
Gaston et al., 2016). The findings in the current study uncover the role of PRH S163C:S177C 
in regulating the levels of cell cycle proteins p21 and cyclin D1 and reveal the proliferative 
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state of VSMCs. The results thus indicate that the antiproliferative effect of PRH 
S163C:S177C in HSV VSMCs is attributable to arrest of the cell cycle in G0/G1 caused, in 
turn, by upregulation of p21 and inhibition of cyclin D1. In line with our proliferation data, PRH 
S163C:S177C have been shown to alleviate the migration of HSV VSMCs. 
 
To determine the role of PRH S163C:S177C in apoptosis and hence cell survival, the 
presence of cleaved caspase-3 protein was quantified. The results showed that PRH 
S163C:S177C had no effect on the number of cells positive for cleaved caspase-3, an 
apoptotic marker, hence, the rate of apoptosis was altered. In agreement with this finding, 
Wadey et al., was unable to detect changes in apoptosis with overexpression of PRH.  
 
 
3.4.3 PRH S163C:S177C stimulates the contractile phenotype 
in VSMCs 
In this chapter, PRH S163C:S177C was discovered to be a novel regulator VSMC phenotype. 
VSMCs are highly differentiated cells with a low proliferative rate and maintain vascular tone 
in mature vessels. In a healthy vessel wall, VSMCs are in a ‘contractile’ state with low 
proliferation and migration rates. However, in disease, they can dedifferentiate into a 
‘synthetic’ phenotype, where they become highly proliferative and migratory, and increase 
ECM protein production. This process is called phenotypic switching and is often the first step 
in vascular pathology (Petsophonsakul et al., 2019). Previous findings by Oyama et al., 
demonstrated induced transcription of the SM22a and smooth muscle α-actin genes in 
response to wild-type PRH using rat embryonic fibroblast cells (Oyama et al., 2004). Yet, 
expression of other contractile markers including calponin and smooth muscle myosin heavy 
chain 1 and 2 did not change in murine embryonic fibroblasts (Oyama et al., 2004). Contrary 
to these findings, the present study found a pronounced increase in smoothelin and calponin 
protein expression following PRH S163C:S177C overexpression. These were further 
validated by the functional collagen contraction assay. For the first time, we have shown that 
cells overexpressing PRH S163C:S177C induced VSMC collagen gel contractile function. 
Conversely, no significant changes were seen in the expression of smooth muscle myosin 
heavy chain 10 and α-SMA (data not shown). Contrary to SM22a and SM α-actin, calponin 
and smoothelin genes are induced at the later stage of differentiation (Beamish et al., 2010). 
Since expression patterns of SM22a and α-SMA occur at the early stages on differentiation, 
difference in our findings could be due to the rate limiting factor of PRH S163C:S177C to 
activate the late stage of VSMC differentiation via SRF. A study by Zhang et al., reported that 
Interferon Regulatory Factor 9 (IRF9) deficiency by IRF9-KO mice have illustrated increased 
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expression of SM22α, α-SMA, and smoothelin in addition to IRF9 overexpression being 
reported to promoting VSMC proliferation, migration and intimal hyperplasia (Zhang et al., 
2014). In another study, loss of glucose-6-phosphate dehydrogenase (G6PD) was reported to 
upregulate the expression of contractile proteins including MYH11, calponin and SM22α in the 
isolated coronary arteries treated with G6PD inhibitor (Chettimada et al., 2016). Most 
importantly, it is essential to note that Oyama’s group performed the experiment using 
pluripotent embryonic fibroblasts in comparison to the present study that utilised HSV VSMCs 
which is more representative the context of vein graft disease. Collectively, the current findings 
show that PRH S163C:S177C regulates VSMC proliferation, migration and survival as well as 
restoring their dedifferentiated, contractile phenotype. 
 
3.4.4  Chapter Summary 
The results of this chapter show that PRH S163C:S177C promoted the contractile phenotype, 
and inhibited migration and proliferation in primary HSV VSMCs. The findings indicate that 
gene therapy to induce elevated levels of PRH could be effective in preventing early-to-mid 
stage VGF, additional methods for increasing levels of PRH S163C:S177C and stabilising the 
protein long-term is attractive when considering therapies for VGF. Hence, the results in this 
chapter provided further evidence that PRH S163C:S177C is a valuable candidate for gene 
therapy in saphenous vein graft failure. Furthermore, it is important to assess the effect of 
PRH S163C:S177C on endothelial cells as endothelial dysfunction could lead to incidences 
of thrombosis. It would be of interest to determine the underlying mechanisms responsible for 
the effect of PRH on VSMC behaviour, hence in Chapter 6, Next Generation Sequencing 
(NGS) was utilised to identify a molecular link and/or mechanism responsible for the effects 








THE EFFECT OF PRH S163C:S177C ON  
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4.1  INTRODUCTION  
The endothelium acts as a crucial functional barrier by controlling the interchange of materials 
between blood and the vessel wall, as well as influencing inflammatory processes, vascular 
tone, thrombogenesis and growth of blood vessels (Ward et al., 2017). During coronary artery 
bypass graft (CABG) surgery, damage to the endothelium occurs as a result of transient 
ischaemia, high pressure distention and tissue handling (Angelini et al.,1987; Conte, 2010). 
Following implantation, exposure of venous endothelial cells to the arterial circulation and 
turbulent blood flow around the sites of anastomoses further exacerbates endothelial 
dysfunction (Gosling et al., 1999, Ward et al., 2017). Disruption of the endothelium is the initial 
step in the pathogenesis of autologous vein graft disease and ultimately restricts the long-term 
efficacy of this surgical intervention (Ward et al., 2017; Favero, 2014, Fitzgibbon et al.,1996, 
Sabik, 2011). Re-endothelialisation begins rapidly after CABG surgery; therefore, it is 
essential that any potential therapy does not retard this process or heighten endothelial 
dysfunction (Ward et al., 2017). Hence, interventions that do not interfere with re-
endothelialisation or can help restore an intact endothelium and normal endothelial function, 
as well as prevent neointima formation and restenosis, are highly desirable to retard VGF. 
Typically, investigation into endothelial dysfunction in disease entails the usage of cultured 
human umbilical vein endothelial cells (HUVECs) (Siow, 2012). HUVECs can be obtained 
relatively easily from umbilical cords which are routinely available from labour and delivery 
wards; however, there is some controversy surrounding whether these cells are representative 
of the adult endothelium as these are isolated from immune-privileged foetal tissue (Zhang et 
al., 2017).  HUVECs express high levels of Fas ligand, which is assumed to encourage 
apoptosis of activated maternal lymphocytes which present the Fas ligand receptor (Guller et 
al., 1999; Zhang et al., 2017). Tan et al., previously reported that HUVECs are very responsive 
to proinflammatory cytokines but have less sensitivity to ox-LDL when compared to adult 
HSVECs (Tan et al., 2004). HSVECs are isolated from excess saphenous vein segments 
remaining after CABG surgery and may therefore be more appropriate for investigating the 
characteristics of the adult large vessel endothelium and for studying the pathogenesis of HSV 
VGF. Thus, the experiments in this current study were conducted in primary cultures of 
HSVECs.  
It has been previously demonstrated that adenovirus-mediated delivery of PRH S163C:S177C 
retarded neointima formation in human saphenous vein organ cultures thereby identifying 
PRH S163C:S177C as a candidate for gene therapeutics in preventing VGF (Wadey et al., 
2017). This study also highlighted that this approach may not impair re-endothelialisation post 
CABG surgery as cell replication, motility and survival was not affected in cultured HUVECs 
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or HSVECs overexpressing wild-type PRH (Wadey et al., 2017); however, the effects of 
introducing PRH S163C:S177C remain to be investigated as well as its impact on other 
aspects of endothelial function including monocyte adhesion and inflammatory cytokine 
production.  
In this chapter, the effect of overexpressing PRH S163C:S177C on endothelial cell behaviour, 
including cellular proliferation, apoptosis and migration was evaluated. Moreover, to discern 
whether PRH S163C:S177C has favourable anti-inflammatory properties, its effects on 







4.2  HYPOTHESES 
The hypotheses for this chapter were: 
▪ PRH S163C:S177C does not affect HSVEC proliferation, apoptosis and migration. 
▪ PRH S163C:177C plays a role in inflammatory responses in HSVECs including 
monocyte adhesion, cytokine release and permeability.  
 
These hypotheses were tested by: 
▪ Quantification of EdU incorporation and Western blotting for proliferative markers p21 
and cyclin D1 was employed to determine the effect of adenovirus-mediated 
overexpression of PRH S163C:S177C on proliferation of HSVECs.  
▪ Immunofluorescence for cleaved caspase-3 was utilised to test the effect of 
adenovirus-mediated overexpression of PRH S163C:S177C on apoptosis of HSVECs.  
▪ The scratch wound assay was utilised to assess the effect of adenovirus-mediated 
overexpression of PRH S163C:S177C on migration of HSVECs.  
▪ Monocyte adhesion assays, qPCR and ELISAs for inflammatory cytokines, and 
permeability assays were used to evaluate the effect of adenovirus-mediated 
















4.3  RESULTS 
4.3.1 Adenovirus-mediated overexpression of PRH 
S163C:S177C in HSVECs 
Previously in Chapter 3, in HSV VSMCs, an approximate 80% infection efficiency was 
achieved with 5 x 108 pfu/ml of adenovirus encoding PRH S163C:S177C. In order to determine 
a concentration for achieving a similar infection efficiency in endothelial cells, HSVECs were 
subjected to infection with c-myc-tagged PRH S163C:S177C expressing recombinant 
adenoviruses at three different viral doses: 0.25 x 108 pfu/ml, 0.50 x 108 pfu/ml and 1 x 108 
pfu/ml. Both uninfected HSVECs and HSVECs infected with identical doses of adenovirus 
encoding an empty vector served as negative controls. Subsequent to an 18-hour incubation, 
culture medium was refreshed with endothelial cell growth medium, and cells were incubated 
for a further 24 hours. Overexpression of the c-myc-tagged PRH S163C:S177C protein was 
assessed via Western blotting and immunofluorescence for c-myc-tagged protein (FIGURE 
4.1 and FIGURE 4.2). As expected, c-myc-tagged protein was not detected in uninfected cells 
or cells subjected to infection with Ad: Control via either Western blotting or 
immunofluorescence (FIGURE 4.1 and FIGURE 4.2). The c-myc-tagged PRH S163C:S177C 
were detected at 42 kDa on Western blots. Immunofluorescence for c-myc-tagged protein 
revealed an approximate infection efficiency of 80% in cells infected with 1 x 108 pfu/ml of Ad: 
PRH S163C:S177C, thus a comparable efficiency was obtained in HSVECs and HSV VSMCs 
(FIGURE 4.2).  
To investigate whether comparable levels of PRH S163C:S177C protein expression is 
achieved between the two cell types, HSVECs and HSV VSMCs were infected with an 
adenovirus encoding c-myc-tagged PRH S163C:S177C as described previously. As the viral 
load must be identical for comparative experiments, HSVECs were infected 1 x 108 pfu/ml Ad: 
PRH S163C:S177C and supplemented with 4 x 108 pfu/ml of Ad: Control to achieve a final 
viral concentration of 5 x 108 pfu/ml as this was used for infection of HSV VSMCs with Ad: 
PRH S163C:S177C. For both cell types, cells were cultured with the virus for 18 hours and 
then were cultured for a further 24 hours in fresh cell growth medium. Subsequently, cell 
lysates were collected for Western blot analysis of the c-myc-tagged PRH S163C:S177C 
transgene. Analysis of Western blots revealed comparable levels of PRH S163C:S177C 

























 FIGURE 4.1 - Detection of c-myc-tagged PRH S163C:S177C in HSVECs using Western 
Blotting 
HSVECs were either infected with 0.25 x 108 pfu/mL, 0.5 x 108 pfu/mL or 1 x 108 pfu/mL Ad: Control  
or Ad: PRH S163C:S177C or were left uninfected. 
A – Densitometry analysis of c-myc-tagged PRH S163C:S177C protein expression normalised to 
stain free gel. * indicates p<0.05 vs. uninfected, $ indicates p<0.05 vs. Ad: Control, ANOVA, Student-
Newman-Keuls Multiple Comparisons Test, n=4. Error bars represent standard error of mean SEM. 
B - Representative Western blot of c-myc-tagged PRH S163C:S177C protein. Stain-free bands 


































FIGURE 4.2 - Detection of c-myc-tagged PRH S163C:S177C in HSVECs using 
Immunocytochemistry. 
HSVECs were either infected with 0.25 x 108 pfu/mL, 0.5 x 108 pfu/mL or 1 x 108 pfu/mL Ad: Control  
or Ad: PRH S163C:S177C or were left uninfected. 
A – Quantification of percentage of cells expressing c-myc-tagged PRH S163C:S177C protein. * 
indicates p<0.05 vs. uninfected, $ indicates p<0.05 vs. all Ad: Control, ANOVA, Student-Newman-
Keuls Multiple Comparisons Test, n=4.Error bars represent SEM. 
B – Representative images of immunocytochemistry for c-myc-tagged protein. Positive cells have 
green nuclei and examples are indicated with red arrows; all nuclei are stained blue with DAPI. Scale 
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FIGURE 4.3 – Comparable overexpression of c-myc-tagged PRH S163C:S177C in HSVECs and 
HSV VSMCs 
HSV VSMCs were infected with 5 x 108 pfu/mL of Ad: PRH S163C:S177C. HSVECs were infected 
with 1 x 108 pfu/mL of adenovirus encoding c-myc-tagged PRH S163C:S177C combined with 4 x 108 
pfu/mL Ad: Control. 
A - Quantification of c-myc-tagged protein by Western blotting; data was normalised by stain-free 
bands. NS denotes not significant, unpaired, two-tailed Student’s t-test, n=4.Error bars represent 
SEM. 
B - Representative Western blot for c-myc-tagged PRH S163C:S177C protein. Stain-free bands 
served as a loading control.  Approximate molecular is indicated on the right in kDa.  
  








































































































4.3.2  PRH S163C:S177C did not affect HSVECs proliferation 
To investigate whether ectopically increasing PRH S163C:S177C protein levels affects 
proliferation of endothelial cells, HSVECs infected with 1 x 108 pfu/ml Ad: PRH S163C:S177C 
supplemented with 4 x 108 pfu/ml of Ad: Control for 18 hours. The controls were HSVECs 
infected with 5 x 108 pfu/ml of Ad: Control or uninfected HSVECs. Cells were cultured for a 
further 24 hours in fresh endothelial cell growth medium supplemented with 10 μM EdU for 
Click-iT EdU, and without EdU for Western blot analysis of proliferative markers cyclin D1 and 
p21. Quantification of EdU incorporation showed that the rate of proliferation in HSVECs 
overexpressing PRH S163C:S177C was not significantly different to that detected in HSVECs 
infected with Ad: Control and uninfected control HSVECs (FIGURE 4.4). CyclinD1 and p21 
were detected at 21 kDa and 36 kDa on Western blots, respectively. Analysis of Western blots 
revealed that overexpression of PRH S163C:S177C protein expression in HSVECs did not 
influence the levels of cyclin D1 or p21 protein compared to uninfected control HSVECs and 








FIGURE 4.4 – Overexpression of c-myc-tagged PRH S163C:S177C in HSVECs did not affect the 
rate of proliferation 
HSVECs were infected with 1 x 108 pfu/mL of Ad:PRH S163C:S177C combined with 4 x 108 pfu/mL 
Ad: Control, or 5 x 108 pfu/mL Ad: Control, or were left uninfected. 
A – EdU incorporation was quantified and expressed as the percentage of EdU-positive cells. NS 
denotes not significant, ANOVA, Student-Newman-Keuls Multiple Comparisons Test, n=4. Error bars 
indicate SEM. 
B – Representative images of Click-iT EdU imaging assay. Positive cells have green nuclei and 
examples are indicated with red arrows; all nuclei are stained blue with DAPI. Scale bar measures 
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FIGURE 4.5 – Overexpression of c-myc-tagged PRH S163C:S177C in HSVECs did not cyclin D1 
and p21 protein levels 
HSVECs were infected with 1 x 108 pfu/mL Ad: PRH S163C:S177C combined with 4 x 108 pfu/mL Ad: 
Control, or 5 x 108 pfu/mL Ad: Control or were left uninfected. 
Quantification of p21 (A) and Cyclin D1 (B) protein expression by Western blotting; data was 
normalised by stain-free bands and expressed as a fold change from uninfected control. NS denotes 
not significant, ANOVA, Student-Newman-Keuls Multiple Comparisons Test, n=4. Error bars indicate 
SEM. Representative Western blot for p21 (C) and Cyclin D1 (D). Stain-free bands served as a 








4.3.3  PRH S163C:S177C reduced HSVECs apoptosis 
To investigate the effect of PRH S163C:S177C overexpression affected HSVEC apoptosis, 
HSVECs infected with 1 x 108 pfu/ml Ad: PRH S163C:S177C supplemented with 4 x 108 pfu/ml 
of Ad: Control, or 5 x 108 pfu/ml of Ad: Control or left uninfected for 18 hours. Cells were then 
cultured for another 24 hours after replenishing the culture medium. As a positive control, cells 
were incubated with 200 ng/mL human recombinant Fas ligand in 2% FBS endothelial cell 
growth medium. Subsequently, apoptosis was assessed via immunocytochemistry for cleaved 
caspase-3. As expected, Fas ligand significantly increased the rate of apoptosis compared to 
that observed in the control uninfected HSVECs (FIGURE 4.6). Quantification of the 
percentage of cleaved caspase-3 positive cells showed that rate of apoptosis in HSVECs 
overexpressing PRH S163C:S177C was significantly lower than the rate of apoptosis in 









FIGURE 4.6 - Overexpression of c-myc-tagged PRH S163C:S177C in HSVECs reduced 
apoptosis 
HSVECs were infected with 1 x 108 pfu/mL Ad: PRH S163C:S177C combined with 4 x 108 pfu/mL Ad: 
Control, or 5 x 108 pfu/mL Ad: Control or were left uninfected. 
A – The percetage of CC-3 positive cells (apoptotic cells) was quantified. ** indicates p<0.01 vs. 
uninfected or Ad: Control. ANOVA, Student-Newman-Keuls Multiple Comparisons Test, n=4. Error 
bars indicate SEM. 
B – Representative images of immunofluorescence for cleaved caspase-3. Positive cells have green 
nuclei and examples are indicated with red arrows; all nuclei are stained blue with DAPI. Scale bar 
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4.3.4  PRH S163C:S177C did not affect HSVECs migration 
The scratch wound assay was utilised to investigate the effect of PRH S163C:S177C 
overexpression on endothelial cell migration. HSVECs infected with 1 x 108 pfu/ml Ad: PRH 
S163C:S177C supplemented with 4 x 108 pfu/ml of Ad: Control, or 5 x 108 pfu/ml of Ad: Control 
or left uninfected for 18 hours. Subsequently, the confluent monolayers of HSVECs were 
wounded then incubated for a further 24 hours. Treatment with 2 mM hydroxyurea inhibited 
cell proliferation and enabled assessment of migration only. The distance migrated was 
quantified by measuring the wound at 0- and 24-hours post-wounding. No significant effect on 
the distance migrated was observed across all treatment conditions: uninfected or infected 











FIGURE 4.7 – Overexpression of PRH S163C:S177C did not affect migration of HSVECs 
HSVECs were infected with 1 x 108 pfu/mL Ad: PRH S163C:S177C combined with 4 x 108 pfu/mL Ad: 
Control, or 5 x 108 pfu/mL Ad: Control or were left uninfected and migration assessed using the 
scratch wound assay.  
A – Migration was quantified and expressed as distance migrated in μm; NS denotes not significant, 
ANOVA, Student-Newman-Keuls Multiple Comparisons Test, n=4.Error bars indicate SEM. 
B – Representative images of the scratch wound assay. Dashed line indicates wound edge. T0 
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4.3.5   PRH S163C:S177C attenuated TNFα-induced monocyte       
...................adhesion 
Adhesion of circulating monocytes to the endothelial surface is a key step in the onset of 
localised vascular inflammation and disease progression (Ley et al.,2007). To investigate the 
effect of PRH S163C:S177C expression on monocyte adhesion, HSVECs were infected with 
1 x 108 pfu/ml Ad: PRH S163C:S177C supplemented with 4 x 108 pfu/ml of Ad: Control, or 5 
x 108 pfu/ml of Ad: Control or left uninfected for 18 hours. Subsequently, cells were stimulated 
with 10 ng/mL TNFα for a further 24 hours to induce endothelial activation and an inflammatory 
response. Calcein-labelled THP-1 cells were then co-cultured with the activated endothelial 
monolayer for 30 minutes and the number of adherent THP-1 cells quantified. At baseline 
levels, HSVECs in the absence of TNFα very few THP-1 cells adhered to the HSVECs (data 
not shown). As expected, stimulation of HSVECs with TNFα induced an approximate 10-fold 
induction in THP-1 cell adhesion in uninfected HSVECs (data not shown).  The number of 
adherent THP-1 monocytes was not affected as a result of infection of HSVECs with the 
control adenovirus compared to uninfected HSVECs (FIGURE 4.8). Interestingly, a significant 
reduction in the number of adherent monocytes was observed when TNFα-treated HSVECs 
were infected with Ad: PRH S163C:S177C compared to uninfected HSVECs and HSVECs 








































FIGURE 4.8 – Overexpression of PRH S163C:S177C attenuated monocyte adhesion in TNFα-
stimulated HSVECs 
HSVECs were infected with 1 x 108 pfu/mL Ad: PRH S163C:S177C combined with 4 x 108 pfu/mL Ad: 
Control, or 5 x 108 pfu/mL Ad: Control or were left uninfected. HSVECs were subsequently stimulated 
with TNFα for 24 hours, then co-cultured with calcein-labelled THP-1 cells to assess monocyte 
adhesion.  
A – Monocyte adhesion was quantified and expressed as the average number of adherent cells per 
field viewed.  *** indicates p<0.001, ANOVA, Student-Newman-Keuls Multiple Comparisons Test, 
n=4. Error bars indicate SEM. 
B – Representative images showing adherent calcein-labelled THP-1 cells. Red arrow indicates some 
of the adherent THP-1 cell. Scale bars represent 1000µm and applies to all panels. 
AD: CONTROL 












































4.3.6 PRH S163C:S177C attenuated monocyte adhesion to 
HSVECs exposed to LSS 
Endothelial cell activation is associated with increased low wall sheer stress (LSS) upon 
implantation of the vein graft into the arterial circulation and its exposure to high pulsatile 
pressures (Ward et al., 2017). A simple rocker‑induced mechanical stimulus can be utilised to 
mimic LSS such that is observed in atheroprone regions of the vasculature exposed to 
disturbed flow (Tucker et al., 2014; Potter et al., 2011; Dhawan et al., 2010). Having shown a 
reduction in monocyte adhesion in TNFα-stimulated HSVECs, we then investigated the effect 
of ectopic overexpression of PRH S163C:S177C on monocyte adhesion in HSVECs exposed 
to LSS. HSVECs were infected with 1 x 108 pfu/ml Ad: PRH S163C:S177C supplemented with 
4 x 108 pfu/ml of Ad: Control, or 5 x 108 pfu/ml of Ad: Control or left uninfected for 18 hours. A 
static control was also included. Then, cells were cultured for another 24 hours after 
replenishing the culture medium under either static or LSS conditions (30 rpm). Calcein-
labelled THP-1 cells were subsequently co-cultured with HSVECs for 30 minutes and the 
number of adherent THP-1 cells quantified. As expected, monocyte adhesion was elevated in 
uninfected HSVECs subjected to LSS with respect to uninfected HSVECs cultured under static 
conditions (FIGURE 4.9). In addition, no significant changes in the number of adherent THP-
1 cells were observed between uninfected and Ad: Control groups, where HSVECs were 
cultured under LSS conditions (FIGURE 4.9). The attachment of monocytes to LSS-stimulated 
endothelial cells was significantly attenuated by the introduction of PRH S163C:S177C in 




FIGURE 4.9 – Overexpression of PRH S163C:S177C attenuated monocyte adhesion in HSVECs 
subjected LSS 
HSVECs were infected with 1 x 108 pfu/mL Ad: PRH S163C:S177C combined with 4 x 108 pfu/mL Ad: 
Control, or 5 x 108 pfu/mL Ad: Control or were left uninfected, and subsequently cultured for a further 
24 hours under LSS conditions, then co-cultured with calcein-labelled THP-1 cells to assess 
monocyte adhesion. A static uninfected control was included.  
A – Monocyte adhesion was quantified and expressed as the average number of adherent cells per 
field viewed.   
*** indicates p<0.001, ANOVA, Student-Newman-Keuls Multiple Comparisons Test, n=4. Error bars 
indicate SEM. 
B – Representative images showing adherent calcein-labelled THP-1 cells. Red arrow indicates some 
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4.3.7 PRH S163C:S177C downregulated ICAM-1 and VCAM-1 
in HSVECs 
Previous studies have demonstrated that upregulation of adhesion molecules ICAM-1 and 
VCAM-1 facilitates recruitment and infiltration of leukocytes into the vessel wall (Kluger, 2004; 
van Buul et al., 2007). Having demonstrated that adenoviral-mediated expression of PRH 
S163C:S177C reduced monocyte adhesion in TNF-α-stimulated HSVECs, down-regulation of 
ICAM-1 and VCAM-1 protein was investigated as a potential mechanism. To investigate the 
effect of PRH S163C:S177C expression on endothelial cell adhesion molecules, HSVECs 
infected with 1 x 108 pfu/ml Ad: PRH S163C:S177C supplemented with 4 x 108 pfu/ml of Ad: 
Control, or 5 x 108 pfu/ml of Ad: Control or left uninfected for 18 hours. Subsequently, cells 
were stimulated with 10 ng/mL TNFα for a further 24 hours to induce endothelial activation 
and an inflammatory response.  Western blotting analysis demonstrated expression of ICAM-
1 and VCAM-1 protein in uninfected HSVECs (FIGURE 4.10). Infection with Ad: Control did 
not significantly alter the amount of ICAM-1 and VCAM-1 proteins compared to uninfected 
HSVECs (FIGURE 4.10). However, a significant reduction in the amount of ICAM-1 and 
VCAM-1 proteins was observed in HSVECs overexpressing PRH S163C:S177C compared to 
















































FIGURE 4.10 – Overexpression of PRH S163C:S177C reduced levels of ICAM-1 and VCAM-1 
proteins in TNFα-stimulated HSVECs 
HSVECs were infected with 1 x 108 pfu/mL Ad: PRH S163C:S177C combined with 4 x 108 pfu/mL Ad: 
Control, or 5 x 108 pfu/mL Ad: Control or were left uninfected. Quantification of VCAM-1 (A) and 
ICAM-1 (B) proteins was achieved using Western blotting. Data were normalised using stain-free 
bands and expressed as a fold change from uninfected control.  ** indicates p<0.01, ANOVA, 
Student-Newman-Keuls Multiple Comparisons Test, n=4. Error bars indicate SEM. 
Representative Western blots of VCAM-1 (C) and ICAM-1 (D). Stain-free bands served as a loading 





















































4.3.8  PRH S163C:S177C downregulated expression of IL-6 and 
MCP-1 in HSVECs 
To ascertain whether adenovirus-mediated overexpression of PRH S163C:S177C inhibited 
the production of key endothelial inflammatory cytokines and mediators, the mRNA and 
protein levels of IL-6 and MCP-1 were quantified.  HSVECs were infected with 1 x 108 pfu/ml 
Ad: PRH S163C:S177C supplemented with 4 x 108 pfu/ml of Ad: Control, or 5 x 108 pfu/ml of 
Ad: Control or were left uninfected for 18 hours. Cells were cultured for a further 24 hours in 
fresh endothelial cell growth medium. Cells were lysed and RNA was collected. IL-6 and MCP-
1 mRNA levels were quantified via qPCR. Additionally, condition media was collected from 
cultured HSVECs to measure the levels of secreted IL-6 and MCP-1 proteins using ELISA.  
 
qPCR analysis and ELISAs revealed that IL-6 and MCP-1 mRNAs and proteins, respectively 
were present in uninfected cells (FIGURE 4.11). Infection of HSVECs with Ad: Control did not 
significantly influence mRNA of IL-6 and MCP-1 compared to uninfected control HSVECs 
(FIGURE 4.11 A&B). Notably, infection of HSVECs with PRH S163C:S177C lowered levels of 
IL-6 and MCP-1 mRNAs with respect to HSVECs infected with Ad: Control and uninfected 
control HSVECs (FIGURE 4.11 A&B). ELISAs showed that compared to uninfected HSVECs, 
infection of HSVECs with Ad: Control did not affect levels of secreted IL-6 and MCP-1 proteins 
(FIGURE 4.11 C&D). Strikingly, adenovirus-mediated gene transfer of PRH S163C:S177C 
suppressed levels of secreted IL-6 and MCP-1 proteins with respect to both control groups 




























FIGURE 4.11 – Overexpression of PRH S163C:S177C downregulated IL-6 and MCP-1 mRNA 
and secreted protein levels in HSVECs 
HSVECs were infected with 1 x 108 pfu/mL Ad: PRH S163C:S177C combined with 4 x 108 pfu/mL Ad: 
Control, or 5 x 108 pfu/mL Ad: Control or were left uninfected. Quantification of IL-6 (A) and MCP-1 
(B) proteins in conditioned media by ELISA; data is expressed in pg/ml. Quantification of IL-6 (C) and 
MCP-1 (D) mRNA levels by qPCR. Data are normalised by 36B4-house keeping gene- and 
expressed as a fold change from uninfected control. * indicates p<0.05, ** indicates p<0.01, *** 






























































4.3.9 PRH S163C:S177C did not alter the permeability of a 
HSVEC monolayer 
Regulation of permeability is maintained through an intricate network of intercellular contacts 
situated in the cleft between endothelial cells (Mundi et al., 2018; Chen and Yeh, 2017). To 
ascertain whether adenovirus-mediated delivery of PRH S163C:S177C affected endothelial 
cell permeability, a simple permeability assay was conducted. HSVECs were infected with 1 
x 108 pfu/ml Ad: PRH S163C:S177C supplemented with 4 x 108 pfu/ml of Ad: Control, or 5 x 
108 pfu/ml of Ad: Control or were left uninfected for 18 hours. Cells were cultured for a further 
24 hours in fresh endothelial cell growth medium.  Treatment of HSVECs with TNFα was 
utilised as a positive control as it is known to significantly enhance endothelial cell permeability 
(Ley et al., 2007). As expected, TNFα markedly enhanced HSVEC permeability compared to 
unstimulated HSVECs (FIGURE 4.12). Permeability was not significantly affected by infection 
with Ad: Control compared to uninfected HSVECs. Similarly, infection with Ad: PRH 
S163C:S177C did not affect endothelial cell permeability compared to uninfected control 





















































FIGURE 4.12 – Overexpression of PRH S163C:S177C did not permeability of HSVEC 
monolayers 
HSVECs were infected with 1 x 108 pfu/mL Ad: PRH S163C:S177C combined with 4 x 108 pfu/mL Ad: 
Control, or 5 x 108 pfu/mL Ad: Control or were left uninfected. TNFα was used a positive control.  
Permeability of HSVECs seeded in Transwell inserts to streptavidin-HRP was quantified and 
expressed as fold change from uninfected. NS denotes not significant, $ indicates p<0.05 vs. 
uninfected, Ad: Control and PRH S163C:S177C, ANOVA, Student-Newman-Keuls Multiple 






4.4  DISCUSSION 
The first aim of this chapter was to determine an appropriate viral dose for Ad: PRH 
S163C:S177C for achieving a comparable infection efficiency in HSVECs as achieved in HSV 
VSMCs. The second aim was to determine whether Ad: PRH S163C:S177C overexpression 
would interfere with HSVEC replication and migration, or apoptosis. The last aim was to 
examine whether PRH S163C:S177C overexpression affected inflammatory properties of 
HSVECs. 
 
4.4.1 Comparable expression of PRH S163C:S177C in VSMCs 
and ECs 
In Chapter 3, infection of HSV VSMCs with adenovirus encoding PRH S163C:S177C at a 
dose of 5 x 108 pfu/mL achieved a transfection efficiency of approximately 80%. Additionally, 
it was shown that infection of HSV VSMCs with 5 x 108 pfu/mL of Ad: PRH S163C:S177C or 
adenovirus expressing an empty vector did not induce apoptotic cell death, suggesting that 
the viral load was not compromising cell viability. As described in section 4.3.1, an equivalent 
infection efficiency was achieved in HSVECs using a much lower viral concentration of 1 x 108 
pfu/mL of Ad: PRH S163C:S177C. Interestingly, adenovirus-mediated gene transfer of PRH 
S163C:S177C at a concentration of 1 x 108 pfu/mL was only sufficient to achieve an 
approximate 10% infection efficiency in primary HSV VSMCs (Section 3.3.1).  However, the 
utilisation of different amount of virus would confound results when comparing the two cell 
types. Hence, in HSVECs, overexpression of PRH S163C:S177C required a combined dose 
of 4 x 108 pfu/mL Ad: Control and 1 x 108 pfu/mL Ad: PRH S163C:S177C to ensure an 
equivalent viral load was delivered as previously in HSV VSMCs.  
Gene therapy for cardiovascular diseases has emerged as a potential therapy to treat vein 
graft stenosis. Major attention has been focused on how saphenous vein grafts can be treated 
ex-vivo prior to grafting (Owens et al., 2015; George et al., 2011). The goal of gene therapy is 
to introduce new genetic material into target cells without invoking toxicity to non-target 
tissues. Genetic material can be transferred via a vector or a vehicle (viral or non-viral) for 
delivery (Mali, 2013). However, gene transfer technologies related to efficacy and safety 
continue to present problems hence hindering significant progress in this field. In a non-viral 
approach, electroporation-mediated plasmid transfer into vein grafts ex vivo achieved 
potentially therapeutic effects (Yamoaka et al., 2005). In 2014, Ohnaka and colleagues had 
demonstrated the ability of a non-viral and plasmid-based miR-145 gene transfer to venous 
grafts abrogated intimal thickening formation (Ohnaka et al., 2014). Unfortunately, the 
efficiency of transfection to the vasculature is relatively poor limiting its success. Furthermore, 
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results of clinical trials of plasmid-mediated cardiovascular gene therapy to date have been 
disappointing as a result of their incapability to prompt high efficiency gene delivery in vivo. 
(Williams and Kingston, 2011). On the other hand, adenovirus has been used extensively for 
vascular gene therapy due to successful efficiencies in vitro and in vivo. Central to the entire 
discipline of achieving overexpression of therapeutic transgenes within the vasculature is the 
utility of adenovirus type-5 (George et al., 2011; Kritz et al.,2008; George et al., 2000); 
however, extremely high doses of adenovirus type-5 (typically >1010 pfu per graft) are often 
required for successful uptake across the vessel wall. For example, it has been previously 
shown that adenoviral overexpression of TIMP-3 in porcine vein grafts promotes VSMCs 
apoptosis and retards intimal thickening (George et al., 2000; George et al., 2011). Although 
utility of adenoviruses is hampered by the potential of generating an immune response against 
DNA and its inability to traverse cells (Young and Dean, 2015; French et al.,1994; Newman et 
al.,1995), adenoviruses remain to have a clear advantage as the most efficient gene delivery 
vector due to it yielding high expression of the transgene which can be achieved in vitro and 
in vivo (Chen, Wilson and Muller, 1995; Kupfer et al.,1994). Hence, the present study utilised 
adenovirus gene transfer system to deliver the PRH S163C:S177C transgene. 
Sensitivity of ECs to adenoviral vectors has been found to be much higher in comparison to 
VSMCs (Zhou et al.,1995). Reportedly, transfection rates of approximately 80% were found in 
ECs although a disappointing transfection efficacy of only 40% in VSMCs at the viral titre of 
10 x 109 pfu/ml (Zhou et al.,1995).  In support of this notion, profiling of receptor expression in 
VSMCs and ECs has illustrated vanishingly low levels of the adenovirus primary attachment 
receptor called as coxsackievirus and adenovirus receptor (CAR) in human VSMCs (Parker 
et al., 2013) and an absence of expression in intact human vessels (Vigl et al., 2009) which 
could explain the discrepancy in infection efficiencies and necessity for high input titres of 
adenovirus for efficient infection in VSMCs in this project and previous studies. Although there 
is a general lack of knowledge to explain this, Parker and colleagues suggested that at high 
titres, it is probable that the observed upregulation of integrin αvβ3 and αvβ5 in human VSMCs 
promotes adenovirus internalisation, though this does not necessarily explain the mechanism 
for cell attachment (Wickham et al.,1993).  
 
4.4.2 PRH S163C:S177C does not have detrimental effects on 
HSVEC proliferation, migration and survival 
In designing therapies for vein graft disease, it is essential that the intervention does not 
exacerbate endothelial cell loss or impair re-growth of endothelium so as to prevent 
postoperative thrombotic occlusion and eventual failure of the vein graft.   
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As mentioned previously, there is evidence to suggest that cultured HUVECs may not be 
representative of the adult endothelium; therefore, in this study, primary cultures of HSVECs 
were utilised as these are the most relevant cell type, particularly for studying HSV graft failure.  
Previously in our laboratory, Wadey et al. subjected primary cultures of HUVECs and HSVECs 
to plasmid-mediated overexpression of wild-type PRH to examine its effects on endothelial 
cell proliferation, migration and survival. Interestingly, in contrast to the effects observed in 
VSMCs, overexpression of wild-type PRH did not significantly affect cell cycle progression, 
cell motility or cell survival indices in HSVECs in vitro (Wadey et al., 2017). Similarly, in this 
study, it was observed that overexpression of PRH S163C:S177C in HSVECs via adenoviral 
delivery did not significantly affect endothelial proliferation, migration or apoptosis (Sections 
3.3.2, 3.3.3 and 3.3.4). Of interest, additional work in the recent years have been conducted 
investigating the effect of wild-type PRH in mouse lung microvascular endothelial cells have 
shown translocation of uPA to the cell nuclei through its kringle or binding motif of wild-type 
PRH upregulates vegfr1 and vegfr2 expression. Such transcriptional repression has been 
reported to induce EC motility, invasion and proliferation thereby promoting angiogenesis. 
Although, the mechanism of how it induces an angiogenic switch through coordinate up-and/or 
down-regulation of genes involved in endothelial cell proliferation, adhesion and migration 
warrants further investigation (Stepanova et al., 2016). 
In summary, these findings demonstrate that forced expression of PRH S163C:S177C did not 
affect apoptosis, proliferation or migration of HSVECs, indicating that using such an 
intervention to reduce intimal thickening via retarding VSMC proliferation should not have 
detrimental effects on re-endothelialisation. Future studies directly measuring re-
endothelialisation may involve investigating the effect of re-endothelialisation in the vessel 
scaffold. 
 
4.4.3 The anti-inflammatory properties of PRH S163C:S177C in 
HSVECs 
The initial reaction to vascular injury is associated to the inflammation of the arterial wall. 
Inflammation may be multifactorial although aberrant influx of monocytes is one of the first 
phenomena seen as a result of vascular injury during intimal hyperplasia (Yang, Chang and 
Wei, 2016). The augmentation of cytokines, chemo-attractants and cell adhesion molecules 
has been increasingly recognised as key indicators of disturbed endothelial function (Ward et 
al., 2017). For instance, Interleukin-6 (IL-6) and monocyte chemotactic factor-1 (MCP-1) are 
pro-inflammatory mediators implicated in the pathogenic mechanism of vascular disease 
progression (Mudau et al., 2012). In addition, it is known that augmented levels of these 
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proinflammatory cytokines mediate the acceleration of neointimal hyperplasia within the 
implanted venous graft (Mudau et al.,2012; Ward et al., 2017). Other inflammatory mediators 
such as the intracellular adhesion molecule-1 (ICAM-1) and vascular cellular adhesion 
molecule-1 (VCAM-1) as well as including those of the selectin family (E-selectin and P-
selectin) permit monocyte trafficking into the blood vessel, via adherence of monocytes to the 
vascular endothelium, and transmigration into the vessel walls (Yang, Chang and Wei, 2016).  
Furthermore, vascular wall impermeability to solutes and lipoproteins is an integral property 
of a functional endothelium (Mundi et al.,2018; Chen and Yeh, 2017). 
Ultimately, monocyte recruitment, cytokine release and increased permeability of the graft wall 
leads to compromised graft efficacy due to subsequent vein wall adaptation and abnormal 
functionality within the endothelium. The total sum of these processes acts as the driving 
mechanisms resulting hyperplastic response and pathological intimal hyperplasia and lumen 
loss failing vein graft (Ward et al., 2017). For example, the macrophage was acknowledged 
as a fundamental cellular mediator of intimal thickening within the SVG in which macrophage 
depletion also reduces hyperplasia of vein grafts (Hoch et al.,1994). Focusing on the 
maintenance of EC functionality post-surgical trauma is integral in pre- and peri-operatively of 
vein grafts. Current treatments addressing the implications of these inflammatory components 
have received attention in the recent years. Anti-inflammatory cytokine-based therapies have 
emerged wherein currently, statins and aspirin treatment remain to be the only recommended 
primary intervention for patients with CAD (Kang et al.,2013; Hillis et al., 2012).  Statins exerts 
several modes of actions during cardiothoracic surgical procedure including primarily through 
cholesterol lowering by inhibiting β-Hydroxy β-methylglutaryl-CoA (HMG-CoA) reductase 
(Kulik et al., 2011). These have been shown to improve endothelial function, thwart VSMC 
proliferation and reduce macrophage activation and improve vascular endothelial function. In 
the CASCADE (Clopidogrel after Surgery for Coronary Artery Disease) trial, statin therapy has 
been proven to improve management of post-operative hyperlipidaemia/dyslipidaemia and 
prevent vein graft stenosis in coronary grafts after CABG (Kulik et al., 2011). Although several 
studies are underway to find new targets and therapies, there are somewhat key unmet needs 
in the field of VGF prevention. The principal findings from the CANTOS trial showed that 
canakinumab (150 mg), a monoclonal antibody targeting Interleukin 1 beta (IL-1β) inhibition, 
has demonstrated positive effects on inflammatory therapy in patients with atherosclerosis 
(Ridker et al., 2017).  Unfortunately, progress in the overall effect of this anti-inflammatory 
agent had been underwhelming and the prospect of targeting inflammation seems to be slim 
to none. This is due to several reasons due to high risk of side effects such as higher rates of 
infection and the significant risk of fatal infection as well as the expensive annual cost of 
approximately $200,000 (Thompson and Nidorf, 2018). 
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In this chapter the anti-inflammatory profile of PRH S163C:S177C has been examined. Two 
VGF relevant inflammatory scenarios were utilised TNFα-activation and LSS. Monocyte 
recruitment is one of the earliest events in VGF (Yang, Chang and Wei, 2016). PRH 
S163C:S177C was able to prevent monocytes from adhering to TNFα-stimulated ECs. TNFα 
is a pleiotropic pro-inflammatory cytokine regulated at both the transcriptional and translational 
level. TNFα is produced by a variety of cell types such as macrophages, monocytes, 
endothelial cells, fibroblasts, and VSMCs (Ley et al., 2007; Ozaki, 2007). It has been 
demonstrated to possess a pivotal role in vein graft neointima by triggering interactions 
between invading monocytes and vascular endothelial cells thereby activating inflammation-
induced endothelial dysfunction and apoptosis (Ward et al., 2017). Additionally, TNFα 
enhances adhesion molecules expression in human vascular endothelial cells (Ley et al., 
2007) and VSMCs (Yan et al., 2017).  
Following implantation into the arterial circulation system, the implanted vein graft undergoes 
haemodynamic adaptation that promotes graft stenosis. Several previous studies have 
implicated LSS in the development of EC inflammatory responses (Chiu et al., 2011; Shyy et 
al.,1994; Dewey et al.,1981). At the site of the end-to-side anastomosis and venous valves, 
LSS on the endothelia-blood interface facilitates recruitment of circulating leukocytes and 
inflammatory cells. LSS often leads to EC activation and consequently impairs the function of 
the endothelium resulting in platelet aggregation and stimulate proliferative VSMCs (Kumar et 
al., 2018). In support of this notion, LSS has been associated with increased expression of 
pro-inflammatory mediators and recruitment of leukocytes in response to release of cytokines 
including TNFa, whereas exposure to laminar blood flow and high shear stress are anti-
inflammatory and thereby atheroprotective (Yoshizumi et al., 2003). 
As observed with TNFα-stimulation, under LSS culture conditions, there was decreased 
monocyte adhesion to HSVECs infected with Ad: PRH S163C:S177C. In activated endothelial 
cells, upregulation and presentation of adhesion molecules VCAM-1 and ICAM-1 has been 
reported to facilitate monocyte adhesion (Chen and Yeh, 2017). Moreover, several studies 
have reported an upregulation of these adhesion molecules in the context of VGF (Zhang et 
al., 2013; George et al., 2011; Hölschermann et al., 2006). Since endothelial cell activation is 
mediated by combinatorial factors, this current study selected to investigate the effects of PRH 
S163C:S177C on the endothelial expression of adhesion molecules, VCAM-1 and ICAM-1 as 
these are recognised to play a critical role in mediating firm adhesion of circulating leukocyte 
into the vascular endothelium under pathological conditions (Sans et al., 1999). On the other 
hand, well-known markers of inflammation, IL-6 and MCP-1 were selected to be examined 
owing to their recognised pro-inflammatory role in VGF (Fu et al.,2012; Christiansen et al., 
2004). For instance, studies have described the critical role of IL-6 stimulation in MCP-1 
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secretion and recruitment of monocytic cells (Su et al., 2017). In response to PRH 
S163C:S177C overexpression, transcript and protein levels of these two inflammatory 
proteins were downregulated in HSVECs. Thus, validating a novel, anti-inflammatory role for 
PRH S163C:S177C. It is important to note that since PRH S163C:S177C is known to be 
important in multiple cell types, this work has important implications for the emerging role of 
highly conserved serine/threonine kinase CK2 in immunity (Gibson and Benveniste, 2019). As 
described in the previous chapters, PRH S163C:S177C is a mutant version of wild-type PRH 
that represses CK2 phosphorylation (Jayaraman et al., 2018; Siddiqui et al., 2017; Wadey et 
al., 2017). Recent work on inflammatory diseases has reported CK2 augments inflammation 
signifying inhibition may warrant anti-tumour immunity. For example, glomerulonephritis is a 
progressive inflammation and CK2 expression have been identified to be markedly increased 
at the inflammatory sites in rat glomerulonephritis model (Yamada et al., 2005). Conversely, 
the decline in pro-inflammatory cytokine secretion of IL-6 was mediated by pharmacologic 
inhibition of CK2 using Silmitasertib (CX-4945) in inflammatory breast cancer xenograft 
models (Drygin et al., 2011). Often linked to chronic inflammation, hepatocellular cancer 
(HCC) has been associated with overexpression of CK2α. In particular, the oncogenic role of 
CK2α in HCC has been demonstrated by its ability to enhance proliferation, colony formation, 
migration, and invasion in vitro (Zhang et al., 2015). 
Under normal circumstances, the quiescent endothelium protects the vascular tree by 
promoting anti-coagulant and anti-inflammatory properties and mediates endothelial 
permeability preventing thrombus formation (Chiu et al., 2011). The exposure of the 
endothelium in vascular injury may cause endothelial barrier disruption and increased vascular 
permeability which has been linked to ICAM-1 expression (Sumagin, Lomanika and Sarelius, 
2008). Previous data have demonstrated that uPA increases EC permeability through VEGF 
signalling although binding of uPA to wild-type PRH inhibits their capacity to repress promoter 
activity of vehgr1 and vehgr2 (Stepanova et al., 2016) highlighting PRH S163C:S177C to 
potentially regulate the control of vascular permeability.  In this study, following confirmation 
of an anti-inflammatory response to PRH S163C:S177C in cultured HSVECs, endothelial 
permeability was examined in unstimulated HSVECs although there were no significant 
differences observed across all conditions. Perhaps pre-treatment of HSVECs with TNFα to 
destabilize endothelial junctions would have yielded a role for PRH S163C:S177C in restoring 
barrier function in activated endothelial cells.  Interestingly, a previous report demonstrated 
Silmitasertib-treatment int mice post TNFα stimulation was associated with decreased 
microvascular permeability. Although, under non-stimulated conditions, the CK2 inhibitor 
Silmitasertib which acts to restore wild-type PRH was unable to modify permeability and EC-
leukocyte binding (Ampofo et al., 2015). 
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4.4.3  Chapter Summary 
To date, no study has comprehensively examined the relationship between PRH 
S163C:S177C and inflammatory markers in endothelial cells. This project has illustrated that 
to achieve a similar infection efficiency in HSVECs and HSV VSMCs different doses of 
adenovirus are required. The results indicate that PRH S163C:S177C is unlikely to 
significantly disrupt re-endothelialisation, though it is unlikely to assist it either. Interestingly, 
PRH has demonstrated efficacy in attenuating inflammatory mediators of VGF suggesting the 
anti-inflammatory properties of Ad: PRH S163C:S177C. These findings may represent an 
exciting and unexplored strategy for improving vein graft outcome, with PRH emerging as a 









OVEREXPRESSION OF PRH S163C:S177C 
ATTENUATED INTIMAL THICKENING IN MURINE 
CAROTID-ARTERY LIGATION MODEL 
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5.1  INTRODUCTION 
Autologous HSV grafts conduits are the most favoured for revascularisation of the distal 
cardiac tissue (Harskamp et al., 2013). Despite the frequent use of HSV, the risks of 
thrombotic occlusions, intimal thickening and superimposed atherosclerotic lesions within 
grafted conduits during 10 years after surgery persists to be a major clinical problem (Wan et 
al., 2012). To date, there are 2,600 gene therapy clinical trials with a remarkable upsurge in 
the number of trials entering late phases, demonstrating the promise of this exciting 
therapeutic approach (Ginn et al., 2018). The previous chapters revealed that overexpression 
of a modified form of the transcription factor PRH to a more stable form resistant to CK2 
phosphorylation in endothelial cells and VSMCs yielded beneficial properties that could result 
in reduced intimal thickening and thereby retard VGF. To directly assess the efficacy of PRH 
S163C:S177C to reduce intimal thickening in vivo use of an animal is required. 
 
Studies utilising animal models of intimal thickening have enabled researchers to better 
evaluate the potential of novel therapies for vein graft failure as well as unravel the molecular 
mechanisms behind restenosis (Holt and Tulis, 2013). For example, vascular injury induced 
by balloon angioplasty in rats has served as a powerful tool for studying vascular remodelling 
(Li et al.,2017). The mouse model of femoral artery denudation injury is another established 
model of intimal thickening (Lindner and Kumar, 1997) which stimulates arterial injury via 
endothelial denudation and arterial stretch (Le et al.,2015). Although in comparison to the 
other two models, ligation of the carotid artery is a robust and reproducible method. Firstly, a 
complete ligation of the vessel near the carotid bifurcation in a mouse disrupts the blood flow 
hence, inducing rapid VSMC proliferation and intimal thickening distal to the ligation site 
(Smolock and Berck, 2012).  Secondly, it is highly achievable, reproducible injury model that 
stimulates intimal thickening without causing injury to the tunica media of the blood vessel. 
Lastly, this model differs from others as it does not require mechanical trauma and protects 
the endothelium (Xu, 2004; Ku, 1985). In line with this notion, there are an accumulating 
evidence from our group demonstrating the utility of a murine model for vascular occlusion 
using carotid artery ligation in C57BL6/J mice to induce intimal thickening.  For example, 
Brown and colleagues were able to demonstrate that Wnt4-mediated proliferation is 
unaffected by age using the same model of stenosis (Brown et al.,2017). In a study by Curtis 
and colleagues, overexpression of the dominant negative N-cadherin using an adenovirus 
permitted significant suppression of intimal thickening in the mouse carotid artery ligation 
model (Hulin-Curtis et al., 2017).  Similarly, we employed the use of C57BL6/J mice which has 
the advantages of strain stability and ease of breeding that makes them predominantly useful 
in our study. It is inexpensive and the easiest model to use because lesions are typically 
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acquired precipitously, and it does not demand much equipment (Xu, 2004). For these 
reasons, this in vivo model of intimal thickening in particular has proven to be successful in 
testing functions of the target genes, thus, an attractive preliminary tool and experimental 
system to elucidate knowledge concerning the pathogenesis of vein graft intimal thickening. 
 
The potential of PRH S163C:S177C in suppressing VSMC proliferation and migration has 
been demonstrated in chapter 3. Additionally, PRH S163C:S177C augmented the VSMCs 
phenotypic differentiation into the ‘contractile’ state with high levels of calponin and 
smoothelin. Moreover, PRH S163C:S177C exerted anti-inflammatory properties in HSVECs 
without influencing endothelial repair capacity through proliferation, migration and apoptosis. 
Together this provides strong in vitro data implicating that artificial modulation of PRH 
S163C:S177C possess the ability to impede the VSMC pathogenic phenotype without 
detrimental effects on endothelial cells. Consequently, assessment of the ability of PRH 
S163C:S177C to retard intimal thickening in a pre-clinical model is warranted. Utilisation of 
the mouse carotid artery ligation model enabled evaluation of the ability of PRH S163C:S177C 




5.2  HYPOTHESIS 
 
The hypothesis for this chapter were: 
Overexpression of PRH S163C:S177C in ligated mouse carotid arteries in vivo: 
• suppresses ligation-induced intimal thickening, 
• upregulates contractile proteins and thereby may prevent VSMC de-
differentiation, 
• does not significantly reduce endothelial coverage. 
 
This hypothesis was tested by: 
• Examining the effect of PRH S163C:S177C overexpression on intimal thickening in 
the murine carotid artery ligation model via assessing: 
o intimal:medial ratio, lumen occlusion, proliferation, migration, and intimal and 
medial cell density in both intimal by histological staining and 
immunohistochemistry for BrdU. 
• expression of contractile markers smoothelin and calponin by immunohistochemistry, 
• endothelial coverage by immunohistochemistry for CD31  
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5.3  RESULTS 
5.3.1 Attenuation of intimal thickening, I/M ratio, and lumen 
occlusion by overexpression of Ad: PRH S163C:S177C in 
the murine carotid artery ligation model 
The first aim was to determine the effect of PRH S163C:S177C on intimal thickening in vivo 
was assessed in a reproducible and established model of restenosis which is routinely 
employed in our laboratory (Williams et al., 2011). The model entails ligation of the left 
common carotid artery near the carotid bifurcation to induce intimal thickening. However, 
before embarking on the 28-day study it was important to ensure expression of c-myc-tagged 
PRH S163:S177C protein at 7 days after adenovirus delivery and ligation. In the pilot study, a 
total of 7 mice (4 males and 3 females) underwent ligation surgery. Following ligation, arteries 
were surrounded by 100ul of 30% (w/v) Pluronic F-127 (Sigma Aldrich) gel containing 1.33 x 
108 pfu/mL replication-defective adenoviral constructs encoding either an empty vector (Ad: 
Control) or c-myc-tagged S163C:S177C PRH. After 7 days left carotid arteries were removed 
for immunofluorescence detection of c-myc-tagged PRH S163C:S177C. Immunofluorescence 
confirmed no expression of c-myc-tagged protein in left carotid arteries from mice infected 
with Ad: Control 7 days after infection, while c-myc-tagged PRH S163C:S177C protein was 
observed within the left carotid arteries 7 days post ligation infected with Ad: PRH 
S163C:S177C (FIGURE 5.1 A&B). As expected, the detected c-myc-tagged PRH 
S163C:S177C protein was exclusively detected within nuclei (FIGURE 5.1 B). Sections 
incubated with non-immune rabbit IgG detected no c-myc-tagged protein (FIGURE 5.1 C&D, 
demonstrating the specificity of the protocol. 
 
For the analysis of intimal thickening in the 28-day study, 14 mice in each group (7 males and 
7 females) underwent ligation surgery. Following ligation, arteries were surrounded by 30% 
(w/v) Pluronic F-127 (Sigma Aldrich) gel containing 1 x 108 pfu/mL replication-defective 
adenoviral constructs encoding either an empty vector (Ad: Control) or c-myc-tagged 
S163C:S177C PRH. After carotid ligation injury, mini-osmotic pump was implanted sub-
cutaneously to deliver BrdU and enable proliferation and migration to be quantified. Intimal 
thickening was allowed for 28 days before retrieval of left carotid arteries. Out of the 28 mice 
that underwent ligation, two mice died during surgery due to the anaesthetic and prior to 
addition of the adenovirus, and one mouse in the Ad: Control group was excluded from 
analysis due to an incomplete artery ligation. Thus, in total, 13 and 12 ligated left carotid 
arteries were analysed in the Ad: Control and Ad: PRH S163C:S177C groups, respectively.  
 
 134 
Miller’s Elastic van Giesen (EVG) staining revealed intimal thickening formation 28 days post 
ligation in the longitudinally oriented formalin-fixed and paraffin-embedded carotid arteries. 
The intimal area, intimal-medial ration and % occlusion was measured as described in 
2.12.2.2. A significant reduction in intimal area in carotid arteries infected with Ad: PRH 
S163C:S177C with respect to the empty vector (Ad: Control) (FIGURE 5.2). The intimal‑
medial ratio was markedly greater in the Ad: Control group compared to the Ad: PRH 
S163C:S177C group (FIGRUE 5.2). Furthermore, the Ad: Control group exhibited 80% lumen 
occlusion whilst the % occlusion observed in the Ad: PRH S163C:S177C group was 


































FIGURE 5.1: Overexpression of c-myc-tagged PRH S163C:S177C protein in ligated carotid 
arteries 
Carotid arteries were ligated in C57BL6/J mice then infected with Ad: Control or Ad: PRH 
S163C:S177C. 
Representative images of immunofluorescence for c-myc-tagged protein at day 7 post ligation and 
infection. White dashed line indicates the intima-lumen boundary. Positive cells have green nuclei 
(some are indicated with red arrows); negative cells are stained with DAPI and have blue nuclei. 













FIGURE 5.2: Overexpression of PRH S163C:S177C protein attenuated neointimal area, I/M ratio 
and % occlusion of the lumen 
Ligated mouse carotid arteries received adventitial delivery of Ad: Control (n=13) or Ad: PRH 
S163C:S177C (n=13). After 28 days the arteries removed and subjected to EVG staining.  
Representative images of EVG-stained left carotid arteries (A) Ad: Control and (B) Ad: PRH 
S163C:S177C. Scale bar represents 200 μm (top panels) and 50 μm (bottom panels). The intimal 
area (C), intimal:medial (I/M) ratio (D) and percentage occlusion of the lumen (E) were measured.  * 
indicates p<0.05, **** indicates p<0.0001, unpaired, two-tailed Student’s t-test, n=13 (Ad: Control) and 
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5.3.2 Overexpression of PRH S163C:S177C attenuated intimal 
proliferation without affecting the cell density 
It was observed in chapter 3 that overexpression of PRH S163C:S177C inhibited proliferation 
of isolated HSV VSMCs (see section 3.3.2). To determine whether PRH S163C:S177C 
suppression of VSMC proliferation in vivo, mini-osmotic pumps containing BrdU were 
implanted subcutaneously at the time of ligation. BrdU release from the mini-osmotic pump 
enabled quantification of the fraction of cells undergoing replication in the media and intima 
using immunohistochemistry for incorporated BrdU. Furthermore, intimal cell density was 
calculated by counting DAPI-stained nuclei and normalising this value by the intimal area. In 
addition, to provide an estimate of intimal-directed VSMC migration, non-proliferative, BrdU-
negative cells were quantified and normalised by the length of the intimal thickening.  
 
The proportion of proliferative BrdU-positive nuclei in the media and intima was significantly 
lower in the Ad: PRH S163C:S177C group than in the Ad: Control group (FIGURE 5.3A&B). 
The estimated number of migratory cells (BrdU-negative nuclei in the intima) was also 
significantly lower in the Ad: PRH S163C:S177C group than in the Ad: Control group (FIGURE 
5.3C). Sections incubated with non-immune mouse IgG showed minimal staining. 
Overexpression of PRH S163C:S177C did not however affect the cell density in both the 
medial and intimal layers (FIGURE 5.4). Together, these data suggest that Ad: PRH 
S163C:S177C inhibits medial and intimal VSMC proliferation as well as migration of cells into 

















FIGURE 5.3: Overexpression of PRH S163C:S177C attenuated cell proliferation and migration 
in ligated carotid arteries 
Carotid arteries were ligated in C57B/L6 mice to induce intimal thickening then infected with Ad: 
Control (A) or Ad PRH S163C:S177C (B). Representative images of immunohistochemistry for BrdU 
at day 28. Black dashed line indicates the intima-media boundary. BrdU-positive cells have brown 
nuclei (some are indicated with red arrows); BrdU-negative cells are stained with haematoxylin and 
have grey/blue nuclei for Ad: Control (C) and Ad PRH S163C:S177C (D) (some are indicated with 
black arrows). The scale bar represents 50 μm and applies to all images. 
Proliferation was quantified in the media (E) and intima (F) and expressed as the percentage of BrdU-
positive cells. The rate of migration (G) was estimated by quantifying the number of BrdU-negative 
nuclei in the intima divided by the length of the intimal thickening. NS denotes not significant, * 
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FIGURE 5.4 Overexpression of PRH S163C:S177C did not affect cellular density in ligated 
carotid arteries 
Carotid arteries were ligated in C57B/L6 mice to induce intimal thickening then infected with Ad: 
Control or Ad PRH S163C:S177C. Quantification of cell density in the medial (A) and intimal (B) 
layers 28 days after ligation. Data is expressed as the number of cells per mm2 of neointima. NS 




5.3.3 Overexpression of PRH S163C:S177C did not influence 
expression of α smooth muscle cell actin 
To identify VSMCs in the ligated left carotids, sections were subjected to immunofluorescence 
detection of αSMA. Almost all cells in the media and the intima (except some on the intimal 
surface) were αSMA positive. There was no significant difference was noted in αSMA density 
between Ad: Control and Ad: PRH S163C:S177C groups (FIGURE 5.5). Negative control 



























FIGURE 5.5: Overexpression of PRH S163C:S177C did not influence expression of αSMA 
protein in ligated carotid arteries  
Carotid arteries were ligated in C57B/L6 mice to induce intimal thickening then infected with Ad: 
Control (A&C) or Ad PRH S163C:S177C (B&D).  
Representative images of immunofluorescence for αSMA (A&B) and non-immune IgG (C&D), 28 
days after ligation. αSMA -positive cells are stained green (some are indicated with red arrows) and 
the nuclei of all cells are stained blue/grey with DAPI. White dashed line indicates the intima-media 












5.3.4 Overexpression of PRH S163C:S177C did not influence 
expression of the contractile markers smoothelin and 
calponin 
In a healthy vessel wall, VSMCs exhibit a ‘contractile’ state which is less proliferative and 
migratory. Injury to the vessel facilitates the transformation of contractile VSMCs to the 
synthetic phenotype, where they rapidly proliferate and migrate, and increase their synthesis 
and secretion of ECM proteins (Petsophonsakul et al., 2019; Biswas et al., 2014). In Chapter 
3 it was observed that infection of cultured HSV VSMCs with Ad: PRH S163C:S177C 
promoted the contractile state of VSMCs by upregulating their expression of contractile 
markers smoothelin and calponin. To investigate whether this effect was also observed in vivo 
in the murine carotid artery ligation model, retrieved carotids were subjected to 
immunohistochemistry for smoothelin and calponin. Results showed that there was no 
difference in the expression of these contractile markers between Ad: Control and Ad: PRH 
































FIGURE 5.6: Overexpression of PRH S163C:S177C did not influence expression of smoothelin 
and calponin proteins 
Carotid arteries were ligated in C57B/L6 mice to induce intimal thickening then infected with Ad: 
Control (A,C&E) or Ad PRH S163C:S177C (B,D&F). Representative images of immunofluorescence 
for calponin (A&B), smoothelin (C&D) and non-immune IgG (E&F) 28 days after ligation. Smoothelin- 
or calponin-positive cells are stained brown (some are indicated with red arrows); the nuclei of all cells 
are stained blue/grey with haematoxylin. Black dashed line indicates intimal: medial boundary. Scale 
bar represents 25 μm and applies to all panels. 
Ad: Control Ad: PRH 
S163C:S177C 
E F 
Ad: Control Ad: PRH 
S163C:S177C 









5.3.5 Overexpression of PRH S163C:S177C did not influence 
endothelial coverage 
It is vital that a therapeutic intervention for vein graft failure must not disrupt the endothelium 
as well as retard the development of intimal thickening (Ward et al.,2017). In Chapter 4, it was 
observed that infection of cultured HSVECs with Ad: PRH S163C:S177C did not affect 
endothelial cell behaviour such as proliferation and migration. To investigate whether Ad: PRH 
S163C:S177C affected endothelial coverage in vivo in the murine carotid artery ligation model, 
retrieved carotids were subjected to immunohistochemistry for cluster of differentiation 31 
(CD31) which is an established marker of endothelial cells. Results showed that there was no 
difference in the expression of CD31 between Ad: Control and Ad: PRH S163C:S177C 
























FIGURE 5.7: Overexpression of PRH S163C:S177C did not influence endothelial coverage 
Carotid arteries were ligated in C57B/L6 mice to induce intimal thickening then infected with Ad: 
Control (A&C) or Ad PRH S163C:S177C (B&D). Representative images of immunofluorescence for 
CD31 (A&B) and non-immune IgG (C&D) 28 days after ligation. CD31-positive cells are stained 
brown (some are indicated with red arrows); the nuclei of all cells are stained blue/grey with 
haematoxylin. Black dashed line indicates intimal: medial boundary. Scale bar represents 25 μm and 
















5.4  DISCUSSION 
To investigate the ability of PRH S16C:S177C overexpression to reduce intimal thickening 
and thereby elucidate its potential as a therapeutic intervention for VGF, the effect of 
overexpression of these proteins in vivo was investigated using a murine carotid artery ligation 
model of intimal thickening.  
 
5.4.1  Inhibition of intimal thickening by PRH 163C:177C 
The findings of chapters 3 and 4 illustrated that overexpression of PRH S163C:S177C can 
impede VSMC proliferation, migration without inducing damaging effects on endothelial 
function in vitro. Therefore, it was hypothesized that overexpression of PRH S163C:S177C 
would result in reduced intimal thickening and resultant luminal narrowing in the established 
murine carotid artery ligation model. To date, the effect of PRH S163C:S177C overexpression 
in VGF and restenosis has not been investigated in vivo. These findings would strengthen the 
current reports on the therapeutic benefits of PRH S163C:S177C overexpression in human 
organ cultures ex vivo. 
 
The central findings of this chapter clearly demonstrate the ability of PRH S163C:S177C 
overexpression in attenuating pathological intimal thickening. Morphological analysis of intimal 
thickening 4 weeks post-carotid artery ligation revealed that occlusion of the arterial lumen, 
intimal area and intima:media ratios were all significantly more pronounced in arteries 
subjected to infection with adenovirus encoding an empty vector versus those infected with 
Ad: PRH S163C:S177C. The influence of PRH S163C:S177C in reducing intimal thickening 
was first proposed by Wadey and colleagues, describing Ad: PRH S163C:S177C and CK2 
inhibitors as suppressors of VSMC proliferation and intimal thickening in human saphenous 
vein organ cultures (Wadey et al., 2017). Although the study by Wadey and colleagues utilised 
human saphenous vein organ culture in order to model intimal thickening, direct experimental 
testing in prospective animal models of human disease is essential to verify the potential of 
PRH S163C:S177C in pre-clinical research and support the proposition of investigations in 
larger animal models of VGF prior to clinical trials. 
 
In this study, a murine carotid artery ligation model was employed in order to tackle the 
obstacles in understanding whether and how overexpression of PRH S163C:S177C might 
influence intima thickening in vivo. In this model, the left carotid artery is ligated near the 
carotid bifurcation and stenotic lesions begin to develop approximately 2-4 weeks post-surgery 
(Brown et al., 2018). This model was selected as it is a well-established robust model that 
reproducibly leads to intimal thickening as a result of VSMC migration and proliferation 
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(Williams et al., 2016; Williams et al., 2014; Tsaousi et al., 2011) and it is amenable to 
adenovirus-mediated gene therapy (Hulin-Curtis et al., 2017).  This reproducible and simple 
model has become a widely appealing tool with minimal mechanical trauma, low ischemic 
injury, and absence of a major inflammatory response (Xu, 2004). However, it has been widely 
postulated that stenotic lesions form at sites of altered haemodynamic or low sheer stress 
(Ley et al., 2007); for this reason, the carotid ligation model may fail to completely replicate all 
of the relevant conditions that lead to VGF in humans (Hulin-Curtis et al., 2017; Xu, 2004). 
Nevertheless, our in vivo murine model of carotid artery ligation remains to be a very suitable 
model for evaluating potential therapies for suppression of VGF and studying the mechanisms 
behind proliferation and migration of VSMCs.  
 
Over-reliance on male mice in scientific animal research has led to female subjects becoming 
underappreciated; this is due to belief that inclusion of females leads to more data variability 
(Beery, 2018; Beery and Zucker, 2011). Utilisation of exclusively male mice was hence 
rationalised as being a means of producing more reproducible data and thereby being more 
cost-effective (Beery, 2018). However, emerging studies claim that gender influences the 
results and may alter data interpretation, thus, new ARRIVE guidelines stipulate that in vivo 
research must involve inclusion and balance of both male and female subjects and must not 
be limited to one gender (Percie du Sert et al., 2020). It has also been assumed that female 
subjects exhibit more variability than males (Beery, 2018), although this has been challenged 
by a meta-analysis centring on neuroscience research (Becker, 2016). Of interest, studies 
have shown that women are more susceptible to comorbid conditions post-CABG surgery 
highlighting the necessity to examine therapeutic interventions for CVD in both genders 
(Nicolini et al., 2016; den Ruijter et al., 2015; Alam et al., 2013; Bukkapatnam et al., 2010; 
Abramov et al., 2000). In this study in vivo study, both male and female mice were included to 




5.4.2  Attenuation of neointimal proliferation and migration by 
overexpression of PRH S163C:S177C  
In vitro analysis revealed a notable reduction in HSV VSMCs proliferation, along with an 
induction in p21 protein expression and a reduction in cyclin D1 protein levels in response to 
PRH S163C:S177C overexpression. Data from the in vivo study showed that PRH 
S163C:S177C overexpression suppressed aberrant proliferation of medial and intimal cells in 
ligated carotid arteries. As such, this implicates the success and effectiveness of the 
 
 150 
adventitial delivery of Ad: PRH S163C:S177C to achieve reduction proliferation that results in 
attenuated intimal thickening. In parallel, detailed analysis revealed that migration from the 
media into the intima was also impaired by infection with Ad: PRH S163C:S177C. However, 
this was only an estimation of cellular migration calculated by measuring the proportion of 
BrdU-negative nuclei in the intima divided by the intimal length. These data indicated that PRH 
S163C:S177C overexpression impaired intima development via antagonising intimal-directed 
migration as well as replication. Comparably, Wadey and colleagues reported adenovirus-
mediated gene transfer of PRH S163C:S177C notably disrupted intimal thickening and 
proliferation ex vivo implicating possible translational aspirations into humans. Conflictingly, 
gene transfer of PRH S163C:S177C did not influence the rate of VSMC migration in human 
organ cultures (Wadey et al., 2017). The discrepancy between the in vivo and ex vivo findings 
may be due to differences between the infection efficiencies and existence of other factors 
such as blood and vasoactivity in vivo. No significant changes were detected in medial and 
intimal VSMC density as determined by the haematoxylin staining and immunohistochemistry 
for α-smooth muscle cell actin.  
 
It is shown in this chapter that PRH S163C:S177C which is a more stable form of PRH, lowers 
the migratory potential of artery cells whilst preventing the rate of VSMC replication in our in 
vivo model. In a clinical setting genetic transfer into the venous graft may occur peri-
operatively prior to implantation of the graft due to its simplicity and it can avoid the systemic 
side-effects of medications. Therefore, it is important that PRH S163C:S177C is a stable 
protein since a single exposure to PRH S163C:S177C-encoding adenoviruses alone is only 
permitted for perivascular therapy in humans during the grafting surgical procedure. 
 
 
5.4.3  PRH S163C:S177C did not affect the levels of αSMA, 
Calponin and Smoothelin 
Upon vascular injury, VSMCs switch from the quiescent and differentiated contractile 
phenotype to the highly proliferative and de-differentiated synthetic phenotype 
(Petsophonsakul et al., 2019; Biswas et al., 2014). This process in is tightly controlled by the 
transcription factor serum responsive factor (SRF). SRF recognises and binds to CArG 
sequences and thereby activates a range of cytoskeletal and contractile genes (Miano, 2012). 
A smooth muscle and cardiac muscle-specific accessory factor called myocardin is recruited 
by SRF to induce the genes involved in VSMC differentiation and proliferation 
(Petsophonsakul et al., 2019). These master regulators functions as a transcriptional switch 
with numerous reports implicating the loss of binding state between SRF and myocardin de-
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activates expression of VSMC-specific contractile genes. Hence, promoting the de-
differentiation phenotype which leads to abnormal proliferation, migration, and matrix 
production in VSMCs (Biswas et al., 2014; Oyama et al., 2004). The only report associating 
PRH to VSMC phenotypic markers was by Oyama and colleagues who showed that PRH 
associates with SRF to induce SM22α and αSMA transcript levels in embryonic fibroblasts, 
which are markers of the VSMC contractile phenotype (Oyama et al., 2004). Similarly, the in 
vitro findings earlier in this thesis have corroborated that gene transfer of PRH S163C:S177C 
drives VSMCs into their contractile state, in part, through upregulating the expression of 
calponin and smoothelin. In the current study, we have demonstrated that almost all of cells 
present in the intima and media are SMCs and therefore it is appropriate to state that the 
detected proliferation and estimate of migration largely relates to VSMCs. 
 
αSMA is an established marker of VSMCs.  In line with the findings of Wadey and colleagues 
(Wadey et al., 2017), our current study found there was no significant difference in the αSMA 
density of cells overexpressing Ad: PRH S163C:S177C compared to the Ad: Control and 
uninfected control (FIGURE 5.5). However, previous studies have shown that αSMA is not a 
good marker of VSMC phenotype as it is not highly regulated during phenotypic switching but 
rather it is preserved in both synthetic and contractile VSMCs (Xu et al., 2012; Aikawa et al., 
1993). In order to evaluate the effect of PRH S163C:S177C on VSMC phenotype, protein 
expression of calponin and smoothelin was examined in ligated carotid arteries, where 
calponin and smoothelin are markers of VSMC differentiation (Lepreux et al., 2013. Although 
PRH S163C:S177C overexpression enhanced levels of calponin and smoothelin in primary 
cultures of human saphenous vein VSMCs, no significant changes in the levels of calponin 
and smoothelin were detected in the media or intima of ligated carotid arteries. The reason for 
the discrepancy is unclear. It is possible that the inconsistency in our findings may be a result 
of temporal factors: in vitro, HSV VSMCs were infected with Ad: PRH S163C:S177C for 18 
hours and then cultured for a further 24 hours whereas in vivo, Ad: PRH S163C:S177C was 
administered for 28 days. Hence, it is possible that ability of PRH S163C:S177C to induce 
expression of the contractile markers smoothelin and calponin is time limited. To investigate 
this, one could retrieve and analyse vessels at an earlier time-point following carotid ligation 
in order to study the ability of PRH S163C:S177C to modulate VSMC phenotype at the early 
stages of intimal thickening. Another added consideration is that of, which was our vector of 
choice to deliver PRH S163C:S177C, high seroprevalence rates of pre-existing neutralizing 
antibodies against Ad5 (Bauer et al., 2005; Sumida et al., 1995) may have restricted infection 
efficiency and delivery of the PRH S163C:S177C transgene. It seems that gene transfer of 
S163C:S177C at 28 days is sufficient to mitigate the proliferative and migratory actions 
although sustained expression of the protein may be required to regulate the expression of 
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the contractile markers smoothelin and calponin. Utilisation of a novel adenovirus vector with 
amplified vascular transduction and improved resistance to serum neutralising antibodies 
(White et al., 2013). It is also worth considering that intimal thickening occurs within 2 weeks 
of vascular injury, and that by day 28 when arteries were retrieved, VSMCs may have returned 
to their contractile phenotype (Kumar and Lindner 1997, Godin et al. 2000).  
 
5.4.4  PRH S163C:S177C did not affect the endothelial coverage 
Thrombosis, intimal thickening and superimposed atherosclerosis are direct consequences of 
endothelial dysfunction or impaired post-operative re-endothelialisation (Wadey et al., 2017). 
In Chapter 4, we provide an in vitro evidence demonstrating that overexpression of PRH 
S163C:S177C did not significantly alter proliferation and migration but reduced apoptosis in 
HSVECs. Data from our in vivo study illustrates that overexpression of PRH S163C:S177C 
had no detrimental effect in the endothelium compared to the control empty virus 28 days 
post-ligation. Similarly, previous work from our laboratory have shown that PRH 
S163C:S177C did not affect endothelial cell coverage via immunohistochemistry for QBEND-
10 in a 14-day human saphenous vein organ culture compared to the controls (unpublished 
data). With respect to these results, data from our current study strengthens the protective 
effects of PRH S163C:S177C overexpression to the endothelium making it an ideal 
preventative measure against VGF.   
 
5.4.4  Chapter Summary 
The long-term benefits of HSV grafts are compromised by intimal thickening. This study 
provides in vivo evidence for the therapeutic benefits of PRH overexpression to reduce 
proliferation and migration of VSMCs in the vessel wall following vascular injury using a robust 
and established model of intimal thickening. Though our evidence suggests that PRH 
S163C:S177C overexpression does not enhance the number of  
VSMCs exhibiting a contractile phenotype, the potential of this gene therapy approach to 
reduce intimal thickening and thereby VGF remains convincing. Overexpression of PRH 
S163C:S177C may therefore prolong viability of vein grafts and improve patency rates. 
Altogether, data is presented that shows for the first time that adenoviral gene delivery of PRH 
S163C:S177C can retard intimal thickening in vivo presenting a novel strategy to combat 
restenosis associated with CABG surgery. It is conceivable that these findings may have 





















IDENTIFICATION OF NOVEL PRH S163C:S177C 




6.1  INTRODUCTION  
Previous studies have revealed PRH regulates several genes directly (Soufi and Jayaraman, 
2008). The first aim of this chapter is to utilise an unbiased transcriptomic approach to identify 
genes that are associated with the anti-mitotic activity of PRH S163C:S177C in VSMCs. The 
second aim is to directly examine the expression and function of some of the identified target 
genes. Next generation sequencing (NGS) was employed to compare mRNA expression in 
VSMCs and HSVECs overexpressing PRH S163C:S177C and thereby identify genes that are 
specifically regulated in VSMCs, but not in HSVECs. HSV VSMCs and HSVECs were infected 
with an empty vector adenovirus (Ad: Control) and PRH S163C:S177C-expressing 
recombinant adenovirus (Ad: PRH S163C:S177C). The function of identified VSMC-specific 
PRH S163C:S177C target genes identified using the NGS was investigated, and to 
characterise the effect of their up- or down-regulation by PRH additional analyses were 
undertaken. This could potentially identify new targets for therapeutic intervention using novel 
small molecules or repurposed pharmacological agents. 
In 2003, Sanger sequencing or ‘first-generation’ DNA sequencing was used to accomplish the 
Human Genome Project (Hagermann, 2015).  First described by Sanger in 1977, the chain-
terminating dideoxynucleotides using DNA polymerase became the primary method for DNA 
sequencing for approximately four decades (Sanger, Nicklen and Coulson, 1977). Since then, 
there has been an extensive demand for low-cost and high-throughput sequencing methods. 
The commercial introduction of NGS in 2005 has transformed identification of novel genes 
progressively more practical where an individual's entire genome can be sequenced 
inexpensively ($0.001/kb) within 2 days (Fogel et al., 2016). Contrary to the conventional 
capillary-based Sanger sequencing, the massively parallel sequencing capabilities of NGS 
allows for sequencing millions of DNA fragments per run. High sequencing coverage via NGS 
technology is now achievable, leading to a significant growth of novel gene discovery 
(Hagermann, 2015). 
Our knowledge of PRH is fundamentally limited by the availability of reports in the literature 
and its novelty as a candidate gene in cardiovascular diseases. With the aim of closing this 
gap NGS enables the identification of target genes throughout the entire proteome. 
Fortunately, the progress in bioinformatic analysis allows us to better interpret the gene 
expression profiles as revealed using NGS. One advanced bioinformatic tool is the Ingenuity 
pathway analysis (IPA) software program, which can analyse the gene expression patterns 
using a build-in scientific literature-based database (according to IPA Ingenuity Web Site, 
www.ingenuity.com). The research in this chapter will integrate the potential of NGS approach 
for accelerating discovery of novel PRH target genes and to determine the molecular 
 
 155 
mechanisms of the development of VGF and made aid the future development of improved 
approaches for coronary artery bypass grafts. 
 
6.2  HYPOTHESIS 
The hypothesis for this chapter were: 
▪ PRH S163C:S177C specifically regulates some genes in VSMC which suppress 
VSMC proliferation and thereby intimal thickening.  
 
This hypothesis was tested using: 
▪ Infecting HSV VSMCs and HSVECs with Ad: Control or Ad: PRH S163C:S177C and 
purified RNA samples submitted to QIAGEN for NGS. 
▪ Bioinformatic filtering utilising Ingenuity Pathway Analysis (IPA) software was applied 
to validate or exclude differentially expressed genes (DEGs) obtained from NGS. 





6. 3  RESULTS 
6.3.1  Next Generation Sequencing 
HSV VSMCs were subjected to infection with 5 x 108 pfu/mL of adenovirus encoding either 
empty vector or c-myc-tagged PRH S163C:S177C, for 18 hours. HSVECs were subjected to 
infection with 1 x 108 pfu/mL of adenovirus encoding c-myc-tagged PRH S163C:S177C 
combined with 4 x 108 pfu/mL of adenovirus encoding empty vector or 5 x 108 pfu/mL of 
adenovirus encoding 5 x 108 pfu/mL empty vector, for 18 hours. Subsequently, cells were 
incubated for another 24 hours after replenishing the culture medium. Total RNA extraction, 
purification and quantification were performed and then submitted to QIAGEN Genomic 
Services (Germany) for NGS, as described in Section 2.14. Whole transcriptomic NGS 
sequencing libraries were successfully prepared, quantified and sequenced for all the 

























6.3.2  Data Annotation and Data Filtering 
Analysing the unprecedented number of molecules identified through NGS is a significant 
challenge. To prioritise potential DEGs from such a large dataset, approximately > 26, 000 
molecules, a series of filtering strategies were implemented, as described in Section 2.14.2. 
To produce a smaller, more manageable dataset, bioinformatic filtering utilising IPA was 
performed. The first criterion used to prioritise the DEGs was to set the parameters of calculate 
metrics (e.g., fold change, p-value). Briefly, raw outcomes from the NGS analysis were first 
uploaded into QIAGEN’s IPA system for data annotation and data filtering. Two datasets were 
utilised in this study; Dataset A (HSV VSMCs): Ad: Control vs Ad: PRH S163C:S177C and 
Dataset B (HSVECs): Ad: Control vs Ad: PRH S163C:S177C. 
Two entities of the filtered datasets were uploaded into the ‘Compare Data tool’ for further 
filtering to obtain DEGs which are VSMC-specific and PRH S163C:S177C-regulated-specific. 
Analysis of genes enriched in HSV VSMCs expressing PRH S163C:S177C were sought by 
subtracting genes identified in HSVECs. IPA identified 2,121 DEGSs that were specifically 
PRH S163C:S177C-regulated in VSMCs. On the other hand, 652 DEGs were identified as 
specifically PRH S163C:S177C-regulated in HSVECs. There were 865 common DEGs shared 













FIGURE 6.1: Venn diagram of PRH S163C:S177C-regulated DEGs 
The previously filtered datasets were uploaded into the ‘Compare Data tool’ for further filtering of 
VSMC-specific and PRH S163C:S177C-specific DEGs.  Dataset A: 2,121 DEGs that were 
specifically PRH S163C:S177C-regulated in VSMCs. Dataset B: 652 DEGs were identified as 











6.3.3 Top-enriched canonical pathways of PRH S163C:S177C-
regulated genes 
In the next filtering step, the 2,121 VSMC-specific PRH-regulated DEGs were submitted in 
IPA for core analysis to explore the molecular mechanisms underlying the effects of PRH 
S163C:S177C. IPA identified canonical pathways, diseases and functions, and gene networks 
that are most significant to NGS outcomes and to categorize DEGs in specific diseases and 
functions. The differentially expressed genes were categorized to related canonical pathways 
based on IPA. The statistically significant enriched canonical pathways with a p-value less 
than 10−3 as well as representative DEGs in each canonical pathway are listed in Figure 6.2. 
A total of 369 DEGs (Supplementary Data 1) were identified in the Top 15 Canonical 
Pathways. This analysis suggests that PRH S163C:S177C may modulate several cellular 
pathways, which are associated with Carcinoma, Cardiac Hypertrophy, Fibrosis etc. (Table 
6.1).  
Further stratification of DEGs was undertaken on the 369 DEGs identified. An extensive 
literature review by means of biological analysis was performed as described in Section 
2.14.2.6. As the focus of this analysis was intracellular signalling DEGs that were extracellular 
were eliminated as non-priority and transcription factors or transcriptional regulators were 
prioritised. An in-depth literature review produced a smaller subset of potential DEG which are 
expressed intracellularly and had published data related to features and biological/clinical 
significance of VGF. This strategy prioritised a smaller subset of potential DEGs 






























FIGURE 6.2 – Top enriched canonical pathways following PRH S163C:S177C overexpression 
in VSMCs 
The significant Canonical Pathways for the dataset that were identified are displayed along the y-axis. 
By default, the x-axis displays the -log of the p-value which is calculated using the right-tailed Fisher’s 
Exact Test, such that larger bars equate to increased significance. The yellow line indicates the 
threshold value. The orange bars in the bar chart indicate predicted pathway activation or predicted 
inhibition, respectively, via another statistic: the z-score. Grey bars indicate pathways for which no 
prediction can be made due to insufficient evidence in the Knowledge Base for confident activity 
predictions across datasets. 
           
 
Axonal Guidance Signalling 
Breast Cancer Regulation by Stathmin 
1 
Cardiac Hypertrophy Signaling 
(Enhanced) 
Synaptogenesis Signaling Pathway 
Hepatic Fibrosis Signaling Pathway 
Hepatic Fibrosis/ Hepatic Stellate Cell 
Activation 
Role of Macrophages, Fibroblasts and 
Endothelial Cells in Rheumatoid Arthritis 
Ga12/13 Signaling 
Calcium Signaling 
Glioblastoma Multiforme Signaling 
Neuropathic Pain Signaling in Dorsal Horn 
Neurons 
G-Protein Coupled Receptor Signaling 
Human Embryonic Stem Cell 
Pluripotency 
Regulation of the Epithelial-
Mesenchymal Transition Pathway 
     positive z-
score 
      z-score = 
0 
     negative z-score      no activity pattern 
available 
-log (p-value) 
1 2 3 4 5 6 7 8 0 9 10 11 12 
Threshold 





Table 6.1: The top enriched PRH S163C:S177C-regulated canonical pathways in VSMCs based on IPA 
 
 
P- value is calculated using Fischer’s exact test indicates the probability of the involvement of the genes in the dataset in a 
given pathway. Ratios represent the number of molecules in the dataset that are found in a given pathway, divided by total 
number of molecules that make up that pathway. Molecules are shown in the dataset (≥1.3 -log (p-value) and p≤0.05). 
Ingenuity Canonical Pathways -log(p-value) Ratio No. of Molecules 
Axonal Guidance Signalling 12.2 0.196 94 
Breast Cancer Regulation by Stathmin1 11 0.179 105 
Cardiac Hypertrophy Signalling (Enhanced) 9.01 0.179 86 
Synaptogenesis Signalling Pathway 8.38 0.199 61 
Hepatic Fibrosis Signalling Pathway 7.78 0.185 67 
Hepatic Fibrosis / Hepatic Stellate Cell 
Activation 
7.04 0.22 40 
Role of Macrophages, Fibroblasts and 
Endothelial Cells in Rheumatoid Arthritis 
6.46 0.183 56 
Gα12/13 Signalling 6.26 0.238 30 
Calcium Signalling 6.21 0.204 41 
Glioblastoma Multiforme Signalling 6.15 0.218 35 
Neuropathic Pain Signalling in Dorsal Horn 
Neurons 
5.49 0.248 24 
G-Protein Coupled Receptor Signalling 5.47 0.18 .48 
Human Embryonic Stem Cell Pluripotency 5.41 0.222 29 
Regulation of the Epithelial-Mesenchymal 
Transition Pathway 
5.36 0.198 37 
Agranulocyte Adhesion and Diapedesis 5.3 0.197 37 
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6.3.4 Functional analysis of PRH S163C:S177C-regulated 
genes 
Further analysis was also conducted in IPA to understand the enriched and significant 
biological functions of genes identified in this dataset. Significantly enriched molecular and 
cellular functions were identified by means of this analysis, using a p-value threshold of 0.001. 
Among them, the p-value significance was shown to be higher for functions associated with 
cellular movement, survival, cellular growth, development, and proliferation (Table 6.2). These 
top functions appear to be linked with cellular proliferation which was supported by the 
presence of canonical cancer or fibrosis pathways and other-related pathways. Of interest, 
the tool determined that 135 DEGs within our dataset were associated with proliferation and 
migration of smooth muscle cells. In line with our previous findings, PRH S163C:S177C have 
been shown to reduce the proliferation and migration of VSMCs. As previously, any DEGs 
that were extracellular were eliminated as non-priority and transcription factors or 
transcriptional regulators were prioritised. An in-depth literature review produced a smaller 
subset of potential DEGs which are expressed intracellularly and had published data related 
to features and biological/clinical significance of VGF (Supplementary Data 3).  
 
It is crucial to confirm the gene expression findings obtained from our NGS data. Thus, 
experimental validation using Western blotting was performed to study the effect of PRH 
S163C:S177C on all the prioritised DEGs. Any DEGs with protein expression that could not 
be confirmed or correlate to NGS data were eliminated as non-priority. Finally, this study 
identified two final target DEGs, STAT-1 and HDAC-9, associated with Cardiac Hypertrophy, 






Table 6.2: Enriched biological functions identified using IPA in VSMCs overexpressing PRH S163C:S177C 
 P-value of inclusion is ≤0.001. The biological functions predicted to be regulated by PRH S163C:S177C in VSMCs. 
Categories Molecular and Cellular Functions No. of 
molecules 
P-value 
Skeletal and Muscular System 
Development and Function 
Muscle contraction 73 1.01E-12 
Inflammatory Response, Respiratory 
Disease 
Inflammation of respiratory system 
component 
142 4.62E-14 
Cellular Movement, Skeletal and 
Muscular System Development and 
Function 
Migration of smooth muscle cells 54 2.02E-14 
Cellular Function and Maintenance Function of phagocytes 80 1.32E-15 
Cellular Development, Cellular 
Growth and Proliferation 
Proliferation of smooth muscle cells 81 1.62E-13 
Cellular Development, Cellular 
Growth and Proliferation 
Proliferation of muscle cells 102 3.88E-13 
Cellular Development, Cellular 
Growth and Proliferation 
Cell proliferation of tumor cell lines 410 4.33E-22 
Cell Death and Survival Cell death of tumor cell lines 361 1.04E-17 
Cell Death and Survival Apoptosis of tumor cell lines 298 4.24E-17 
Cell Cycle Cell cycle progression 247 4.09E-16 
Cardiovascular System 
Development 
Development of endothelial tissue 115 1.1E-17 
Cardiovascular Disease Peripheral vascular disease 126 5.46E-16 
Cancer, Organismal Injury and 
Abnormalities 
Cancer  9.06E-100 
Cancer, Organismal Injury and 
Abnormalities 
Breast or pancreatic cancer 925 1.05E-41 
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6.3.5  Identification of STAT-1 as a novel PRH S163C:S177C-
regulated gene 
STAT-1 was identified as one of the putative targets of PRH S163C:S177C using the 
bioinformatic analysis. The observation of decreased amounts of STAT-1 mRNA from NGS 
warranted further validation with regards to its protein expression. To validate the findings 
obtained from NGS and determine whether PRH S163C:S177C regulates translation of STAT-
1 protein, analysis was performed using Western blotting. HSV VSMCs were subjected to 
infection with 5 x 108 pfu/ml of adenovirus encoding either empty vector or c-myc-tagged PRH 
S163C:S177C or left uninfected. Subsequently, cells were incubated for another 24 hours 
after replenishing the culture medium. STAT-1 was detected at similar levels in uninfected 
VSMCs and those infected with Ad: Control. However, the level of STAT-1 protein detected in 
VSMCs infected with Ad: PRH S163C:S177C-infected VSMCs was significantly lower than 
that detected in uninfected VSMCs and VSMCs infected with Ad: Control (FIGURE 6.3). This 
finding indicates that overexpression of PRH S163C:S177C reduces the protein expression 





















FIGURE 6.3 – Overexpression of PRH S163C:S177C downregulated STAT-1 protein in HSV 
VSMCs 
HSV VSMCs were infected with Ad: Control or Ad: PRH S163C:S177C or left uninfected. 
(A) Quantification of STAT-1 protein expression using Western blotting. Data was normalised using 
stain-free bands and expressed as a fold change from uninfected control. ** indicates p<0.01 vs. 
uninfected or Ad: Control, ANOVA, Student-Newman-Keuls Multiple Comparisons Test, n=5. 
Error bars indicate SEM. 
(B) Representative Western blot for STAT-1. Stain-free bands served as a loading control. 

































6.3.6 Inhibition of STAT-1 using fludarabine attenuated HSV 
VSMC proliferation 
To directly investigate the role of STAT-1 in VSMC proliferation, HSV VSMCs were treated 
with 50 μM fludarabine (STAT-1 inhibitor) or DMSO (control). The dose of 50 μM fludarabine 
was selected as established by previous reports (Torella et al., 2007). Assessment of cell 
growth was performed using measuring EdU incorporation 24 hours later. Treatment with 50 
μM fludarabine significantly decreased VSMC proliferation compared to the DMSO control 
(FIGURE 6.4). Western blotting analysis for the cell cycle proteins, p21 and cyclin D1, revealed 
that fludarabine significantly decreased cyclin D1 levels (FIGURE 6.5). However, there 






























































FIGURE 6.4 – Fludarabine retarded HSV VSMC proliferation detected using quantification of 
EdU incorporation 
HSV VSMCs were cultured with 50 μM fludarabine in DMSO or DMSO control alone. 
(A) EdU incorporation was quantified and expressed as the percentage of EdU-positive cells. ** 
indicates p<0.01, paired, two-tailed Student’s t-Test, n=4. Error bars indicate SEM. 
(B) Representative images of Click-iT EdU assay. Positive cells are green (some positive cells are 
indicated by red arrows), and all nuclei are stained blue with DAPI. Scale bar measures 50 μM and 
applies to all panels. 
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CONTROL CONTROL CONTROL 
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FIGURE 6.5 – Fludarabine reduced cyclin D1 protein levels in HSV VSMCs 
HSV VSMCs were cultured with 50 μM fludarabine in DMSO or DMSO control alone. 
Quantification of p21 protein (A) and cyclin D1 protein (B) using Western blotting; data was 
normalised using stain-free bands and expressed as a fold change from uninfected control. NS 
denotes not significant, * indicates p<0.05, paired, two-tailed Student’s t-Test, n=4.Error bars indicate 
SEM. Representative Western blot for p21 protein (C) and cyclin D1 (D). Stain-free bands served as a 







6.3.7 Inhibition of STAT-1 using fludarabine did not affect HSV 
VSMC apoptosis 
To assess whether fludarabine affects VSMC apoptosis, HSV VSMCs were treated with 50 
μM fludarabine (STAT-1 inhibitor) or DMSO (control) for 24 hours. As a positive control, cells 
were incubated with 200 ng/mL human recombinant Fas-ligand in 2% serum-free media. 
Subsequently, apoptosis was assessed via immunofluorescence for cleaved caspase-3. As 
expected, Fas ligand significantly induced apoptotic cell death with respect to uninfected 
control (FIGURE 6.6). Quantification of cleaved caspase-3 positive cells showed that 


















FIGURE 6.6: Fludarabine did not affect apoptosis 
HSV VSMCs were subjected to treatment of with or without 50 μM fludarabine. Fas ligand was used 
as a positive control. 
A – The rate of apoptosis was quantified and expressed as the percentage of cleaved caspase-3-
positive cells. NS denotes not significant, paired, two-tailed Student’s T-Test, n=4. 
B – Representative images of immunocytochemistry for cleaved caspase-3 (CC-3). Positive cells (red 
arrow) are green, and all nuclei are stained blue with DAPI. Scale bar measures 25 μM and applies to 
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6.3.8 Inhibition of STAT-1 using fludarabine did not affect HSV 
VSMC migration 
To assess whether fludarabine affects VSMC migration, HSV VSMCs were treated with 50 
μM fludarabine (STAT-1 inhibitor) or DMSO (control). Subsequently, confluent HSV VSMCs 
were wounded then incubated for a further 24 hours. Treatment with 2 mM hydroxyurea in 
10% FBS/DMEM inhibited cell proliferation. The distance migrated was quantified using 
measuring the wound at 0- and 24-hours post-wounding. No significant difference in distance 



























FIGURE 6.7– Fludarabine did not affect migration of HSV VSMCs 
Migration of HSV VSMCs treated with 50 μM fludarabine in DMSO or DMSO control was assessed 
using the scratch wound assay. (A) Migration was quantified and expressed as distance migrated 
(μM); NS denotes not significant, paired, two-tailed Student’s T-Test, n=4. Error bars indicate SEM. 
(B) Representative images of scratch wound assay. Dashed line indicates wound edge. T0 indicates 









6.3.9 Inhibition of STAT-1 using fludarabine did not affect 
contractile proteins in HSV VSMC 
To investigate the role of STAT-1 in the regulation of VSMC contractile protein markers, HSV 
VSMCs were treated with 50 μM fludarabine (STAT-1 inhibitor) or DMSO (control) in 10% 
FBS/DMEM. After 24 hours, cells were lysed for Western blotting analysis of the VSMC-
specific contractile proteins, calponin and smoothelin. The level of calponin and smoothelin 
proteins detected in the fludarabine treated VSMCs was not significantly different from that 

























FIGURE 6.8 – Fludarabine did not regulate the level of contractile protein markers in HSV 
VSMCs 
HSV VSMCs were cultured with 50 μM fludarabine in DMSO or DMSO control alone. 
 Quantification of smoothelin (A) and calponin (B) proteins using Western blotting. Data was 
normalised using stain-free bands and expressed as a fold change from control. NS denotes not 
significant, paired, two-tailed Student’s t-Test, n=4.. Error bars indicate SEM. Representative Western 
blots for smoothelin (C) and calponin (D). Stain-free bands served as a loading control. Approximate 





6.3.10 STAT-1 protein in vivo 
To identify whether STAT-1 protein was expressed in control mouse carotid arteries 
(unligated) and those subjected to ligation for 7 days to initiate intimal thickening, 
immunohistochemistry for STAT-1 protein was performed (FIGURE 6.10A). In addition, 
immunohistochemistry for STAT-1 protein was performed on sections of mouse ligated carotid 
arteries at 7 days after infection with Ad: Control and Ad: PRH S163C:S177C to determine 
whether overexpression of PRH S163C:S177C protein affects the level of STAT-1 protein. 
The positively stained tissue detected using ImageJ analysis was calculated as a fold change 
from that detected in the Ad: Control. The results have shown that unligated mice carotids had 
a significantly lower HDAC-9 levels in comparison to the ligated carotids (FIGURE 6.9B and 
C). STAT-1 protein levels appeared slightly lower in the ligated carotid arteries infected with 
Ad: PRH S163C:S177C compared to ligated carotid arteries infected with Ad: Control 
(FIGURE 6.9A and C) however the difference did not reach significance. Negative control 




FIGURE 6.9 – STAT-1 protein in unligated and ligated left carotid arteries after 7 days with and 
without infection with Ad: Control or Ad: PRH S163:S177C 
Mouse carotid arteries were ligated in C57B/L6 mice to induce intimal thickening then subjected to 
infection with adenoviruses encoding either Ad: Control or Ad: PRH S163C:S177C. The right carotid 
arteries were used as an unligated controls. 
A - Quantification of STAT-1 protein in Ad: Control vs. Ad: PRH S163C:S177C infected ligated carotid 
arteries, expressed as the fold change, ns indicates not significant, unpaired, two-tailed Student’s t-
test, n=3. Error bars indicate SEM. 
B - STAT-1 expression in ligated vs unligated mice carotids was quantified and expressed as the fold 
change, NS denotes not significant, * indicates p<0.05, paired, two-tailed Student’s t-test, 
n=4Student’s t-Test, unpaired, two-tailed Student’s t-test, n=4 (ligated), n=5 (unligated).  
C - Representative images of immunohistochemistry for STAT-1 protein at day 7. Positive cells have 
brown nuclei (red arrow); negative cells are stained with haematoxylin and have blue nuclei (black 
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6.3.11 Identification of HDAC-9 as a novel PRH S163C:S177C-
regulated gene 
In addition to the discovery of STAT-1, HDAC-9 was identified as one of the putative targets 
of PRH S163C:S177C. The first aim was to determine whether the observed depleted levels 
of HDAC-9 mRNA detected using NGS could be confirmed at the protein level and therefore 
Western blotting for HDAC-9 protein was employed. HSV VSMCs were subjected to infection 
with 5 x 108 pfu/ml of Ad: Control or Ad: PRH S163C:S177C, or left uninfected, for 18 hours. 
Subsequently, cells were incubated for another 24 hours after replenishing the culture 
medium. HDAC-9 protein was detected at a similar level in uninfected VSMCs and those 
infected with Ad: Control. Whilst HDAC-9 protein was significantly lower in VSMCs infected 
with Ad: PRH S163C:S177C compared to both the uninfected VSMCs and VSMCs infected 



















FIGURE 6.10 – Overexpression of PRH S163C:S177C reduced HDAC-9 protein in HSV VSMCs 
HSV VSMCs were infected with Ad: Control or Ad: S163C:S177C PRH or left uninfected. 
(A) Quantification of HDAC-9 protein using Western blotting. Data was normalised using stain-
free bands and expressed as a fold change from uninfected control. * indicates p<0.05, 
ANOVA, Student-Newman-Keuls Multiple Comparisons Test, n=5. Error bars indicate SEM. 
(B) Representative Western blot for HDAC-9. Stain-free bands served as a loading control. 






























6.3.12 Inhibition of HDAC-9 using TMP269 attenuated HSV 
VSMC proliferation 
To investigate the role of HDAC-9 in VSMC proliferation, HSV VSMCs were treated with 50 
nM TMP269 (HDAC-9 inhibitor) in DMSO or DMSO alone (control). In addition, 10% 
FBS/DMEM were supplemented with 10 μM EdU for Click-iT EdU analysis. Assessment of 
cell growth was performed using measuring EdU incorporation 24 hours later. Treatment with 
50nM significantly decreased VSMC proliferation compared to the DMSO control (FIGURE 
6.11). Western blotting analysis for the cell cycle proteins, p21 and cyclin D1, revealed that 
TMP269 significantly decreases cyclin D1 levels albeit at a non-significant level although 
























































FIGURE 6.11 – TMP269 retarded HSV VSMC proliferation detected using quantification of EdU 
incorporation 
HSV VSMCs were cultured with 50 nM TMP269 in DMSO or DMSO control alone. 
A - EdU incorporation was quantified and expressed as the percentage of EdU-positive cells. ** 
indicates p<0.01, paired, two-tailed Student’s t-test, n=4. Error bars indicate SEM. 
B - Representative images of Click-iT EdU assay. Positive cells are green (some positive cells are 
indicated by red arrows), and all nuclei are stained blue with DAPI. Scale bar measures 50 μM and 
applies to all panels. 
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FIGURE 6.12 – TMP269 reduced cyclin D1 protein levels in HSV VSMCs 
HSV VSMCs were cultured with 50 nM TMP269 in DMSO or DMSO control alone. 
Quantification of p21 protein (A) and cyclin D1 protein (B) using Western blotting; data was 
normalised using stain-free bands and expressed as a fold change from uninfected control. NS 
denotes not significant, * indicates p<0.05, paired, two-tailed Student’s t-Test, n=4.Error bars indicate 
SEM. Representative Western blot for p21 protein (C) and cyclin D1 (D). Stain-free bands served as a 






6.3.13 Inhibition of HDAC-9 using TMP269 did not affect HSV 
VSMC apoptosis 
To assess whether fludarabine affects VSMC apoptosis, HSV VSMCs were treated with 50 
nM TMP269 (HDAC-9 inhibitor) or DMSO (control) for 24 hours. As a positive control, cells 
were incubated with 200 ng/mL human recombinant Fas-ligand in 2% serum-free media. 
Subsequently, apoptosis was assessed via immunofluorescence for cleaved caspase-3. As 
expected, Fas ligand significantly induced apoptotic cell death with respect to uninfected 
control (FIGURE 6.13). Quantification of cleaved caspase-3 positive cells showed that rate of 
















FIGURE 6.13 - TMP269 in HSV VSMCs had no effect on apoptosis 
HSV VSMCs were subjected to treatment of with or without 50 nM TMP269. Fas ligand was used as a 
positive control. 
A – The rate of apoptosis was quantified and expressed as the percentage of cleaved caspase-3-
positive cells. NS denotes not significant, paired, two-tailed Student’s t-Test, n=4. 
 B – Representative images of immunocytochemistry for cleaved caspase-3 (CC-3). Positive cells 
(red arrow) are green, and all nuclei are stained blue with DAPI. Scale bar measures 10μM and 
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6.3.14 Inhibition of HDAC-9 using TMP269 attenuated HSV 
VSMC migration 
To assess whether HDAC-9 affects VSMC migration, HSV VSMCs were treated with 50 nM 
TMP269 in DMSO (HDAC-9 inhibitor) or DMSO alone (control). Subsequently, confluent HSV 
VSMCs were wounded then incubated for a further 24 hours. Treatment with 2 mM 
hydroxyurea inhibited cell proliferation. The distance migrated was quantified by measuring 
the wound at 0- and 24-hours post-wounding. Quantification of the migrated distance from the 
wound revealed that TMP269 significantly attenuated HSV VSMCs migration compared to 























































FIGURE 6.14 TMP269 reduced migration of primary HSV VSMCs 
Migration of HSV VSMCs treated with 50 nM TMP269 in DMSO or DMSO control was assessed using 
the scratch wound assay. (A) Migration was quantified and expressed as distance migrated (μM); ** 
indicates p<0.01, paired, two-tailed Student’s t-test, n=4. Error bars indicate SEM. (B) Representative 
images of scratch wound assay. Dashed line indicates wound edge. T0 indicates Time = 0 hr; T24 













6.3.15 Inhibition of HDAC-9 using TMP269 increased contractile 
marker proteins 
To investigate the role of HDAC-9 in the regulation of VSMC contractile protein markers, HSV 
VSMCs were treated with 50 nM TMP269 (HDAC-9 inhibitor) in DMSO or DMSO alone 
(control) in 10% FBS/DMEM. After 24 hours, cells were lysed for Western blotting analysis of 
the VSMC-specific contractile proteins, calponin and smoothelin. The level of smoothelin and 
calponin proteins detected in the TMP269-treated VSMCs was significantly higher than that 















FIGURE 6.15 – The effect of TMP269 on contractile protein markers in HSV VSMCs 
 
HSV VSMCs were cultured with 50 nM TMP269 in DMSO or DMSO control alone. 
 Quantification of smoothelin (A) and calponin (B) proteins using Western blotting. Data was 
normalised using stain-free bands and expressed as a fold change from control. * indicates p<0.05 
vs. uninfected, paired, two-tailed Student’s t-test, n=4. Representative Western blots for smoothelin 
(C) and calponin (D). Stain-free bands served as a loading control. Approximate molecular weights 





6.3.17 HDAC-9 protein in vivo  
To identify the expression of HDAC-9 in the 7-day ligated left carotids, sections were 
immunostained for HDAC-9 and the percentage of positively stained tissue was calculated 
using Image-J analysis. Interestingly, HDAC-9 expression was significantly downregulated in 
the Ad: PRH S163C:S177C group vs control group (FIGURE 6.16A and C). Next, we 
examined the HDAC-9 expression in unligated vs ligated mice carotids. Our results have 
shown that unligated mice carotids had a significantly lower HDAC-9 levels in comparison to 
the ligated carotids (FIGURE 6.16B and C). Negative control sections probed with non-












































FIGURE 6.16 – HDAC-9 protein in unligated and ligated left carotid arteries after 7 days with 
and without infection with Ad: Control or Ad: PRH S163:S177C 
Mouse carotid arteries were ligated in C57B/L6 mice to induce intimal thickening then subjected to 
infection with adenoviruses encoding either Ad: Control or Ad: PRH S163C:S177C. The right carotid 
arteries were used as an unligated controls. 
A - Quantification of HDAC-9 protein in Ad: Control vs. Ad: PRH S163C:S177C infected ligated 
carotid arteries, expressed as the fold change, NS denotes not significant, unpaired, two-tailed 
Student’s t-test, n=3. Error bars indicate SEM. 
B - HDAC-9 expression in ligated vs unligated mice carotids was quantified and expressed as the 
fold change, * indicates p<0.05, unpaired, two-tailed Student’s t-test, n=4 (ligated), n=5 
(unligated). 
C - Representative images of immunohistochemistry for HDAC-9 protein at day 7. Positive cells have 
brown nuclei (red arrow); negative cells are stained with haematoxylin and have blue nuclei (black 






































6. 4  DISCUSSION 
It was previously observed that overexpression of PRH S163C:S177C caused cessation of 
VSMC proliferation, migration, apoptosis, and de-differentiation in vitro. Additionally, gene 
transfer of PRH S163C:S177C markedly decreased intimal thickening in the mouse carotid 
artery ligation model. The mechanism underlying this phenotype is partly related to PRH 
S163C:S177C mediated upregulation of p21 expression and downregulation of cyclin D1. 
Activation of PRH:CC induces a cell cycle block at G1 to S phase transition by inhibition of 
p21 degradation, leading to a rise in cellular p21 protein levels, and consequent inhibition of 
cyclin D1. However, the underlying intracellular signalling pathway responsible for modulation 
of p21 and cyclin D1 have not been elucidated. 
In this chapter, IPA was used to identify and validate genes regulated by PRH S163C:S177C. 
This research utilised NGS data analysis, stringent bioinformatics filtering strategies and 
literature reviewing. Dysregulated transcriptional hubs, including transcription factors and their 
gene expression signatures are characteristic of mechanisms which may fundamentally 
elucidate pathological processes and underlying mechanisms.  Thus, for the purpose of this 
study, we have focused on identifying potential transcription factors and transcriptional 
regulators regulated by PRH S163C:S177C. Further IPA analysis narrowed down the 
candidate DEG list, with the potential of identifying novel PRH target genes including STAT-1 
and HDAC-9. 
 
6.4.1 Identification of STAT-1 as a downstream target of  
PRH S163C:S177C 
The Signal Transducer and Activator of Transcription (STAT) proteins are intracellular 
facilitators of cell growth, apoptosis and lineage-specific differentiation. To date, seven well-
conserved members of the STAT family have been discovered (Akira, 1999). Under normal 
conditions, transient activation of STATs is stimulated by extracellular signals although such 
activation is often selective and bind to the promoters of specific target (Dorritie, McCubrey 
and Johnson et al., 2013). Post-transcriptional modifications of these transcription factors can 
regulate their transcriptional activity. Accumulating evidence suggests that phosphorylation of 
STATs can occur upon activation by endogenous receptor tyrosine kinases, Src and abl and 
serine/threonine kinases including protein kinase CK2 and mitogen-activated protein kinase 
(MAPK) (Aparicio-Siegmund et al., 2014).  
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In this study, NGS and bioinformatic analysis identified STAT-1 as a potential downstream 
target of PRH S163C:S177C. Data from NGS analysis demonstrated downregulation of STAT-
1 at the mRNA level as a result of PRH S163C:S177C overexpression. In agreement with this 
finding, Western blot analysis showed a marked reduction of STAT-1 at the protein level. It 
has been formerly reported that induction of janus kinases and STATs, STAT-1 and STAT-3, 
was evident within intimal thickenings one week after balloon-injury of rat arteries and 
subsequently declined at day 14 (Seki, 2000). To explore whether the levels of STAT-1 protein 
was modulated during intimal thickening induced by carotid ligation immunohistochemistry 
was performed on mouse carotid arteries 7 days after ligation and compared with unligated 
arteries. There was no statistical difference in the amount of STAT-1 protein in the ligated 
carotid controls compared to the unligated carotid controls. However, the sample sizes for the 
groups were small due to the lack of suitable samples and it would be beneficial to repeat this 
analysis with increased numbers of samples in the future. Immunohistochemical detection of 
STAT-1 was employed in the ligated left carotids of mice treated with either Ad: Control or Ad: 
PRH S163C:S177C for 7 days. Interestingly, although fails to reach a significant level, it seems 
that STAT-1 expression was downregulated in the left carotids which received adenoviral-
mediated PRH S163C:S177C gene delivery in comparison to the control group. It is important 
to highlight that data was conducted for this experiment base on n=3 as these samples were 
prepared for the pilot study to evaluate efficiency of gene delivery and not powered to detect 
altered protein expression. 
Hence, we hypothesize that PRH S163C:S177C overexpression mediates VSMC proliferation 
and function, in part, by repressing the activation of STAT-1 activity. Having said this, the role 
of STAT-1 in VSMC function and other cell types remains unclear.  
 
6.4.2 Suppression of VSMC proliferation using Fludarabine 
Fludarabine, also known as Fludara®, is an established specific inhibitor of STAT-1 (Feng et 
al., 2017), which is a standard chemotherapy treatment for patients suffering with chronic 
lymphocytic leukaemia (CLL) (Lukenbill and Kalaycio, 2013).  In the present study, 
incorporating fludarabine was employed to specifically inhibit the function of the STAT-1 in 
HSV VSMCs.  
To date, only one publication exists reporting the protective role of the STAT-1 inhibitor in 
dysregulated growth of VSMCs. Fludarabine is a selective STAT-1 inhibitor which have been 
previously reported to arrest rat VSMC growth (Torella et al., 2007). These results agree with 
the findings of this chapter in which data demonstrates that STAT-1 suppressed HSV VSMC 
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growth without affecting the migratory capabilities of VSMC. The effect of fludarabine on cell 
cycle regulatory proteins demonstrated its ability to decrease cyclin D1 significantly. On the 
other hand, fludarabine did not affect p21 which may be due to the timings or reveal that PRH 
affects multiple pathways and it is the combined affects that lead to most effective inhibition 
of proliferation and changes in cell cycle proteins. Hence, the Western blotting results 
corroborate the EdU analysis and are strengthened by the existing report on the anti-
proliferative actions of STAT-1 in rat primary VSMCs. To support our data, using A10 tTA-
IRES-Neo cells, heparin inhibited VSMC proliferation and this is mediated via STAT-1 
phosphorylation on serine 727 via activation protein kinase, RNA activated leading to the cell 
cycle arrest of VSMCs (Handy and Patel, 2013). Despite the anti-atherogenic potential of 
STAT-1 inhibitors, the potential of fludarabine is hampered by its toxicity due to its purine 
(adenine) nucleoside analogue (Sikorski et al., 2011). However, our findings illustrated that 
fludarabine treatment did not affect apoptotic cell death. Nonetheless, these contrasting 
findings may serve as a basis for designing novel therapeutic regiments which are less toxic 
for STAT-1 inhibition. Engineering an improved therapy to outwit the development of vein graft 
disease or restenosis by creating inhibitors to stall DNA replication of VSMCs will provide a 
better understanding of the molecular mechanisms associated to the pathophysiology of the 
disease and may enhance the long-term patency of grafts.  
 
6.4.3 Fludarabine did not affect VSMC phenotype 
Under pathological conditions, VSMCs de-differentiate into a pro-proliferative, pro-migratory 
and synthetic phenotype. Contrary to this under normal conditions, quiescent VSMCs usually 
exhibit a contractile phenotype. Since PRH S163C:S177C promoted the contractile VSMC 
phenotype it was of interest to determine whether STAT-1 contributed to the regulation of the 
contractile proteins, smoothelin and calponin. The results showed that STAT-1 inhibition did 
not regulate smoothelin and calponin protein levels and therefore may not contribute for the 
phenotypic switching of VSMCs to the protective contractile phenotype.  
 
In conclusion, the findings suggest that STAT-1 inhibition retards VSMC proliferation and 
therefore may be responsible at least in part for the anti-proliferative effects of PRH 
S163C:S177C. It does not, however, appear mediate the effects of PRH S163C:S177C-
associated phenotypic switching which may perhaps occur through a different mechanism and 
other PRH S163C:S177C-regulated targets may be involved instead in this process. One 
possible mechanism could be that although STAT-1 does not alter the expression of 
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contractile markers, PRH:CC may modulate VSMC contractility through interacting directly or 
indirectly with other molecules which warrants further studies to be conducted. 
 
6.4.4 Histone deacetylases (HDACs) and Histone deacetylases 
Inhibitors (HDACis) 
In non-dividing cells, the DNA is tightly bound to prevent and govern binding of transcription 
factors. Eukaryotes package their DNA into a highly ordered structure with proteins called 
chromatin.  Within chromatin lies the core nucleosome which is comprised of positively 
charged proteins termed histones that form an octamer; (H3–H4)2 tetramer and two H2A-H2B 
dimers (Haggarty and Tsai, 2012). The structure of chromatin is not inert, post-transcriptional 
modification (PTMs) of the histones occur and alter the chromatin structure and thereby 
influence gene transcription. A myriad of different PTMs including methylation, 
phosphorylation, SUMOylation, ubiquitination, and acetylation occur. Acetylation is the most 
extensively characterised type of modification (Wolffe and Hayes, 1999). In 1964, Allfrey and 
colleagues first documented histone acetylation which requires the interplay and opposing 
actions between histone deacetylases (HDACs) and histone acetyltransferases (HATs) 
(Allfrey et al., 1964). In an open chromatin conformation, HATs recruit acetyl coA as a cofactor 
to acetylate lysine residues residing on histone proteins forming ε-N-acetyllysine and relaxes 
the highly ordered chromatin architecture. This increases the specific DNA-binding activity and 
access to transcription factors. For the maintenance of a closed chromatin conformation, 
HDACs counterbalance the effects of HATs and catalyse the removal of the acetyl moiety 
(deacetylation) from lysine residues in both histone and non-histone substrates, thus, restoring 
lysine’s positive charge and thereby stabilise the histone-DNA interaction (Xhemalce, Dawson 
and Bannister, 2011; Peserico and Simone, 2011; Choudhary et al., 2009). HDACs are a 
group of chromatin-modifying enzymes which play a critical role in the regulation of gene 
expression. In mammals, eighteen HDACs have been discovered and the members of the 
HDACs family are categorised into four classes based on their structure, function and tissue 
distribution: class I (HDAC-1, 2, 3, and 8), class IIa (HDAC-4, 5, 7, and 9), class IIb (HDAC-6 
and 10), class III (sirtuins1-7), and class IV (HDAC-11) (Peserico and Simone, 2011). 
Moreover, aberrant gene transcription regulation of HDACs have been extensively studied to 
be involved in regulating cellular homeostasis including proliferation, apoptosis and DNA 
repair (Telles and Seto, 2014). 
In disease states such as cancer, abnormal HDAC upregulation has been linked to diverse 
malignancies in gastrointestinal, prostate and breast carcinomas (Liu et al., 2019). 
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Accordingly, HDAC inhibitors (HDACi) which block/interfere with the function of HDACs have 
emerged as an attractive approach for cancer therapy. To date, there are seven HDACis in 
clinical trials for various diseases (Table 6.3) and four HDACis are US-FDA approved for 
clinical use (Lyu et al., 2019). Moreover, HDACis continue to be developed as anti-cancer 
drugs based on their ability to induce cytotoxic effects and repress proliferation especially in 
cancer cells (Lyu et al., 2019). Cumulative evidence also implicates a role of HDACs in 
modulation of cardiovascular diseases, opening up the possibility of therapeutic potential of 
HDACis (Chen et al., 2020; Pickell et al., 2020). Firstly, studies have revealed that HDAC 
inhibition also repressed myocardial hypertrophy and fibrosis (Lyu at al., 2019; Eom and Cook, 
2015).  The Class I HDACi (HDAC 1, 2, 3 and 8), valproic acid (VPA), inhibited cardiac 
hypertrophy and fibrosis via acetylation of the mineralocorticoid receptor (Jung et al., 2018; 
Kang et al., 2015). In a more recent paper by Barbosa and colleagues, the HDAC I/II inhibitor, 
Rhein, was reported to inhibit collagen contraction and cardiac remodelling thereby suggesting 
it is protective against cardiac hypertrophy and progression of fibrosis (Barbosa et al., 2020). 
It has been suggested that the HDAC inhibitor, Butyrate, modulates VSMC proliferation 
through H3 posttranslational modification by H3K9 acetylation, reduced H3K9 dimethylation 
and low levels of H3S10 phosphorylation (Matthew et al., 2010). This implied that inhibition of 
HDACs could potentially reduce intimal thickening. Indeed, it was recently described that 
trichostatin A, a pan-inhibitor of HDAC Class I/II, suppressed intimal hyperplasia induced by 
balloon-injury of the rat carotid artery (Kee et al., 2011). Of interest, another Class IIa HDAC, 
HDAC-4, has been previously reported to play a role in the regulation of intimal thickening 
(Chen et al., 2020). Silencing HDAC-4 using siRNA resulted in inhibition of aberrant VSMC 
proliferation and migration (Chen et al., 2020; Zhang et al., 2019; Usui et al., 2014). Consistent 
with these findings, it was also shown that the HDAC Class IIa inhibitor, MC1568, prohibited 
intimal thickening induced by ligation of the carotid artery in mice (Usui et al., 2014). Tubastatin 
A, an inhibitor of HDAC-6, was also reported to attenuate intimal thickening in a balloon-injured 
rat artery (Zhang et al., 2018). These findings suggest that class I and class II HDACs at least 
in part mediate intimal thickening. Since HDACs are now beginning to be appreciated in 
cardiovascular disease processes (Chen et al., 2020; Liu at al., 2019), the utility of HDACis 
have also been implicated in pre-clinical studies for stroke, cardiac arrest, myocardial 
infarction and fibrosis (Pickell et al., 2020). However, to date clinical trials using HDACis in 
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6.4.5 Identification of HDAC-9 as a downstream target of PRH 
S163C:S177C 
Previous genome-wide association studies have shown that genetic polymorphisms in HDAC-
9 are linked to several cardiovascular diseases including coronary artery disease (Nelson et 
al., 2017), atherosclerotic stroke (Malik et al., 2018) and atherosclerotic aortic calcification 
(Malhotra et al., 2019), suggestive of a role in disease pathogenesis. Consistent with these 
observations, expression of HDAC-9 was upregulated in carotid atherosclerotic plaques 
compared to atherosclerosis free left internal thoracic artery controls (Markus et al., 2013).  
HDAC-9 knockout mice induced a stable atherosclerotic plaque phenotype by reducing 
proinflammatory responses in the arterial wall, in part by deacetylation of inhibitory kappa B 
kinase (Asare et al., 2020). This present study is the first to identity HDAC-9 as a downstream 
target of PRH S163C:S177C. RNA sequencing performed to analyse RNA expression 
revealed that PRH S163C:S177C significantly downregulated the mRNA expression of HDAC-
9 by approximately 4-fold in HSV VSMCs. In the top-enriched canonical pathways, HDAC-9 
was discovered in both Cardiac Hypertrophy and Calcium Signalling. Previous studies have 
revealed an association between VSMC contractility and the intracellular calcium signalling 
control (Zhu et al., 2019; Brozovich et al., 2016; Lipskaia et al., 2012). For these reasons, 
confirmation of HDAC-9 downregulation at the protein level was performed. These findings 
highlight a direct transcriptional regulation by PRH S163C:S177C. The in vivo results show 
for the first time that HDAC-9 expression upregulated by ligation of the carotid artery in mice 
and induction of intimal thickening and is downregulated in the ligated left carotid arteries 
which received Ad: PRH S163C:S177C in comparison to the control left carotids receiving the 
control virus.  
 
6.4.6 Pharmacologic inhibition of HDAC-9 as a novel strategy 
to repress VSMC proliferation and migration 
Unwarranted proliferative and migratory action of VSMCs are hallmark features of several 
vascular pathologies and occlusive diseases such as atherosclerosis, hypertension, and 
arterial and in-stent restenosis. Besides having the ability to deacetylate signal mediators 
including STAT-3, Smad family member 7 and β-catenin (Eom and Kook 2014), there had 
been early reports of the role of HDACs in regulating cell cycle progression since HDACs act 
redundantly to promote deacetylation of p53-, E2 factor (E2F)-, and Rb protein (pRb)- cell 
proliferation transcription factors thereby coordinating cell cycle arrest during G0 (relative to S 
phase) (Glozak et al., 2005). For example, histone deacetylase-mediated transcriptional 
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inhibition can arise from retinol binding protein 1 (RBP1) employing HDACs to catalyse 
formation of the E2F-pRb-RBP1-Sin3-HDAC complex situated at the promoter region of the 
E2F-responsive gene (Lai et al., 2001). Due to the lack of isoform-specific HDAC-9 inhibitor, 
the therapeutic potential of inhibiting HDAC-9 was evaluated using the novel HDAC Class IIa 
inhibitor, TMP269, and whether TMP269 can substantiate the previous in vitro findings 
governed by PRH S163C:S177C. TMP269 is a novel and selective class IIa HDACi with IC50s 
of 157 nM, 97 nM, 43 nM and 23 nM for HDAC-4, HDAC-5, HDAC-7 and HDAC-9, 
respectively.  
In this study, the biological impact of the class IIa HDAC inhibitor using 50 nM TMP269. The 
following dose had been chosen with the aim of specifically inhibiting the activity of HDAC-9. 
The data illustrated that compared to HSV VSMCs incubated in 10% FCS with DMSO 
(Control), HSV VSMCs treated with TMP269 exhibited a significantly lower mitotic activity of 
VSMCs and modulation of p21 protein levels. This is in line with the prior data from Chapter 
3, highlighting the capability of PRH S163C:S177C as a negative regulator of cell proliferation 
by repressing cyclin proteins and inducing the cell cycle inhibitors p21. Contrary to PRH 
S163C:S177C, TMP269 did not have any effect on cyclin D1 protein expression. A recent 
paper by Malhotra and colleagues highlighted the possible physiological role of HDAC-9 
activity in VSMCs, siRNA, suppression of HDAC-9 reduced human aortic VSMC proliferation 
by over 50% (Malhotra et al., 2019). In support of the role of HDAC-9 in the cell cycle 
regulation, Zhang and co-workers previously reported that knockdown of HDAC-9 coordinated 
the cell cycle arrest during G1 phase in retinoblastoma cells (Zhang et al., 2016). In pancreatic 
cancer, TMP269 treatment at 57.5 μM also prevented cell growth via p21 induction, cyclin 
D1/D2 and CDK 2/4/6 inhibition in pancreatic AsPC-1 cells (Usami et al., 2020). Clearly, these 
data suggest inhibiting HDAC class IIa resulted in cell growth suppression in various cell types. 
To add, TMP269 prevents cell cycle progression, DNA synthesis, and proliferation by 
modulating the cell cycle proteins, thereby, inducing cellular arrest.  TMP269 additionally 
suppressed the migration of VSMCs. Importantly, hydroxyurea was added to the VSMCs as 
an anti-proliferative agent, hence, any changes observed in VSMC migration was restricted to 
that alone. Interestingly, trophoblast cell line migration was enhanced by HDAC-9 
overexpression via TIMP-3 (Xie et al., 2019). Li and colleagues also demonstrated silencing 
HDAC-9 can attenuate the migration activity of pancreatic cell lines (Li et al., 2020). To date, 
no previous data exists associating TMP269 with modulating VSMC motility. Collectively, 
these data implicate the ability of TMP269 in supressing both VSMC proliferation and 
migration via HDAC-9 inhibition and support the proposition that PRH S163C:S177C inhibits 
VSMC proliferation and migration and intimal thickening via suppression of HDAC-9 levels. 
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Moreover, it reveals the potential utility of TMP269 for the reduction of intimal thickening and 
vein graft failure.  
Because TMP269 inhibits all the members in the HDAC class IIa family, future work may seek 
to determine whether specific knockdown of HDAC-9 mRNA levels with siRNA (siHDAC-9) 
was sufficient to validate the findings observed in TMP269 in vitro experiments.  
 
6.4.7 Pharmacologic inhibition of HDAC-9 promoted the 
contractile phenotype in VSMCs 
VSMC phenotypic switching is a crucial determinant of atherosclerosis and late vein graft 
failure (Wadey et al., 2018). Further investigation was warranted to elucidate the precise 
mechanism by which PRH S163C:S177C regulates the phenotypic state of VSMCs, 
consequently whether HDAC-9 inhibition by TMP269 induced the expression of VSMC 
contractile phenotype markers was examined. The first study to associate HDAC-9 in 
phenotypic switching was by Cardenas and co-workers which investigated the role of HDAC-
9 in thoracic aortic aneurysm (Cardenas et al., 2018). Smooth muscle cell phenotypic 
modulation is a key contributing factor to the development of aortic aneurysm (Petsophonsakul 
et al., 2019). Disruption of HDAC-9 and long noncoding RNA (lncRNA) Metastasis Associated 
Lung Adenocarcinoma Transcript 1 (MALAT-1) has been illustrated to inhibit aneurysm growth 
by improving VSMC contractility. Their outcomes have shown that the HDAC-9-MALAT1-
BRG1 complex represses VSMC contractile genes TGF-beta receptor type-2 (TGFR2) and 
ACTA2 expression (Cardenas et al., 2018). Whether or how pharmacological inhibition of 
HDAC-9 by TMP269 regulates VSMC dedifferentiation has not been investigated. Whether 
HDAC-9 and TMP269 regulate the expression of any of the contractile proteins was previously 
unknown. In our study, TMP269 substantially induced the expression of VSMC contractile 
phenotype markers, with prominently enhanced protein levels of calponin (> 1.5-fold) and 
smoothelin (> 2-fold). The current study was the first to demonstrate that addition of TMP269 
can not only reduce VSMC proliferation and VSMC migration, but it can also augment VSMC 
contractility and thus reduce the phenotypic switching from contractile to the synthetic 
phenotype. Moreover, the findings represent that TMP269 elicits increased by regulating the 
contractile proteins calponin and smoothelin. These observations are consistent with the 
unanticipated findings described in Chapter 3 that PRH S163C:S177C overexpression 
induced similar levels of induction in calponin (> 1.5-fold) and smoothelin (> 2-fold). It can be 
speculated that there is a mechanistic link in which PRH S163C:S177C plays a role in the 
VSMC differentiation by supressing the translational activity of HDAC-9. As a result, VSMCs 
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sustains and exhibit a ‘contractile’ or differentiated phenotype which is associated with the low 
rate of proliferation, low synthetic activity, and expression of contractile phenotype proteins. 
This differentiated phenotype is a powerful inhibitor of VSMC mitotic activity and migratory 
properties, hence, suppresses the formation of intimal thickening that underlies late vein graft 
failure.  
The role of HDACs in phenotypic switching remains an incompletely explored territory. Having 
said this, the HDAC family seems to play a dual role in the VSMC phenotypic transformation. 
For example, targeted inhibition of HDAC-6 (Class IIb) using Tubastatin A, but not inhibition 
of HDAC-3 (Class I) using RGFP966, considerably stimulated α-SM actin expression at a 
significant level both in vitro and in vivo (Zhang et al., 2018). Both inhibitors did not upregulate 
SMHC expression. However, their data also demonstrated that pharmacological inhibition 
using RGFP966 reduced α-SM actin expression at a significant level (Zhang et al., 2018). The 
results in this chapter are consistent with the literature that HDAC-9 inhibition promotes the 
contractile phenotype in VSMCs. However, this study is the first to show that TMP269 can 
promote the contractile phenotype of VSMC by upregulating the expression of smoothelin and 
calponin. In accordance with the study by Cardenas and colleagues, it seems that the role of 
TMP269 in phenotypic modulation is not restricted to governing the expression of calponin 
and smoothelin alone. Rather, an interesting further investigation could include looking at the 
effect of TMP269 in other repertoire of VSMC-restricted contractile proteins including smooth 
muscle alpha actin, h-caldesmon, transgelin, and smooth muscle myosin heavy chain.  
 
6.4.8  Chapter Summary 
Collectively, this chapter identified that PRH S163C:S177C-regulated downstream target 
genes as a result of transcriptomic profiling and bioinformatics filtering analysis. STAT-1 and 
HDAC-9 were identified as candidates involved in governing the underlying the effects of PRH 
S163C:S177C in the regulation of VSMC behaviour. In this study, fludarabine, a specific 
STAT-1 inhibitor, repressed VSMC growth but not migration of VSMC phenotype. With 
regards to investigating the potential of HDAC-9 as another PRH S163C:S177C target gene, 
the data strongly suggest that HDAC-9 modulates, at least in part, the effects of PRH 
S163C:S177C-mediated regulation via specific mechanisms concerning VSMC proliferation, 
migration, and contractile responses. Of course, a question arises as to whether the outcomes 
from TMP269 treatment in our study were mediated specifically by HDAC-9. This scenario is 
highly likely considering the following facts. Although the HDACi TMP269 binds to Class IIa 
HDACs, there is an exception: its selectivity for HDAC-4, HDAC-5, HDAC-7 and HDAC-9 
exhibiting IC50s of 157 nM, 97 nM, 43 nM and 23 nM, respectively. In this study, low-dose 
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treatment using 50 nM TMP269 was sufficient to for inhibition of VSMC growth and migration 
whilst promoting SMC phenotypic modulation to the contractile phenotype. Unlike fludarabine, 
TMP269 seems to be more favourable to conduct further intensive investigation because it 
can promote contractile phenotypic modulation in VSMCs. Furthermore, the observed 
increase in HDAC-9 expression during intimal thickening induction with ligation highlights 
therapeutic potential. The combined treatments using HDAC-9 inhibitor, TMP269, and STAT-
1 inhibitor, Fludarabine, should be investigated in the future as a combined approach may be 
beneficial. 
Further stratification of the mechanistic link between the PRH S163C:S177C and HDAC-9 is 
an attractive direction to be taken for future studies. For instance, IPA’s upstream regulator 
analysis revealed HDAC-9 as an upstream regulator of NPPA, SLC2A4, MYH7, CCNB1, 
RGS2 and CEBPA with an algorithm of a negative z-score (-2.0) which reflects the overall 
predicted inhibition state of the regulator. This analysis was able to determine genes within 
our dataset which are directly regulated by HDAC-9; NPPA, CEBPA, SLC2A4, and have 
association to govern cardiac fibrosis and apoptosis of cardiomyocytes. In as much as HDAC-
9 inhibition by TMP269 also attenuates VSMC proliferation and migration and preserves the 
contractile phenotype, controlling HDAC-9 activity may open a new method to retard intimal 
thickening by abrogating “full-spectrum” VSMC pathogenic phenotypes. In line with this theory, 











7.1  SUMMARY OF THESIS AIMS  
The aims of this thesis were:  
7. To determine the effect of overexpression of non-phosphorylatable PRH S163C:S177C 
on human SV (HSV) EC and VSMC proliferation, migration and apoptosis in vitro. 
8. To determine the effect of overexpression of non-phosphorylatable PRH S163C:S177C 
on phenotypic switching in HSV VSMCs in vitro. 
9. To determine the effect of overexpression of non-phosphorylatable PRH S163C:S177C 
on vascular inflammation in HSV ECs in vitro. 
10. To compare PRH target genes in HSV VSMCs and ECs and thereby identify genes that 
specifically repress VSMC proliferation. 
11. To validate PRH target genes repress HSV VSMC proliferation in vitro. 
12. To determine the effect of overexpression of non-phosphorylatable PRH S163C:S177C 





7.2.  SUMMARY OF THE MAIN FINDINGS OF THIS 
THESIS AND FUTURE DIRECTIONS 
7.2.1  Regulation of HSV VSMCs and intimal thickening by 
(Aims 1, 2 and 6) 
There is a continued reliance on saphenous veins as the most preferred graft conduits for 
coronary revascularization although they possess a poor lifespan owing to their susceptibility 
to degenerate within a decade (Harskamp et al., 2013). The de-differentiation of VSMCs to 
the synthetic phenotype and subsequent migration and proliferation of VSMCs into the intima 
are the underlying cause of intimal thickening and thereby progressive saphenous vein graft 
failure. It was hypothesised that PRH S163C:S177C can retard excessive VSMC 
accumulation and migration in primary human cells harvested form the saphenous veins of 
CABG surgical patients. Prior to the commencement of this PhD, previous work in our 
laboratory demonstrated that overexpression of the PRH S163C:S177C mutant with putative, 
enhanced stability can mitigate excessive and uncontrolled proliferation and migration in rat 
VSMCs (Wadey et al., 2017). Primarily, it was necessary to validate these previous findings 
in vitro using human VSMCs and in vivo. This present study demonstrated that artificially 
augmenting the levels of PRH S163C:S177C can suppress the mitotic action and migratory 
capabilities of human saphenous vein VSMCs comparable to control cells, indicating that the 
anti-proliferative and anti-migratory effects are not restricted to rat VSMCs. PRH 
S163C:S177C did not, however, significantly affect the rate of apoptosis, which corroborated 
the findings by Wadey and colleagues (Wadey et al., 2017). Data presented in Chapter 4 of 
this report illustrated that PRH S163C:S177C overexpression resulted in downregulation of 
Cyclin D1 accompanied by elevation of p21, indicating inhibition of the G1/S cell cycle 
transition.  Clearly, augmenting the levels of PRH S163C:S177C mutant robustly effects on 
VSMC behaviour. 
 
A novel finding of this thesis is the observation that PRH S163C:S177C overexpression 
resulted in upregulation, of the SMC-specific contractile phenotype markers calponin and 
smoothelin in vitro. This indication of phenotypic switching to the contractile phenotype was 
substantiated in functional assessments using the collagen contraction assay which 
demonstrated augmented contractile capacity in VSMCs overexpressing PRH S163C:S177C.  
 
In this thesis, ligation of the mouse left carotid artery was performed to examine the effect of 
PRH S163C:S177C overexpression on intimal thickening. In Chapter 5, it was shown that the 
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adenoviral gene transfer of PRH S163C:S177C was achieved via adventitial delivery and this 
caused a significant attenuation of proliferation and intimal thickening. Following occlusion of 
the mouse left carotid artery fas a result of the vessel ligation, cell replication occurs in the 
intimal layer of the vessel and also in the media. The overexpression of PRH S163C:S177C 
inhibited proliferation in both the intima and media. Additionally, migration can be estimated 
by means of quantifying the number of BrdU negative cells divided by the length of the intima. 
Using this approach, it was apparent that VSMC migration was retarded by PRH 
S163C:S177C, corroborating the in vitro migration assay results. It is important to note 
however, that this is an estimate of migration as it is technically difficult to directly measure 
VSMC migration in vivo. Together these findings from in vitro and in vivo analyses provide 
evidence for the potential of PRH S163C:S177C regulate the behaviour of VSMCs which may 
be beneficial in the goal to inhibit intimal thickening.  
 
Despite the positive results in terms of inhibition of intimal thickening, the question remains 
regarding the long-term efficacy of PRH S163C:S177C due to the transient nature of Ad-based 
gene therapy.  Previous report demonstrated the potential of an Ad-based TIMP-3 in 
supressing porcine vein graft occlusion at 3 months despite lack of TIMP-3 expression at this 
point (George et al., 2011). Because there is a therapeutic window early after implantation, 
inhibiting the early detrimental remodelling via PRH could enable the graft to adapt and ECs 
to regrow. Hence, longer term expression of the transgene is not needed. Though results from 
TIMP-3 is promising, one novel finding from our study suggests that PRH S163C:S177C 
promotes VSMC contractility. Another advantage is the beneficial effects of PRH 
S163C:S177C on HSVECs although this was not directly assessed in TIMP-3. Prior to 
continuing with our approach, further investigation exploring the durability of PRH 
S163C:S177C expression is necessary to prevent aberrant vein graft intimal thickening at a 
longer time point is necessary. Although we have confirmed the benefit of Ad-based gene 
transfer of PRH at 28 days using a mouse ligation model, it would be of great interest to 
perform future studies using a porcine model, employing either an interpositional or coronary 
vein graft, for up to 3 months to validate our findings and assess the efficacy for long-term 
graft patency. Although, these studies may take time due to the inherent difficulties and cost 
of expenses. In a clinical setting, hindering the development of intimal thickening must occur 
outside of the patient’s body. This implies that a perioperative intervention presents a unique 
window of opportunity to directly deliver Ad: PRH S163C:S177C to the arterial wall in solution 





7.2.2  Identification and investigation of downstream genes 
regulated by PRH S163C:S177C in VSMCs: STAT-1 and 
HDAC-9 (Aims 4 and 5) 
The mechanisms underlying how PRH S163C:S177C modulates inhibition of VSMC 
proliferation and migratory may lead to the discovery of novel therapeutic targets for the 
alleviation of intimal hyperplasia during vein graft disease which circumvent the need for 
adenoviral gene delivery but permit the use of pharmacological approaches. In Chapter 6, 
transcriptomic profiling data obtained from NGS identified STAT-1 and HDAC-9 as 
downstream genes modulated by PRH S163C:S177C overexpression. 
 
To investigate the role of STAT-1 in VSMC proliferation and support the proposal that STAT-
1 contributes to the anti-proliferative effects of PRH S163C:S177C, in vitro experiments were 
performed by means of pharmacological inhibition. This approach also gave the opportunity 
to evaluate whether the use of a STAT-1 inhibitor could be investigated as a pharmacological 
inhibitor of intimal thickening and provide similar effects to PRH S163C:S177C. Fludarabine 
was employed to specifically block STAT-1 activity. The experiments conducted in Chapter 6 
demonstrated that VSMC proliferation, but not migration, was markedly suppressed upon 
treatment with Fludarabine. Notably, an apparent downregulation of Cyclin D1 was a shared 
feature with PRH S163C:S177C emphasizing its anti-proliferative role. Having observed the 
pro-contractile phenotype induction as a result of PRH S163C:S177C overexpression in 
VSMCs, the effect of Fludarabine on phenotype was investigated. In contrast to PRH 
S163C:S177C overexpression, fludarabine did not upregulate the expression of smoothelin 
and calponin proteins. Whilst this finding did not support the role of STAT-1 in the PRH 
S163C:S177C mediated effects on VSMC contractility and migration, they are able to provide 
initial insight into the mechanisms of the anti-proliferative role of PRH S163C:S177C. 
However, further examination different ways of inhibiting STAT-1, such as siRNA or other 
inhibitors, could be a possible approach to help broaden the understanding of its role in 
modifying VSMC behaviour. Quantification of the post-translational modification, such as 
phosphorylation levels would be beneficial to expand our understanding of its involvement and 
determine whether STAT-1 downstream genes or proteins are regulated, and which biological 
processes are significantly enriched.  
 
HDAC-9 was also identified as a downstream target of PRH S163C:S177C overexpression 
and it has been identified as a major risk locus for vasculopathies (Prestel et al., 2019). In this 
study a Class IIa HDACi, TMP-269 was identified as the most suitable pharmacological 
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inhibitor due to lack of a specific HDAC-9 inhibitor. To date, there are no existing reports 
associating the link between HDAC-9 and PRH. Excitingly, the data presented in Chapter 6 
suggested TMP-269 can inhibit VSMC proliferation and, for the first time it was shown that it 
also retards migration of human saphenous vein VSMCs, mirroring the effects observed with 
PRH S163C:S177C overexpression. Further analysis observed that treatment of TMP-269 
considerably increased the SMC-specific contractile markers calponin and smoothelin which 
again was comparable to the data observed from PRH S163C:S177C overexpression. Hence, 
providing a pathway by which PRH S163C:S177C modulates the VSMC proliferation, 
migration, and differentiation to the contractile phenotype. As stated previously, the 
‘contractile’ effect of PRH S163C:S177C is restricted to regulating smoothelin and calponin 
expression except other markers of the contractile phenotype demonstrating that contractile 
mechanisms within VSMCs may be more diverse than usual.  The role of TMP-269 in 
activating other contractile markers is currently unknown and represents an interesting route 
for further investigation. Excitingly, these data offer the first mechanistic link between PRH 
S163C:S177C and HDAC-9 which could be involved in smooth muscle contraction 
vasculopathies such as aortic aneurysms. As described in Chapter 3, the effect of PRH 
S163C:S177C in modulation the contractile phenotype of VSMCs was not apparent in vivo. 
As a future direction, myograph studies can be conducted to test contraction in whole vessels. 
From the evidence generated in this thesis it is indicated that blocking the HDAC-9 pathway 
may be the best candidate to reduce diseases related to smooth muscle phenotypic switching 
within the vasculature including vein graft disease, atherosclerosis, abdominal aortic 
aneurysm and pulmonary arterial hypertension, however, future studies are needed to verify 
this point of view.   
 
Having said this, TMP269 is a potent inhibitor which is specific to class IIa HDACs with IC50 
values of 23 nM for HDAC-9. Therefore, it will be important to determine whether the effect 
was solely due to HDAC-9. Additional work using siRNA experiments to silence HDAC-9 may 
be valuable to test the role of HDAC-9 in the observed effects of PRH S163C:S177C. 
Examining the physical interaction between PRH S163C:S177C and HDAC-9 by 
immunoprecipitation studies may also be valuable parameters to assess. Alternatively, HDAC-
9 heterozygous knockout mice or TMP-269-treated mice subjected to left carotid artery ligation 
could be studied to strengthen the in vitro data. Thus, we consider that pharmacological 
inhibition through TMP-269 has a potential protective role in abrogating a thickened VSMC-
rich intima by controlling the VSMC phenotype, proliferation and migration. Further to this, it 
is necessary for continuation of this work to execute a collagen gel contraction assay in human 




Future experiments concentrating on efficient delivery of TMP-269 to vein grafts would also 
be a considerable undertaking. This report has not explored innovative methods for 
periadventitial drug delivery of biotherapeutics. The use of polymer hydrogels (Terry et al., 
2012), sheaths/wraps (Sanders et al., 2012), microspheres (Rajathurai et al., 2010) and 
nanoparticles materials is accumulating and revealing an exciting direction for translational 
drug delivery (Tee et al., 2019; Chaudhary et al., 2017).  By way of demonstration, polylactic-
polyglycolic acid (PLGA) wraps incorporated around the porcine external jugular vein have 
been shown to be effective in mitigating intimal thickening (Sanders et al., 2012). In our 
laboratory, the utility of integrating anti-proliferative inhibitors into a biodegradable polylactic-
polyglycolic acid (PLGA) sheaths or microspheres are currently being investigated to eliminate 
off-target drug infusion and improve sustained compound release. Currently, we are delivering 
CK2 inhibitors that are known to increase PRH levels and have been shown to reduce 
proliferation and migration (Brown et al., unpublished data). To assess in vivo sheaths/wraps 
or microspheres containing TMP-269 could be produced from dissolving PLGA in 
dichloromethane (DCM) and delivered into porcine saphenous vein grafts. There are also 
opportunities to test in the ex vivo flow model which was developed in our laboratory. 
Alternatively, the success of ‘nanocarriers’ strategy has been formerly demonstrated in the 
delivery of microRNA-145-loaded PLGA nanoparticles to VSMCs (Nishio et al., 2019). 
Promising preventative measures of this delivery system remarkably arrested venous 
neointimal hyperplasia in vivo. With respect to further translational aspirations, future research 
may aim to consider immersing porcine jugular veins into TMP-269-loaded PLGA 
nanoparticles solution to yield the desired therapeutic effects with local and sustained TMP-
269 release that may prolong graft patency. 
 
7.2.3  The anti-inflammatory effects of PRH S163C:S177C as a 
beneficial effect for enhancing vein graft patency (Aim 3) 
As a direct effect of HSV bypass grafting, endothelial cells become activated, causing 
disruption of the vascular endothelium function which may predispose grafts to early and late 
vein graft failure (Ward et al., 2017). Data from our laboratory previously demonstrated that 
overexpression PRH S163C:S177C mutant had no detrimental effect on the human umbilical 
vein endothelial cell proliferation, migration or survival (Wadey et al., 2017). The results 
presented in Chapter 4 corroborated these findings in HSV ECs, showing that the normal cell 
cycle functions such as proliferation, motility and viability were not different between cells 
overexpressing PRH S163C:S177C and the control groups. These findings implicate that 
gene transfer of PRH S163C:S177C did not impair the capacity for re-endothelialisation, via 
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migration and proliferation, that is important for vein graft patency. Consequently, the results 
prompted the investigation of other aspects of endothelial function. Release of cytokines, 
chemokines and other inflammatory mediators and monocyte adherence are important 
regulators of intimal thickening (Yang, Chang and Wei, 2016). Therefore, the discovery that 
PRH S163C:S177C can act as a biological mediator to achieve anti-inflammatory responses 
is both intriguing and potentially of high importance. The suppression of interleukin-6 and 
MCP-1 proteins by PRH S163C:S177C overexpression, which are critical molecules 
controlling monocyte recruitment to endothelium, combined with reduced monocyte adhesion 
and expression of VCAM-1 and ICAM-1 highlight the possibility that PRH could retard 
inflammation within the vein graft. Moreover, the reduced permeability highlights the potential 
to reduce monocyte invasion and plasma lipid infiltration. It would be of great interest to 
determine whether these benefits are realised in vivo post PRH S163C:S177C overexpression 
in endothelial cells. Crucially, these data unveiled the potential benefit of artificially enhancing 
levels of PRH S163C:S177C to effectively avert endothelial dysfunction and inflammation 
associated to the pathogenesis of intimal thickening and vein graft failure. 
 
The ever-persistent clinical demand for bioengineered blood vessels has been acknowledged 
due poor selection of vascular conduits (Song et al., 2019). Excitingly, local method of 
genetically manipulating the saphenous vein using the multifunctional transcription factor PRH 
S163C:S177C incorporated into endothelial cells or perivascular VSMCs prior to implantation 
of the conduit provides an exciting opportunity for future studies. To minimize graft rejection, 
patient-derived autologous cells could be isolated for therapeutic efficacy.  Alternatively, a 
previous study demonstrated that induced pluripotent stem cells (iPSCs) have been 
successfully differentiated into functional SMCs (Lee et al., 2010). iPSC-derived endothelial 
cells or smooth muscle cells infected with the adenovirus-encoding PRH S163C:S177C could 
be seeded into the vascular grafts vessels to recapitulate the anti-proliferative and anti-
inflammatory function of PRH within a vein graft. 
 
7.2.4  Identifying endothelial cell-specific PRH S163C:S177C 
downstream targets that may modulate its protective role 
in the vascular endothelium 
Having established the anti-inflammatory capabilities of PRH S163C:S177C, it remains 
unknown as to how PRH S163C:S177C regulates the endothelial cell behaviour and function. 
DEGs identified as specifically PRH S163C:S177C-regulated in HSV ECs represent an 
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unknown and a vital part for the continuance of this project. Firstly, similar bioinformatic filtering 
strategies as described in Chapter 2 may be performed focusing on the 652 genes identified 
to be specifically regulated in endothelial cells (Supplementary Material). Secondly, such 
findings require validation at the protein level. Western blotting or immunocytochemistry 
experiments may be performed to confirm whether PRH S163C:S177C affects their protein 
expression. Lastly, pharmacological strategies, overexpression or knockdown experiments 
could be conducted to evaluate the functional effect of these target genes in HSV ECs. To 
assess the therapeutic efficacy of these targets, similar in vitro experiments examining its anti-
inflammatory role are necessary for continuation of this work. 
 
7.3   LIMITATIONS OF THE STUDY 
Relevant findings in animals are difficult to associate with humans because of animal-to-
human translational success rates are frequently low. The carotid artery ligation model in mice 
is an attractive method to induce vascular injury and intimal thickening in order to address 
research questions. However, several inherent limitations have to be acknowledged as the 
clinical relevance of the carotid artery ligation model remains problematic. Firstly, the model 
features an intact endothelium which does not mimic clinical conditions observed in CABG 
patients where graft harvesting, distension and implantation causes endothelial damage and 
denudation (Holt and Tulis, 2013). Secondly, complete occlusion of the vessel from ligation 
restricts the ability to analyse the effect of haemodynamic forces which is an important 
contributing factor in early vein graft stenosis (Ward et al., 2017; Ley et al., 2007; Fernandez 
et al.,2004). Thirdly, the effect of macrophages and vascular inflammation is difficult to analyse 
using this model and in Chapter 4, PRH S163C:S177C was shown to have a protective role 
against vascular inflammation. To overcome these shortcomings, more appropriate animal 
models are desirable. A clinically more relevant model to investigate intimal thickening in the 
vein graft is the porcine saphenous vein-to-carotid artery interposition grafts (Rajathurai et al., 
2010). Although the potential benefits of porcine model include the ongoing issues of its 
technical complexity and high cost (Caramori et al., 1997). Therefore, the mouse carotid artery 
ligation model remains to be a robust and established pre-clinical model model which permits 
substantial understanding of adenoviral-mediated gene therapy of restenosis in vein graft 
degeneration. 
 
An additional limitation of the current study was the decision to focus on the transcription 
factors within VSMC-specific regulated DEGs due to the limited time to follow up on all of the 
regulated genes from NGS. Evidence presented in this thesis suggests the anti-inflammatory 
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role of PRH S163C:S177C in endothelial cells. Therefore, future work on the analysis of 
HSVEC-specific regulated DEGs from NGS would be optimal to provide a mechanistic link on 
the effect of PRH S163C:S177C in the endothelium.  Although in vitro work in this thesis relied 
on isolated cells, patients with vein grafts have lots of risk factors including diabetes, age and 
high lipids (McKavanagh et al., 2017). Future experiments may look into ex vivo bioreactor 
studies where cells are embedded in the native matrix.  
 
The 7-day in vivo pilot study was originally set up to confirm the viral protein expression of 
PRH S163C:S177C transgene in the ligated mouse carotids. Due to the disruption caused by 
coronavirus (COVID-19) on this project (i.e., national lockdown and laboratory closures), 
we’ve faced difficulties in setting up the animal studies. Therefore, we had to move forward 
with the 28-days in vivo main study. As a future direction, more animals could be set up to 
look at the effect of PRH S163C:S177C overexpression at an earlier-point in the 7-day mouse 
carotid artery ligation model. 
 
 
7.4   FINAL REMARKS 
The fundamental goal of this thesis to evaluate the potential of PRH S163C:S177C as a 
therapeutic modality for long term venous graft patency is extremely clinically relevant. 
Together the data presented in this thesis clearly demonstrate the benefit of an adenoviral-
based overexpression of the mutant and stabilised form PRH (S163C:S177C). In conclusion, 
evidence that PRH S163C:S177C may reduce vein graft failure by inhibiting intimal thickening 
through modulation of VSMC behaviour at least in part mediated by STAT-1 and HDAC-9, 
and reduction of endothelial inflammation. Hence, a clinically applicable strategy for delivering 
PRH S163C:S177C can limit the requirement for repeat revascularisation procedures in 
patients undertaking arterial reconstruction each year. Alternatively, the utilisation of 
pharmacological inhibitors of STAT-1 and HDAC-9 may be beneficial for the suppression of 







FIGURE 7.1: Overexpression of PRH S163C:S177C can retard the development of intimal 
thickening 
Schematic diagram illustrating PRH S163C:S177C can effectively retard VSMC proliferation and 
migration while promoting VSMC contractility without damaging endothelial function.  Next Generation 
Sequencing (NGS) identified HDAC-9 as a novel PRH S163C:S177C-regulated target gene. 
Pharmacological inhibition of HDAC-9 using TMP269 inhibited   VSMC proliferation and migration   



































Supplementary Data 1: The top enriched PRH S163C:S177C regulated canonical pathways based on 
Ingenuity Pathway Analysis (IPA). 
P-value for inclusion here is ≤ .05. P- value is calculated using Fischer’s exact test indicates the probability of the 
involvement of the genes in the dataset in a given pathway. Ratios represent the number of molecules in the 
dataset that are found in a given pathway, divided by total number of molecules that make up that pathway. 








Axonal Guidance Signalling 12.2 0.196 ABLIM1 ABLIM2 ADAM23 ADAM33 ADAMTS1 ADAMTS17 ADAMTS6 ADAMTS8 BAIAP2 BDNF 
BMP8B CXCL12 EFNA4 EFNB1 EFNB2 EFNB3 EGF EPHA3 EPHA7 EPHB2 EPHB3 EPHB4 
EPHB6 FZD7 FZD9 GLIS2 GNAZ GNG12 GNG2 ITGA2 ITGA3 ITSN1 KCNJ12 MET MMP11 
MMP9 MRAS MYL10 MYL2 MYL3 MYL4 MYL7 NFATC1 NTN5 NTNG2 PAPPA SEMA3A SEMA3B 
SEMA3F SEMA5A SEMA6A SEMA6B SHH SLIT2 SRGAP1 UNC5A VEGFA VEGFC WNT1 
WNT10A WNT10B WNT11 WNT3 WNT3A WNT6 WNT9B 
Breast Cancer Regulation 
by Stathmin1 
11 0.179 ACKR3 ADGRA1 ADGRB1 ADGRG1 ADGRG6 ADGRL1 ADGRL4 ADRA1B ADRA2B APLNR 
ARHGEF4 AURKB BDKRB2 CAMK1D CAMK2A CASR CCR10 CCR7 CCRL2 CDK1 CELSR1 
CELSR2 CHRM1 CHRM4 CRHR1 CRHR2 CX3CR1 EGF F2RL2 FFAR2 FFAR3 FGF2 FOXM1 
FPR2 FZD7 FZD9 GALR2 GLP1R GLP2R GNG12 GNG2 GPR150 GPR153 GPR157 GPR162 
GPR19 GPR20 GPR37L1 GPR4 GPR65 GPR78 GPR83 GPR84 GPRC5C GRM4 GRM8 GRPR 
HCRTR1 HGF HRH2 HTR2A HTR7 KISS1R LPAR1 LPAR2 MC1R MC5R MCHR1 MMP9 MRAS 
NTSR1 OPRD1 P2RY1 P2RY11 P2RY2 PDGFB PIK3C2B PIK3CD PIK3R3 PLCB2 PPP2R3B 
PRKCB PRKCD PRKCZ PRKD1 PTGER2 PTGER4 PTGFR RALA RRAS2 S1PR2 S1PR5 
SLC52A1 SSTR1 SSTR2 SSTR3 STMN1 SUCNR1 TBXA2R TUBA1A TUBA1C TUBA4A TUBA8 
TUBB4A VEGFA VEGFC 
Cardiac Hypertrophy 
Signalling (Enhanced) 
9.01 0.179 ADCY4 ADRA1B ADRA2B AGT CACNA1A CAMK2A CD70 DIAPH3 EDN1 FGF11 FGF18 FGF19 
FGF2 FGF21 FGF3 FGFR4 FZD7 FZD9 GNG2 HAND1 HAND2 HDAC9 IFNLR1 IL12RB1 IL17RC 
IL1A IL1B IL21R IL27RA IL33 IL4R IL6 ITGA ITGA3 ITPR3 LEP LTA MAP3K20 MAP3K5 MEF2A 
MEF2C MEF2D MRAS MYOCD NFATC1 NPPA PDE3A PDE4A PDE4C PDE5A PDE6C PDE7B 
PDE8B PIK3C2B PIK3CD PIK3R3 PLCB2 PLCD1 PLCG2 PLCH2 PLCL1 PLN PRKCB PRKCD 
PRKCZPRKD1 RALA RRAS2 RYR1 SMPDL3B STAT1 TGFB3 TGFBR2 TNF TNFRSF11B 
TNFSF13 TNFSF14  TNFSF15 TNFSF4 TNFSF9WNT1 WNT10A WNT10B WNT11 WNT3 
WNT3A WNT6 WNT9B 






8.38 0.199 ADCY4 APOE BDNF CACNB4 CAMK2A CDH10 CDH18 CDH2 CDH22 CDH23 CDH24 CDH3 
CDH5 CDH6 CDH8 CNTNAP1 CPLX1 EFNA4 EFNB1 EFNB2 EFNB3 EPHA3 EPHA7 EPHB2 
EPHB3 EPHB4 EPHB6 FGR GRIA1 GRIN1 GRIN2A GRIN2C GRM4 GRM8 ITSN1 MRAS 
NECTIN3 NLGN1 NRXN3 PIK3C2B PIK3CD PIK3R3 PLCG2 PRKCD RALA RASGRF1 RASGRP2 
RELN RRAS2 SHC2 SHF SNCB SNCG STX1B STXBP5 SYN3 SYNGAP1 SYT11 SYT2 SYT3 
SYT5 SYT7 
Hepatic Fibrosis Signalling 
Pathway 
7.78 0.185 AGT CACNA1A CCL2 CCN2 COL11A2 COL18A1 COL2A1 DIRAS3 EDN1 FGF2 FLT4 FZD7 FZD9 
GLIS2 IL1A IL1B IL1RN IL33 IRAK2 ITGA2 ITGA3 LEF1 LEP MRAS MYL10 MYL2 MYL3 MYL4 
MYL7 MYLK2 NFKBIE PDGFA PDGFB PIK3C2B PIK3CD PIK3R3 PLCG2 PRKCB PRKCD 
PRKCZ PRKD1 RALA RHOD RHOF RHOU RHOV RND3 RRAS2 SHH SNAI1 SOD2 SUCNR1 TF 
TGFB3 TGFBR2 TLR4 TNF TNFRSF11B VEGFA VEGFC WNT1 WNT10A WNT10B WNT11 
WNT3 WNT3A WNT6 WNT9B 
Hepatic Fibrosis / Hepatic 
Stellate Cell Activation 
7.04 0.22 AGT CCL2 CCN2 CCR7 COL11A2 COL18A1 COL27A1 COL2A1 COL9A2 CXCL2 EDN1 EGF 
EGFR FGF2 FLT4 HGF IL1A IL1B IL4R IL6 LBP LEP MET MMP9 MYH10 MYH11 MYH7 MYL2 
MYL3 MYL4 MYL7 PDGFA PDGFB STAT1 TGFB3 TGFBR2 TLR4 TNF TNFRSF11B VEGFA 
VEGFC 
Role of Macrophages, 
Fibroblasts and Endothelial 
Cells in Rheumatoid 
Arthritis 
6.46 0.183 CAMK2A CCL2 CEBPA CEBPD CXCL12 DKK2 FGF2 FZD7 FZD9 IL16 IL17RC IL1A IL1B IL1RN 
IL33 IL6 IRAK2 LEF1 LTA MRAS NFATC1 NFKBIE NOS2 PDGFA PDGFB PIK3C2B PIK3CD 
PIK3R3 PLCB2 PLCD1 PLCG2 PLCH2 PLCL1 PRKCB PRKCD PRKCZ PRKD1 RALA RRAS2 
SFRP1 SFRP4 SOCS3 TLR4 TLR5 TNF TNFRSF11B TRAF1 VEGFA VEGFC WNT1 WNT10A 
WNT10B WNT11 WNT3 WNT3A WNT6 WNT9B 
Gα12/13 Signalling 6.26 0.238 CDH10 CDH18 CDH2 CDH22 CDH23 CDH24 CDH3 CDH5 CDH6 CDH8 F2RL2 LPAR1 LPAR2 
MAP3K5 MEF2A MEF2C MEF2D MRAS MYL10 MYL2 MYL3 MYL4 MYL7 NFKBIE PIK3C2B 
PIK3CD PIK3R3 RALA RRAS2 TBXA2R VAV1 
Calcium Signalling 6.21 0.204 ACTA1 ASPH ATP2B1 ATP2B2 ATP2B3 CACNA1A CACNA1H CACNA1I CACNA2D2 CACNB4 
CACNG4 CAMK1D CAMK2A CHRNA3 CHRNA4 CHRNB1 CHRNB4 GRIA1 GRIN1 
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GRIN2A GRIN2C HDAC9 ITPR3 MEF2A MEF2C MEF2D MYH10 MYH11 MYH7 MYL2 MYL3 
MYL4 MYL7 NFATC1 RYR1 SLC8B1 TNNC1 TNNI3 TNNT2 TRPC4 TRPC6 TRPV6 
Glioblastoma Multiforme 
Signalling 
6.15 0.218 CDKN2A DIRAS3 EGF EGFR FZD7 FZD9 ITPR3 LEF1 MRAS NF2 PDGFA PDGFB PIK3C2B 
PIK3CD PIK3R3 PLCB2 PLCD1 PLCG2 PLCH2 PLCL1 PRKCD RALA RHOD RHOF RHOU RHOV 
RND3 RRAS2 WNT1 WNT10A WNT10B WNT11 WNT3 WNT3A WNT6 WNT9B 
Neuropathic Pain Signalling 
In Dorsal Horn Neurons 
5.49 0.248 BDNF CAMK1D CAMK2A GRIA1 GRIN1 GRIN2A GRIN2C GRM4 GRM8 ITPR3 KCNH2 KCNQ2 




5.47 0.18 ADCY4 ADRA1B ADRA2B APLNR CAMK2A CHRM1 CHRM4 CRHR1 DUSP6 DUSP9 FFAR3 
FPR2 GLP1R GRM4 GRM8 HRH2 HTR2A HTR7 LPAR1 MC1R MC5R MRAS NFKBIE NPR3 
OPRD1 PDE3A PDE4A PDE4C PDE5A PDE6C PDE7B PDE8B PIK3C2B PIK3CD PIK3R3 PLCB2 
PRKCB PTGER2 PTGER4 RALA RAP1GAP RAPGEF3 RGS2 RPS6KA1 RRAS2 SMPDL3B 
SSTR3 SYNGAP1 TBXA2R 
Human Embryonic Stem 
Cell Pluripotency 
5.41 0.222 BDNF BMP8B FGF2 FGFR4 FZD7 FZD9 INHBA LEF1 LEFTY2 MRAS PDGFA PDGFB PIK3C2B 
PIK3CD PIK3R3 POU5F1 S1PR2 S1PR5 SMAD6 SOX2 TGFB3 TGFBR2 WNT1 WNT10A 
WNT10B WNT11 WNT3 WNT3A WNT6 WNT9B 
Regulation of the Epithelial-
Mesenchymal Transition 
Pathway 
5.36 0.198 CDH2 EGF EGFR EGR1 FGF11 FGF18 FGF19 FGF2 FGF21 FGF3 FGFR4 FZD7 FZD9HGF 
HMGA2 JAG2 LEF1 LOX MET MMP9 MRAS NOTCH1 PIK3C2B PIK3CD PIK3R3 RALA RRAS2 
SNAI1 TGFB3 TGFBR2 WNT1 WNT10A WNT10B WNT11 WNT3 WNT3A WNT6 WNT9B 
Agranulocyte Adhesion and 
Diapedesis 
5.3 0.197 ACTA1 AOC3 CCL11 CCL19 CCL2 CCL20 CCL22 CD34 CDH5 CLDN1 CLDN12 CLDN18 
CLDN2 CX3CL1 CXCL1 CXCL12 CXCL16 CXCL2 CXCL3 CXCL5 IL1A IL1B IL1RN IL33 ITGA2 








 Supplementary Data 2: DEGs prioritised from the top-enriched canonical pathways approach.  
Gene Protein Function  Fold Change P-value 
HDAC-9 Histone Deacetylase 9 transcription regulator/ repressor -3.318 5.14E-05 
 
NFATC-1 Nuclear Factor of Activated T Cells 1 transcription factor 3.783 2.80E-05 
 
STAT-1 Signal Transducer and Activator of 
Transcription 1 
transcription factor -2.369 6.54E-03 
 
HAND-1 Heart and Neural Crest Derivatives 
Expressed 1 
transcription factor 121.350 1.48E-05 
CEBPD CCaAT Enhancer Binding Protein 
delta 
transcription factor -2.043 2.31E-02 
 
Supplementary Data 1: DEGs prioritised from the canonical pathways approach. 
P-value for inclusion here is ≤ .05. P- value is calculated using Fischer’s exact test indicates the probability of the involvement of the genes in the dataset in either ‘proliferation’ 









Supplementary Data 3: DEGs prioritised from the ‘proliferation’ and ‘migration’ disease and function approach.  
Gene Protein Function  Fold Change P-value 
STAT-1 Signal Transducer and Activator of 
Transcription 1 
transcription factor -2.369 6.54E-03 
 
FOXM-1 Forkhead Box M1 transcription factor -1.877 1.20E-02 
NFATC-1 Nuclear Factor of Activated T Cells 1 transcription factor 3.783 2.80E-05 
 
CEBPA CCaAT Enhancer Binding Protein 
alpha 
transcription factor 10.992 1.64E-03 
KLF-11 Kruppel Like Factor 11 transcription factor 2.411 7.33E-03 
Supplementary Data 1: DEGs prioritised from the ‘proliferation’ and ‘migration’ disease and function approach.  
P-value for inclusion here is ≤ .05. P- value is calculated using Fischer’s exact test indicates the probability of the involvement of the genes in the dataset in either ‘proliferation’ 
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